[go: up one dir, main page]

WO2005097791A1 - Inhibitors of iap - Google Patents

Inhibitors of iap Download PDF

Info

Publication number
WO2005097791A1
WO2005097791A1 PCT/EP2005/003619 EP2005003619W WO2005097791A1 WO 2005097791 A1 WO2005097791 A1 WO 2005097791A1 EP 2005003619 W EP2005003619 W EP 2005003619W WO 2005097791 A1 WO2005097791 A1 WO 2005097791A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
ethyl
cycloalkyl
substituted
Prior art date
Application number
PCT/EP2005/003619
Other languages
French (fr)
Inventor
Mark G. Palermo
Sushil Kumar Sharma
Christopher Straub
Run-Ming Wang
Leigh Zawel
Yanlin Zhang
Zhuoliang Chen
Yaping Wang
Fan Yang
Wojciech Wrona
Gang Liu
Mark G. Charest
Feng He
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005097791(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to RS20120557A priority Critical patent/RS52545B/en
Priority to MEP-2012-557A priority patent/ME02125B/en
Priority to ES05716547T priority patent/ES2394441T3/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Priority to CA2560162A priority patent/CA2560162C/en
Priority to NZ549925A priority patent/NZ549925A/en
Priority to US10/594,413 priority patent/US20080242658A1/en
Priority to CN2005800186137A priority patent/CN1964970B/en
Priority to BRPI0509721-5A priority patent/BRPI0509721A/en
Priority to EP05716547A priority patent/EP1735307B1/en
Priority to AU2005231956A priority patent/AU2005231956B2/en
Priority to JP2007506718A priority patent/JP4691549B2/en
Publication of WO2005097791A1 publication Critical patent/WO2005097791A1/en
Priority to IL178104A priority patent/IL178104A/en
Priority to TNP2006000323A priority patent/TNSN06323A1/en
Priority to NO20065114A priority patent/NO20065114L/en
Priority to HK07106025.9A priority patent/HK1100930A1/en
Priority to US13/178,946 priority patent/US8207183B2/en
Priority to US13/456,274 priority patent/US8338440B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs).
  • the present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
  • Programmed cell death plays a critical role in regulating cell number and in eliminating stressed or damaged cells from normal tissues. Indeed, the network of apoptotic signaling mechanisms inherent in most cell types provides a major barrier to the development and progression of human cancer. Since most commonly used radiation and chemo-therapies rely on activation of apoptotic pathways to kill cancer cells, tumor cells which are capable of evading programmed cell death often become resistant to treatment.
  • Apoptosis signaling networks are classified as either intrinsic when mediated by death receptor-ligand interactions or extrinsic when mediated by cellular stress and mitochondrial permeabilization. Both pathways ultimately converge on individual Caspases. Once activated, Caspases cleave a number of cell death-related substrates, effecting destruction of the cell.
  • Tumor cells have devised a number of strategies to circumvent apoptosis.
  • One recently reported molecular mechanism involves the overexpression of members of the IAP (Inhibitor of Apoptosis) protein family.
  • lAPs sabotage apoptosis by directly interacting with and neutralizing Caspases.
  • the prototype lAPs, XIAP and clAP have three functional domains referred to as BIR 1 , 2 & 3 domains.
  • BIR3 domain interacts directly with Caspase 9 and inhibits its ability to bind and cleave its natural substrate, Procaspase 3.
  • a proapoptotic mitochondrial protein Smac (also known as DIABLO), is capable of neutralizing XIAP and/or clAP by binding to a peptide binding pocket (Smac binding site) on the surface of BIR3 thereby precluding interaction between XIAP and/or clAP and Caspase 9.
  • Smac also known as DIABLO
  • the present invention relates to therapeutic molecules that bind to the Smac binding pocket thereby promoting apoptosis in rapidly dividing cells.
  • Such therapeutic molecules are useful for the treatment of proliferative diseases, including cancer.
  • Smac analogs would bind to BIR3 domain of lAPs and will remove the lAP's inhibition of activated Caspase 9 which would then go on to induce apoptosis.
  • the present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs).
  • the present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
  • the present invention relates to compounds of the formula (1)
  • Ri is H; C1-C4 alkyl; C ⁇ -C 4 alkenyl; C- ⁇ -C 4 alkynyl or C 3 -C ⁇ 0 cycloalkyl which are unsubstituted or substituted;
  • R2 is H; C 1 -C 4 alkyl; C ⁇ -C 4 alkenyl; C ⁇ -C alkynyl or C 3 -C ⁇ 0 cycloalkyl which are unsubstituted or substituted;
  • R 3 is H; -CF 3 ; -C 2 F 5 ; C C 4 alkyl; C C 4 alkenyl; d-C 4 alkynyl; -CH 2 -Z or R 2 and R 3 together with the nitrogen form a het ring;
  • Z is H; -OH; F; Cl; -CH 3 ; -CF 3 ; -CH 2 CI; -CH 2 F or -CH 2 OH;
  • R 4 is C1-C 16 straight or branched alkyl; C- 1 -C 16 alkenyl; C 1 -C- 16 alkynyl; or -C 3 - C 10 cycloalkyl; -(CH 2 ) ⁇ -6-Z ⁇ ; -(CH 2 )o-6-aryl; and -(CH 2 )o-6-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
  • Zi is -N(R 8 )-C(O)-C 1 -C 10 alkyl; -N(R 8 )-C(O)-(CH 2 ) ⁇ - 6 -C 3 -C 7 cycloalkyl; -N(R 8 )-C(O)- (CH 2 )o-6-phenyl; -N(R 8 )-C(O)-(CH 2 ) ⁇ - 6 -het; -C(O)-N(R 9 )(R ⁇ 0 ); -C(O)-O-C ⁇ -C 10 alkyl; - C(O)-O-(CH 2 ) ⁇ - 6 -C 3 -C 7 cycloalkyl; -C(O)-O-(CH 2 )o- 6 -phenyl; -C(O)-O-(CH 2 ) ⁇ - 6 -het; -O- C(O)-C C 10 alkyl; -O-C(O
  • R 8 is H; -CH 3 ; -CF 3 ; -CH 2 OH or -CH 2 CI;
  • R 9 and R 10 are each independently H; CrC- t alkyl; C 3 -C 7 cycloalkyl; -(CH 2 ) ⁇ - 6 -C 3 - C 7 cycloalkyl; -(CH2)o-6-phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or R 9 and R 10 together with the nitrogen form het;
  • R 5 is H; C-i-Cio-alkyl; aryl; phenyl; C 3 -C cycloalkyl; -(CH 2 ) ⁇ - 6 -C 3 -C 7 cycloalkyl; -Cr
  • n 0-5;
  • X is -CH or N
  • Ra and Rb are independently an O, S, or N atom or C 0 - 8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
  • alkyl may be unsubstituted or substituted
  • Rd is selected from: (a) -Re - Q - (Rf) p (Rg) q ; or (b) AP,-D- Ar 2 ;
  • Re is H or Re and Rd may together form a cycloalkyl or het; where if Rd and Re form a cycloalkyl or het, R 5 is attached to the formed ring at a C or N atom;
  • p and q are independently 0 or 1 ;
  • Re is d-a alkyl or alkylidene, and Re which may be unsubstituted or substituted;
  • Q is N, O, S, S(O), or S(O) 2 ;
  • An and Ar2 are substituted or unsubstituted aryl or het;
  • Rf and Rg are each independently H; -d-C 10 alkyr, d-Cioalkylaryl; -OH; -O-d- Cioalkyl; -(CH 2 )o- 6 -C 3 -C 7 cycloalkyl; -O-(CH 2 )o- 6 -aryl; phenyl; aryl; phenyl-phenyl; - (CH 2 ) ⁇ - 6 -het; -O-(CH 2 ) ⁇ - 6 -het; -0R 11 ; -C(O)-R 1 i ; -C(O)-N(R 11 )(R 12 ); -N(Rn)(R 12 ); -S- R11; -S(O)-Rn; -S(O) 2 -Rnl -S(O) 2 -NRnR 12 ; -NRn-S(O) 2 - R 12 ; S-C ⁇ -
  • D is -CO-; -C(O)-d- 7 alkylene or arylene; -CF 2 -; -O-; -S(O) r where r is 0-2; 1 ,3dioaxolane; or C ⁇ - 7 alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-d-C ⁇ alkyl, -S-d- C ⁇ alkyl or -CF 3 ; or D is -N(Rh) wherein Rh is H; d. 7 alkyl (unsub or substituted); aryl; -O(C 1 .
  • R 7 , R' ⁇ and R' 7 are each independently H; -C ⁇ -C 10 alkyl; -C 1 -C 10 alkoxy; aryl-d- C10 alkoxy; -OH; -O-C ⁇ -C ⁇ 0 alkyl; -(CH 2 )o- 6 -C 3 -C 7 cycloalkyl; -O-(CH 2 )o-6-aryl; phenyl; - (CH 2 ) ⁇ -6-het; -O-(CH 2 ) ⁇ - 6 -het; -ORn; -C(O)-R 1i ; -C(O)-N(Rn)(R 12 ); -N(Rn)(R ⁇ 2 ); -S- Rn; -S(O)-Rn; -S(O) 2 -Rn; -S(O) 2 -NRnR 12 ; -NRn-S(O) 2 - R 12 ; where
  • R11 and R 12 together with the nitrogen atom form het; wherein the alkyl substituents of Rn and R 12 may be unsubstituted or substituted by one or more substituents selected from C ⁇ -C ⁇ 0 alkyl, halogen, OH, -O-C ⁇ -C 6 alkyl, -S-
  • substituted cycloalkyl substituents of R- ⁇ and R 12 are substituted by one or more substituents selected from a C ⁇ -C ⁇ o alkene; d-C 6 alkyl; halogen; OH; -O-C ⁇ -C 6 alkyl; -
  • S-C ⁇ -C 6 alkyl or -CF 3 substituted phenyl or aryl of Rn and R 12 are substituted by one or more substituents selected from halogen; hydroxy; C 1 -C 4 alkyl; d-C 4 alkoxy; nitro; -CN; -O-C(O)-C ⁇ - dalkyl and -C(O)-O-d-C 4 -aryl, or pharmaceutically acceptable salts thereof.
  • the present invention also related to the use of compound of formula I in the treatment of proliferative diseases, especially those dependent on the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs), or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of compounds of formula (I) in the treatment of said diseases, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said diseases, compounds of formula (I) for use in the treatment of said diseases.
  • lAPs Inhibitor of Apoptosis Proteins
  • Aryl is an aromatic radical having 6 to 14 carbon atoms, which may be fused or unfused, and which is unsubstituted or substituted by one or more, preferably one or two substituents, wherein the substituents are as described below.
  • Preferred "aryl” is phenyl, naphthyl or indanyl.
  • Het refers to heteroaryl and heterocyclic rings and fused rings containing aromatic and non-aromatic heterocyclic rings. "Het” is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1 , 2 or 3 heteroatoms selected from N, O, and S.
  • Suitable het substituents include unsubstituted and substituted pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1 ,4-diazapane, 1 ,4-oxazepane, 1 ,4-oxathiapane, furyl, thienyl, pyrrole, pyrazole, triazole, 1 ,2,3- triazole, tetrazolyl, oxadiazole, thiophene, imidazol, pyrrolidine, pyrrolidone, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine, quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, in
  • the het substituents are unsubstituted or substituted on a carbon atom by halogen, especially fluorine or chlorine, hydroxy, C 1 -C 4 alkyl, such as methyl and ethyl, d-C 4 alkoxy, especially methoxy and ethoxy, nitro, -O-C(O)-C ⁇ -C 4 alkyl or -C(O)-O-d-C 4 alkyl or on a nitrogen by d-C 4 alkyl, especially methyl or ethyl, -O-C(O)-C ⁇ : C 4 alkyl or -C(O)-O- C ⁇ -C alkyl, such as carbomethoxy or carboethoxy.
  • halogen especially fluorine or chlorine
  • hydroxy C 1 -C 4 alkyl, such as methyl and ethyl, d-C 4 alkoxy, especially methoxy and ethoxy, nitro, -O-C(O
  • heterocyclic ring is a nitrogen-containing ring, such as aziridine, azetidine, azole, piperidine, piperazine, morphiline, pyrrole, pyrazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, and the like.
  • Halogen is fluorine, chlorine, bromine or iodine, especially fluorine and chlorine.
  • alkyl includes straight or branched chain alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and branched pentyl, n-hexyl and branched hexyl, and the like.
  • a "cycloalkyl” group means C 3 to Ciocycloalkyl having 3 to 8 ring carbon atoms and may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • cycloalkyl is cycloheptyl.
  • the cycloalkyl group may be unsubstituted or substituted with any of the substituents defined below, preferably halo, hydroxy or C ⁇ -C 4 alkyl such as methyl.
  • the amino acid residues include a residue of a standard amino acid, such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
  • the amino acid residues also include the side chains of uncommon and modified amino acids. Uncommon and modified amino acids are known to those of skill in the art (see for example G. B. Fields, Z.
  • the side chain of the amino acid residue contains a derivatizable group, such as COOH, -OH or amino
  • the side chain may be derivatized by a substituent that reacts with the derivatizable group.
  • a substituent that reacts with the derivatizable group.
  • acidic amino acids like aspartic and glutamic acid, or hydroxy substituted side chains, like those of serine or threonine
  • the derivative may be a substituent that facilitates transport across a cell membrane.
  • any carboxylic acid group in the amino acid residue for example, an alpha carboxylic acid group, may be derivatized as discussed above to form an ester or amide.
  • Such lipophillic substituents include a C 6 -C 30 alkyl which is saturated, monounsaturated, polyunsaturated, including methylene-interrupted polyene, phenyl, phenyl which substituted by one or two C ⁇ -C 8 alkyl groups, C 5 -C 9 cycloalkyl, C 5 -C 9 cycloalkyl which is substituted by one or two d-C 8 alkyl groups, - Xrphenyl, -X ⁇ phenyl which is substituted in the phenyl ring by one or two C ⁇ -C 8 alkyl groups, X 1 -C 5 -C 9 cycloalkyl or X 1 -C 5 -C 9 cycloalkyl which is substituted by one or two C ⁇ -C 8 alkyl groups; where X 1 is C 1 -C 24 alkyl which is saturated, monounsaturated or polyunsaturated and straight or branched chain.
  • any of the above defined aryl, het, alkyl, cycloalkyl, or heterocyclic groups may be unsubstituted or independently substituted by up to four, preferably one, two or three substituents, selected from the group consisting of: halo (such as Cl or Br); hydroxy; lower alkyl (such as C 1 -C 3 lower alkyl); lower alkyl which may be substituted with any of the substituents defined herein; lower alkenyl; lower alkynyl; lower alkanoyl; alkoxy (such as methoxy); aryl (such as phenyl or benzyl); substituted aryl (such as fluoro phenyl or methoxy phenyl); amino; mono- or disubstituted amino; amino lower alkyl (such as dimethylamino); acetyl amino; amino lower alkoxy (such as ethoxyamine); nitro; cyano; cyano lower alkyl; carboxy; ester
  • piperazinyl e.g. piperazinyl, pyrazinyl, lower alkyl-piperazinyl, pyridyl, indolyl, thiophenyl, thiazolyl, n-methyl piperazinyl, benzothiophenyl, pyrrolidinyl, piperidino or imidazolinyl
  • alkyl, cycloalkyl, aryl or het groups may be substituted by halogen, carbonyl, thiol, S(O), S(O 2 ), -OH, -SH, -OCH 3 , -SCH 3> -CN, -SCN or nitro.
  • salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts.
  • Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate.
  • metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt.
  • ammonium salts are ammonium salt and tetramethylammonium salt.
  • organic amine addition salts are salts with morpholine and piperidine.
  • amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine.
  • Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts.
  • any reference to the compounds hereinbefore and hereinafter especially the compounds of the formula I is to be understood as referring also to the corresponding tautomers of these compounds, especially of compounds of the formula I, tautomeric mixtures of these compounds, especially of compounds of the formula I, or salts of any of these, as appropriate and expedient and if not mentioned otherwise.
  • Any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration.
  • the compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as enantiomer-pure diastereomers or pure enantiomers.
  • IAPS Apoptosis Proteins
  • An embodiment of the present invention relates to compounds of the formula (I)
  • Ri is H; C 1 -C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, -OH, -SH, -OCH 3 , -SCH 3 , -CN, -SCN and nitro;
  • R 2 is H; d-C 4 alkyl; C 1 -C 4 alkenyl; C 1 -C 4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, -OH, -SH, -OCH 3l -SCH 3 , -CN, -SCN and nitro;
  • R 3 is H; -CF 3 ; -C 2 F 5 ; d-C 4 alkyl; C C 4 alkenyl; C1-C4 alkynyl; -CH 2 -Z or R 2 and R 3 together with the nitrogen form a het;
  • Z is H; -OH; F; Cl; -CH 3 ; -CF 3 ; -CH 2 CI; -CH 2 F or -CH 2 OH;
  • R 4 is C1-C16 straight or branched alkyl; d-C- ⁇ 6 alkenyl; C 1 -C16 alkynyl; or -C 3 -C 16 cycloalkyl; -(CH 2 ) ⁇ -6-Z ⁇ ; -(CH 2 ) 0 - 6 -phenyl; and -(CH 2 ) 0 - 6 -het, wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
  • Z is -N(R 8 )-C(O)-d-C 10 alkyl; -N(R 8 )-C(O)-(CH 2 ) 1 - 6 -C 3 -C 7 cycloalkyl; -N(R 8 )-C(O)- (CH 2 )o- 6 -phenyl; -N(R 8 )-C(O)-(CH 2 ) ⁇ - 6 -het; -C(O)-N(R 9 )(R ⁇ 0 ); -C(O)-O-d-C 10 alkyl; - C(O)-O-(CH 2 ) ⁇ - 6 -C 3 -C 7 cycloaIkyl; -C(O)-O-(CH 2 )o- 6 -phenyl; -C(O)-O-(CH 2 ) ⁇ - 6 -het; -O- C(O)-C ⁇ -C ⁇ oalkyl; -O
  • het is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon atom by halogen, hydroxy, C ⁇ -C 4 alkyl, C ⁇ -C 4 alkoxy, nitro, -O-C(O)-d- C 4 alkyl or -C(O)-O-C 1 -C 4 -alkyl or on a nitrogen by d-C 4 alkyl, -O-C(O)-d-C 4 alkyl or -C(O)-O-d-C 4 alkyl;
  • R 8 is H, -CH 3 , -CF 3 , -CH 2 OH or -CH 2 CI;
  • Rg and R 10 are each independently H; C ⁇ -C alkyl; C 3 -C 7 cycloalkyl; -(CH 2 ) ⁇ - 6 -C 3 - C 7 cycloalkyl; -(CH 2 ) 0 - 6 -phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or Rg and R 10 together with the nitrogen form het;
  • R 5 is H; C ⁇ -C ⁇ o-alkyl; C 3 -C 7 cycloalkyl; -(CH 2 ) ⁇ - 6 -C 3 -C 7 cycloalkyl; -d-doalkyl-aryl; -
  • n 0-5;
  • X is -CH or N;
  • Ra and Rb are independently an O, S, or N atom or C 0 - 8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
  • alkyl may be unsubstituted or substituted
  • Rd is selected from: (a) -Re - Q - (Rf) p (Rg) q ; or (b) An-D- Ar 2 ;
  • Re is H or Rd and Re together form cycloalkyl or het; where if Rd and Re form a cycloalkyl or heteroring, R 5 is attached to the formed ring at a C or N atom; p and q are independently 0 or 1 ;
  • Re is C- ⁇ - 8 alkyl, or alkylidene, preferably methylidene, and Re rriay be unsubstituted or substituted;
  • Q is N, O, S, S(O), or S(O) 2 ;
  • An and Ar 2 are substituted or unsubstituted aryl or het;
  • Rf and Rg are each independently H; -C 1 -C 10 alkyl; d-C ⁇ 0 alkylaryl; -OH; -O-d-
  • D is -CO-; -C(O)-d- 7 alkylene or arylene; -CF 2 -; -O-; -S(O) r where r is 0-2; 1 ,3dioaxolane; or d- alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-d-C ⁇ alkyl, -S-d- C 6 alkyl or -CF 3 ; or D is -N(Rh) wherein Rh is H; d- 7 alkyl (unsub or substituted); aryl; -O(d- 7 cycloalkyl) (unsub or substituted); C(O)-d-C ⁇ oalkyl; C(O)-C o -C 10 alkyl- aryl; C-O-d-C 10 alkyl; C-O-C 0 -C 10 alky
  • R ⁇ , R7, R' ⁇ and R' 7 are each independently H; -C 1 -C 10 alkyl; -C 1 -C 10 alkoxy; aryl-Ci- C 0 alkoxy; -OH; -O-d-C 10 alkyl; -(CH 2 )o- 6 -C 3 -C 7 cycloalkyl; -O-(CH 2 ) 0 - 6 -aryl; phenyl; - (CH 2 ) ⁇ - 6 -het; -0R 11 ; -C(0)-R 11 ; -C(O)-N(Rn)(R 12 ); -N(Rn)(R 12 ); -S- R11; -S(O)-Rn; -S(O) 2 -R ⁇ ; -S(O) 2 -NRnR 12 ; -NRn-S(O) 2 - R12; wherein alkyl, cycloalkyl and
  • R11 and R12 are independently H; C 1 -C 10 alkyl; -(CH 2 )o-6-C 3 -C 7 cycloalkyl; -(CH 2 )o- 6 - (CH) 0 -i(aryl) 1 - 2 ; -C(O)-d-C 10 alkyl; -C(O)-(CH 2 ) ⁇ - 6 -C 3 -C 7 cycloalkyl; -C(O)-O-(CH 2 )o- 6 - aryl; -C(O)-(CH 2 )o- 6 -O-fluorenyl; -C(O)-NH-(CH 2 )o- 6 -aryl; -C(O) (CH 2 )o- 6 -aryl; -C(O)- -C(S)-C ⁇ -C ⁇ oalkyl; -C(S)-(CH 2 ) 1 - 6 -C 3 -C 7
  • phenyl or aryl of Rn and R 12 may be unsubstituted or substituted by one or more substituents selected from halogen, hydroxy, d-C 4 alkyl, C 1 -C 4 alkoxy, nitro,
  • a further embodiment the present invention relates to the use of compound of formula I in the treatment of proliferative diseases, especially those dependent on the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs), or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of compounds of formula (I) in the treatment of said diseases, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said diseases, compounds of formula (I) for use in the treatment of said diseases.
  • lAPs Inhibitor of Apoptosis Proteins
  • One embodiment of the present invention relates to compounds of the formula (I) wherein
  • Ri and R 2 are independently H or substituted or unsubstituted C ⁇ -C 4 alkyl
  • R 4 is d-C- 16 straight or branched alkyl, or C 3 -C ⁇ 0 cycloalkyl, wherein the alkyl or cycloalkyl may be unsubstituted or substituted;
  • R 5 is H; C ⁇ -C 10 alkyl; d-doalkyl-aryl; -C(O)-(CH 2 )o- 6 -Phenyl; -(CH 2 )o- 6 -C(O)- Phenyl; aryl; indanyl; naphthyl or R 5 is a residue of an amino acid, wherein the alkyl or aryl substituents are unsubstituted or substituted;
  • n 0-5;
  • X is -CH or N
  • Ra and Rb are independently an O, S, or N atom or Co- 8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
  • alkyl may be unsubstituted or substituted
  • Rd is selected from (a) -Re - Q - (Rf) p (Rg) q ; or (b) Ar ⁇ -D- Ar 2 ;
  • Re is H or Re and Rd together form cycloalkyl or het; where if Rd and Re form a cycloalkyl or heteroring, R 5 is attached to the formed ring at a C or N atom; p and q are independently 0 or 1 ;
  • Re is C- ⁇ - 8 alkyl, or methylidene which may be unsubstituted or substituted;
  • Q is N, O, S, S(O), or S(O) 2 ;
  • An and Ar 2 are substituted or unsubstituted aryl or het;
  • Rf and Rg are each independently H or substituted or unsubstituted Co-C 10 alkyl; C 1 -
  • Cioalkylaryl aryl-d-C 10 alkyl; het-d-C 10 alkyl -C(O)-d-C 4 -alkyl-phenyl; -C(O)-d-C 4 - alkyl; -SO 2 -C 1 -C 2 alkyl; -SO 2 -C C 2 alkylphenyl; -O-d-C 4 -alky;
  • D is -C(O)-; d- 7 alkylene or arylene; -O-, or -S(O) r where r is 0-2; where alkyl, alkylene or arylene which may be unsubstituted or substituted r vvith one or more halogens; -OH; -O-d-C 6 alkyl; -S-C C 6 alkyl or -CF 3 ; or D is NRh wherein Rh is H; C 1 - 7 alkyl (unsubtituted or substituted); aryl; -OC ⁇ - 7 cycloalkyl (unsubstituted or substituted); -CO-C 0 . ⁇ o alkyl or aryl or SO 2 -C 0 - ⁇ o -alkyl or aryl; and R 6> R ⁇ , R' ⁇ and R' 7 are each independently H, -d-Cio alkyl, or -OH, alkoxy, or
  • U is a bicyclic saturated or unsaturated ring system, consisting of all carbon skeleton or with one or more heteroatoms such as O, N, S but preferably as shown in structure III:
  • any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R 6 , R 7 , R & and R 7 ';
  • X is CH or N
  • V is O, F 2 , Cl 2 , Br 2 , l 2 , S, YH, H 2) NH, or d-C 4 alkyl;
  • W is -CH, or -N; n is 0-3; and m is 0-3.
  • the ring atoms may be substituted with subsituents independently selected from halo, H, OH, lower alkyl or lower alkoxy, wherein alkyl or alkoxy are unsubstituted or substituted by halogen, OH, lower alkyl or lower alkoxy.
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H; methyl; ethyl; chloromethyl; diehloromethyl or trifluoromethyl;
  • R 4 is -C ⁇ -C alkyl; -C 3 -C 7 cycloalky; -(CH ) ⁇ - 6 cycloalkyl; or -(CH )o- 6 aryl.
  • R4 is particularly ethyl; propyl; isopropyl; t-butyl; cyclopentyl; or cyclohexyl; -CH 2 - cyclopentyl; -CH 2 -cyclohexyl or -CH 2 -phenyl.
  • R 5 is -d-dalkyl-phenyl; -C(O)-d-C 4 alkyl-phenyl; -C 1 -C 4 alkyI-C(O)-pheny or aryl; R 5 is particularly phenylmethyl, phenylethyl and phenylpropyl; indanyl, naphthyl; -C(O) -
  • R 6 and R are H or methyl
  • any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for Re, R 7 , Re- and R 7 ';
  • X is N
  • V is O or H 2 ;
  • W is -N; n is 1; and m is 1 or 2.
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is H
  • R is d-C alkyl; C 3 -C 7 cycloalkyl; C 1 -C 7 cycloalkyl-C 1 .C 7 alkyl; phenyl-C ⁇ .C alkyl or aryl.
  • R is particularly methyl; ethyl; butyl; isopropyl; t-butyl; or cyclohexyl; -CH 2 - cyclopentyl; -CH 2 -cyclohexyl; -CH -cyclopropyl; phenyl or -CH 2 -phenyl;
  • R 5 is -d-dalkyl-phenyl; -C(O)-d-C 4 alkyl-phenyl; -C C 4 alkyl-C(O)-pheny or aryl.
  • R 5 is particularly phenylethyl; indanyl, naphthyl; -C(O) -CH 2 -phenyl; -CH 2 -C(O)-phenyl or (CF 3 O)phenylethyl;
  • R 6 , R'e. R and R are H;
  • U has the structure of formula III wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R 6 , R 7 , R ⁇ ' and R 7 ';
  • X is N
  • V is O or H 2 ;
  • W is -N; n is 1 ; and m is 1 or 2.
  • Another embodiment is directed to a compound of formula (I) wherein
  • Ri and R3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-dalkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R 5 is H
  • X is N
  • Re, R'e, Ry, and R' 7 are H; n is O;
  • An and Ar 2 are substituted or unsubstituted phenyl or het particularly tetrazolyl, 1 ,
  • Another embodiment is directed to a compound of formula (I) wherein
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is CrC 4 alkyl; C 3 -C 7 cycloalkyl; C 1 -C 7 cycloalkyl-d-C 7 alkyl; phenyl-d-C 7 alkyl or aryl.
  • R 4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH 2 - cyclopentyl, -CH 2 -cyclohexyl; -CH 2 -cyclopropyl; phenyl or -CH 2 -phenyl;
  • X is N
  • R'e, R7, and R' 7 are H; or R 6 is -C(O)-C 1 -C alkyl-phenyl and R' 6 , R7. and R' 7 are
  • An and Ar 2 are substituted or unsubstituted phenyl or het, particularly triazine, pyrimidine, pyridine, oxazole, 2,4-difluorophenyl, Cl-phenyl or fluorophenyl; and D is
  • Rh is H, Me, -CHO, -SO 2 , -C(O), -CHOH, -CF 3 or -SO 2 CH 3 .
  • Another embodiment is directed to a compound of formula (I) wherein
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-C 4 alkyl; C 3 -C 7 cycloa!kyl; C ⁇ .C 7 cycloalkyl- C ⁇ .C 7 alkyl; phenyl-C ⁇ -C 7 alkyl or aryl.
  • R is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH 2 - cyclopentyl, -CH 2 -cyclohexyl; -CH 2 -cyclopropyl; phenyl or -CH 2 -phenyl;
  • R 5 is H
  • X is N
  • Re, R'e, R7, and R' 7 are H; n is O;
  • Rc is H
  • a and Ar 2 are substituted or unsubstituted phenyl or het particularly pyrimidine, pyridine, oxazole, 2-methyloxazole; and D is -O-.
  • Another embodiment is directed to a compound of formula (I) wherein
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-dalkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R 5 is H;
  • U has the structure of formula II wherein X is N;
  • Re, R'e, R7, and R' 7 are H; n is O; Re is H;
  • An and Ar 2 are substituted or unsubstituted phenyl or het; and D is S, S(O), or S(O) 2 .
  • Another embodiment is directed to a compound of formula (I) wherein R-i and R 3 are preferably methyl or ethyl;
  • R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is Ci-dalkyl or C 3 -C cycloalkyI particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R 5 is H;
  • U has the structure of formula II wherein X is N;
  • Re, R'e, R7, and R' 7 are H; n is O; Re is H;
  • Ari and Ar 2 are substituted or unsubstituted phenyl or het, particularly oxazole, thaizole and ozadiazole; and D is C(O), or 1 ,3-dioxolane.
  • Another embodiment is directed to a compound of formula (I) wherein
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-dalkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R 5 is H or phenyl C C ⁇ oalkyl such as phenylethyl
  • U has the structure of formula II wherein X is N;
  • Re, R'e, R7, and R' 7 are H; n is O;
  • Re and Rd are a heterocyclic ring, particularly pyrrolidine; pyrrolidin-2-one; or pyrrolidin-3-one.
  • Another embodiment is directed to a compound of formula (I) wherein
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R is d-C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R 5 is H, indanyl or phenyl
  • X is N
  • Re, R'e, R7, and R' 7 are H; n is O;
  • Re is d alkyl; and p and q are 0.
  • a further embodiment is directed to a compound of formula (I) wherein
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-C alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R 5 is H, indanyl or phenyl
  • X is N
  • Re, R'e, R7, and R' 7 are H; n is O; Re is Ci alkyl; and
  • R g is H C ⁇ -C 8 alkyl, methyl, ethyl, hexyl, heptyl, octyl; or CH CF 3 ; or aryl-C ⁇ -C 4 alkyl particularly phenylethyl, furanylethyl; d-dcycloalkyl particularly cyclohexyl; ethylphenyl; -C(O)-d-C 4 aIkyl-phenyl; -C(O)-C 1 -C 4 alkyl; -C 1 -C 4 alkyl-aryl particularly -
  • R f is d-C 2 alkyl; d-C 2 alkylphenyl; -SO 2 -C 1 -C 2 alkyl; -SO 2 -C C 2 alkylphenyl; -O-
  • CrC alkyl particularly O-ethyl; phenyl-phenyl, 1 ,2,3,4-tetrahydronapthalene and indanyl.
  • a further embodiment is directed to a compound of formula (I) wherein
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-C alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R5 is H, indanyl or phenyl
  • X is N
  • Re, R'e, R7, and R' 7 are H; n is O;
  • Re is C 1 alkyl
  • R g and R f form a ring selected from het or aryl particularly 2,3,4,5- tetrahydrobenzo[c]azepine; 1 ,2,3,4 tetrahydroquinoline; indanyl which may be substituted with C ⁇ -C 4 alkylphenyl
  • a further embodiment is directed to a compound of formula (I) wherein
  • R-i and R 3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-C 4 alkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R 5 is phenyl;
  • X is N
  • Q is O, S, S(O) or S(O) 2 ;
  • R 6> R' 6 ⁇ R 7> and R' 7 are H; n is O;
  • Re Ci alkyl
  • q 0;
  • Re is H; and R f is C 2 alkyl.
  • a further embodiment is directed to a compound of formula (I) wherein
  • Ri and R3 are preferably methyl or ethyl
  • R 2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
  • R 4 is d-dalkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R5 is phenyl
  • X is N
  • Re, R'e, R7, and R' 7 are H; n is O;
  • Re is CH; q is 0;
  • Re is H; and R f is OC 1 alkyl.
  • R 3 and R 4 have the stereochemistry indicated in formula IV, with the definitions of the variable substituents and preferences described herein above also applying to compounds having the stereochemistry indicated in formula IV.
  • Ri and R 3 are preferably methyl or ethyl
  • R 2 is H, methyl, ethyl, or substituted methyl especially chloromethyl, diehloromethyl and trifluoromethyl; preferably R 2 is H or unsubstituted methyl;
  • R4 is d-dalkyl or C 3 -C 7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
  • R5 is -C ⁇ -C -alkyl-phenyl, particularly phenylmethyl, phenylethyl and phenylpropyl, indanyl, naphthyl;
  • Re and R 7 are H or methyl.
  • R 6 , R7, Res and Ry is H. If one of R 6 , R 7 , R & , and R 7 > is other than H, it is especially hydroxyl or phenoxy.
  • KOTMS is defined as potassium trimethysilanoate.
  • PG benzyl or benzylic protecting group
  • Step A This step involves the formation of an aziridine ring via standard base mediated conditions.
  • Step B This step involves the formation of a secondary amine via the reaction of an alkyl bromide with excess amine in the presence of a base.
  • Step C This step involves the coupling of a secondary amine with an activated derivative of the aziridine methyl ester to form an amide substituted aziridine.
  • Step D This step involves the intramolecular cycloaddition of the aziridine to the tethered alkene through a thermally accessible azomethine ylide intermediate.
  • Step E This step involves the reduction of the amide to an amine via standard reduction conditions employing DIBAL-H.
  • Step F This step involves the removal of the benzylic protecting group using standard palladium conditions under a hydrogen atmosphere.
  • Step G This step involves coupling of the scaffold with a f-Boc protected natural or unnatural amino acid using standard peptide coupling conditions followed by the removal of the f-Boc group with TFA.
  • Step H This step involves the coupling of the amine generated in the preceding step with a f-Boc protected or tertiary natural or unnatural amino acid using standard peptide coupling conditions followed by the removal of the f-Boc group with TFA if applicable. The product is then purified by high-performance liquid chromatography (HPLC).
  • HPLC high-performance liquid chromatography
  • the compounds of the present invention are useful for treating proliferative diseases.
  • the present invention further relates to a method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of the invention to a mammal, preferably a human, in need of such treatment.
  • a proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases).
  • the inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or (iii)
  • a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • the inventive compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
  • the compounds of the present invention may be administered alone or in combination with other anticancer agents, such as compounds that inhibit tumor angiogenesis, for example, the protease inhibitors, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors and the like; cytotoxic drugs, such as antimetabolites, like purine and pyrimidine analog antimetabolites; antimitotic agents like microtubule stabilizing drugs and antimitotic alkaloids; platinum coordination complexes; anti-tumor antibiotics; alkylating agents, such as nitrogen mustards and nitrosoureas; endocrine agents, such as adrenocorticosteroids, androgens, anti-androgens, estrogens, anti-estrogens, aromatase inhibitors, gonadotropin-releasing hormone agonists and somatostatin analogues and compounds that target an enzyme or receptor that is overexpressed and/or otherwise involved a specific metabolic pathway that is upregulated in the tumor cell
  • the present invention further relates to a method of promoting apoptosis in rapidly proliferating cells, which comprises contacting the rapidly proliferating cells with an effective apoptosis promoting amount of a non-naturally-occurring compound that binds to the Smac binding site of XIAP and/or clAP proteins.
  • the non- naturally-occurring compound a compound of present formula 1 or IV.
  • the present invention further relates to a method of treating or inhibiting myeloma, especially multiple myeloma.
  • myeloma as used herein relates to a tumor composed of cells of the type normally found in the bone marrow.
  • multiple myeloma as used herein means a disseminated malignant neoplasm of plasma cells which is characterized by multiple bone marrow tumor foci and secretion of an M component (a monoclonal immunoglobulin fragment), associated with widespread osteolytic lesions resulting in bone pain, pathologic fractures, hypercalcaemia and normochromic normocytic anaemia. Multiple myeloma is incurable by the use of conventional and high dose chemotherapies.
  • the invention relates to a method of treating myeloma, especially myeloma which is resistant to conventional chemotherapy.
  • compositions comprising a compound of formula I, to their use in the therapeutic (in a broader aspect of the invention also prophylactic) treatment or a method of treatment of a kinase dependent disease, especially the preferred diseases mentioned above, to the compounds for said use and to pharmaceutical preparations and their manufacture, especially for said Uses.
  • the present invention also relates to pro-drugs of a compound of formula I that convert in vivo to the compound of formula I as such. Any reference to a compound of formula 1 is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula I, as appropriate and expedient.
  • pharmacologically acceptable compounds of the present invention may be present in or employed, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula I, or a pharmaceutically ac- ceptable salt thereof, as active ingredient together or in admixture with one or more inorganic or organic, solid or liquid, pharmaceutically acceptable carriers (carrier materials).
  • compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier.
  • the dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • the invention relates also to a method of treatment for a disease that responds to inhibition of a protein kinase and/or a proliferative disease, which comprises administering a (against the mentioned diseases) prophylactically or especially therapeutically effective amount of a compound of formula I according to the invention, or a tautomer thereof or a pharmaceutically acceptable salt thereof, especially to a warm-blooded animal, for example a human, that, on account of one of the mentioned diseases, requires such treatment.
  • the dose of a compound of the formula I or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals preferably is from approximately 3 mg to approximately 10 g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1000 mg /person/day, divided preferably into 1-3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
  • compositions comprise from approximately 1 % to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
  • Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
  • compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
  • a compound of the formula I may also be used to advantage in combination with other antiproliferative agents.
  • antiproliferative agents include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active agents; alkylating agents; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; tel
  • aromatase inhibitor as used herein relates to a compound which inhibits the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively.
  • the term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole.
  • Exemestane can be administered, e.g., in the form as it is marketed, e.g.
  • AROMASIN Formestane can be administered, e.g., in the form as it is marketed, e.g. under the trademark LENTARON. Fadrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark AFEMA. Anastrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark ARIMIDEX. Letrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark FEMARA or FEMAR. Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g. under the trademark ORIMETEN.
  • a combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g. breast tumors.
  • antiestrogen as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level.
  • indydes but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.
  • Tamoxifen can be administered, e.g., in the form as it is marketed, e.g. under the trademark NOLVADEX.
  • Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g. under the trademark EVISTA.
  • Fulvestrant can be formulated as disclosed in US 4,659,516 or it can be administered, e.g., in the form as it is marketed, e.g. under the trademark FASLODEX.
  • a combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g. breast tumors.
  • anti-androgen as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g. as disclosed in US 4,636,505.
  • gonadorelin agonist includes, but is not limited to abarelix, goserelin and goserelin acetate.
  • Goserelin is disclosed in US 4,100,274 and can be administered, e.g., in the form as it is marketed, e.g. under the trademark ZOLADEX.
  • Abarelix can be formulated, e.g. as disclosed in US 5,843,901.
  • topoisomerase I inhibitor includes, but is not limited to topo- tecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO99/ 17804).
  • Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark CAMPTOSAR.
  • Topotecan can be administered, e.g., in the form as it is marketed, e.g. under the trademark HYCAMTIN.
  • topoisomerase II inhibitor includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, e.g. CAELYX), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide.
  • Etoposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark ETOPOPHOS.
  • Teniposide can be administered, e.g. in the form as it is marketed, e.g.
  • Doxorubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ADRIBLASTIN or ADRIAMYCIN.
  • Epirubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark FARMORUBICIN.
  • Idarubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZAVEDOS.
  • Mitoxantrone can be administered, e.g. in the form as it is marketed, e.g. under the trademark NOVANTRON.
  • microtubule active agent relates to microtubule stabilizing, microtubule destabilizing agents and microtublin polymerization inhibitors including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca alkaloids, e.g., vinblastine, especially vin- blastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermo- lides, cochicine and epothilones and derivatives thereof, e.g. epothilone B or D or derivatives thereof.
  • Paclitaxel may be administered e.g. in the form as it is marketed, e.g. TAXOL.
  • Docetaxel can be administered, e.g., in the form as it is marketed, e.g. under the trademark TAXOTERE.
  • Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark VINBLASTIN R.P..
  • Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark FARMISTIN.
  • Discodermolide can be obtained, e.g., as disclosed in US 5,010,099.
  • Epothilone derivatives which are disclosed in WO 98/10121 , US 6,194,181 , WO 98/25929, WO 98/08849, WO 99/43653, WO 98/22461 and WO 00/31247. Especially preferred are Epothilone A and/or B.
  • alkylating agent includes, but is not limited to, cyclophospha- mide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel).
  • Cyclophosphamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark CYCLO- STIN.
  • Ifosfamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark HOLOXAN.
  • histone deacetylase inhibitors or "HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO 02/22577, especially N-hydroxy-3-[4-[[(2- hydroxyethyl)[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N- hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2- propenamide and pharmaceutically acceptable salts thereof. It further especially includes Suberoylanilide hydroxamic acid (SAHA).
  • SAHA Suberoylanilide hydroxamic acid
  • anti-plastic antimetabolite includes, but is not limited to, 5-Fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating agents, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed.
  • Capecitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark XELODA.
  • Gemcitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark GEMZAR.
  • the monoclonal antibody trastuzumab which can be administered, e.g., in the form as it is marketed, e.g. under the trademark HERCEPTIN.
  • platinum compound as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin.
  • Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark CARBOPLAT.
  • Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATIN.
  • the term "compounds targeting/decreasing a protein or lipid kinase activity and further anti- angiogenic compounds” as used herein includes, but is not limited to: protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g.: a) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGF-Rs); b) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the IGF-IR receptor, such as those compounds disclosed in WO 02/092599; c) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family; d) compounds targeting, decreasing or inhibiting the activity of the Axl receptor tyrosine kinase family;
  • examples of further compounds include e.g. UCN-01 , safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521 ; LY333531/LY379196; isochinoline compounds such as those disclosed in WO 00/09495; FTIs; PD184352 or QAN697 (a P13K inhibitor); g) compounds targeting, decreasing or inhibiting the activity of a protein-tyrosine kinase, such as imatinib mesylate (GLIVEC/GLEEVEC) or tyrphostin.
  • a protein-tyrosine kinase such as imatinib mesylate (GLIVEC/GLEEVEC) or tyrphostin.
  • a tyrphostin is preferably a low molecular weight (Mr ⁇ 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S-arylbenzenemalonirile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG- 50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4- ⁇ [(2,5-dihydroxyphenyl)methyl]amino ⁇ -benzoic acid adamantyl ester; NSC 680410, adaphostin); and h) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of
  • EGF receptor ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO 97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, US 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/30347 (e.g. compound known as CP 358774), WO 96/33980 (e.g.
  • compound ZD 1839 and WO 95/03283 (e.g. compound ZM105180); e.g. trastuzumab (HERCEPTIN), cetuximab, Iressa, Tarceva, CI-1033, EKB-569, GW-2016, E1.1 , E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO 03/013541.
  • trastuzumab HERCEPTIN
  • cetuximab cetuximab
  • Iressa Iressa
  • Tarceva Tarceva
  • CI-1033 EKB-569
  • GW-2016 E1.1 , E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO 03/013541.
  • anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e.g. thalidomide (THALOMID) and TNP-470.
  • Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1 , phosphatase 2A, PTEN or CDC25, e.g. okadaic acid or a derivative thereof.
  • Compounds which induce cell differentiation processes are e.g. retinoic acid, ⁇ - ⁇ - or ⁇ - tocopherol or ⁇ - ⁇ - or ⁇ -tocotrienol.
  • cyclooxygenase inhibitor includes, but is not limited to, e.g. Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2-aryl- aminophenylacetic acid, e.g. 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
  • Cox-2 inhibitors e.g. Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2-aryl- aminophenylacetic acid, e.g. 5-methyl-2-(2'-ch
  • mTOR inhibitors relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (Rapamune®), everolimus (CerticanTM), CCI-779 and ABT578.
  • bisphosphonates as used herein includes, but is not limited to, etridonic, clo- dronic, tiludronic, pamidronic, alendronic, ibandronic, risedronie and zoledronic acid.
  • Etridonic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark DIDRONEL.
  • Clodronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONEFOS.
  • titaniumudronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark SKELID.
  • “Pamidronic acid” can be administered, e.g. in the form as it is marketed, e.g. under the trademark AREDIATM.
  • “Alendronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark FOSAMAX.
  • “Ibandronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONDRANAT.
  • “Risedronie acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark ACTONEL.
  • "Zoledronic acid” can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZOMETA.
  • the term "heparanase inhibitor” as used herein refers to compounds which target, decrease or inhibit heparin sulphate degradation. The term includes, but is not limited to, PI-88.
  • biological response modifier refers to a lymphokine or inter- ferons, e.g. interferon ⁇ .
  • inhibitor of Ras oncogenic isoforms e.g. H-Ras, K-Ras, or N-Ras
  • H-Ras, K-Ras, or N-Ras refers to compounds which target, decrease or inhibit the oncogenic activity of Ras e.g. a "famesyl transferase inhibitor”, e.g. L-744832, DK8G557 or R115777 (Zamestra).
  • telomerase inhibitor refers to compounds which target, decrease or inhibit the activity of telomerase.
  • Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g. telomestatin.
  • methionine aminopeptidase inhibitor refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase.
  • Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are e.g. bengamide or a derivative thereof.
  • proteasome inhibitor refers to compounds which target, de- crease or inhibit the activity of the proteasome.
  • Compounds which target, decrease or inhibit the activity of the proteasome include e.g. PS-341 and MLN 341.
  • matrix metalloproteinase inhibitor or (“MMP inhibitor”) as used herein includes, but is not limited to collagen peptidomimetie and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g. hydroxamate peptidomimetie inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251 , BAY 12-9566, TAA211 , MMI270B or AAJ996.
  • MMP inhibitor matrix metalloproteinase inhibitor
  • agents used in the treatment of hematologic malignancies includes, but is not limited to FMS-like tyrosine kinase inhibitors e.g. compounds tar- geting, decreasing or inhibiting the activity of Flt-3; interferon, 1-b-D- arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors e.g. compounds which target, decrease or inhibit anaplastic lymphoma kinase.
  • FMS-like tyrosine kinase inhibitors e.g. compounds tar- geting, decreasing or inhibiting the activity of Flt-3
  • ALK inhibitors e.g. compounds which target, decrease or inhibit anaplastic lymphoma kinase.
  • the term "compounds which target, decrease or inhibit the activity of Flt-3” are especially compounds, proteins or antibodies which inhibit Flt-3, e.g. PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
  • HSP90 inhibitors includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteasome pathway.
  • Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90 e.g.,17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.
  • antiproliferative antibodies includes, but is not limited to trastuzumab (HerceptinTM), Trastuzumab-DM1 , erlotinib (TarcevaTM), bevacizumab (AvastinTM), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 Antibody.
  • trastuzumab HerceptinTM
  • Trastuzumab-DM1 erlotinib
  • TarcevaTM bevacizumab
  • AvastinTM bevacizumab
  • rituximab Renuxan®
  • PRO64553 anti-CD40
  • compounds of formula I can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML.
  • compounds of formula I can be administered in combination with e.g. farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
  • drugs useful for the treatment of AML such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
  • the structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).
  • a compound of the formula I may also be used to advantage in combination with known therapeutic processes, e.g., the administration of hormones or especially radiation.
  • a compound of formula I may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
  • ком ⁇ онент there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula I and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g. synergistic, effect, or any combination thereof.
  • the organic layer is dried and concentrated under vacuum.
  • the residue is purified by flash chromatography (silica gel; Hexane/EtOAc 1 :9) to provide a yellow oil.
  • the yellow oil is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 h.
  • the mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate.
  • the solution is extracted with dichloromethane (3x50 mL).
  • the organic extracts are combined, dried and concentrated under vacuum to provide1.75 g (79% two steps) of the title compound which is used in next step without further purification or characterization.
  • the LDA solution is cooled to -70 °C and added to a solution of [But-3-enyl-((S)-1-phenyl-ethyl)-amino]- acetic acid ethyl ester(7.8 g, 29.8 mmol) in THF(80 mL) slowly at -70 °C.
  • the light yellowish reaction solution is stirred at -20 °C for 30 min to become a deep yellow solution, and then cooled to -70 °C.
  • reaction solution After stirring at RT for 1.5hrs, the reaction solution is cooled to 0 °C and added a solution of CuCN(3.47 g, 38.74 mmol) and LiCI(3.29 g, 77.48 mmol) in THF(80 mL) slowly. After stirring at 0 °C for 10 min, allyl bromide(7.26 g, 60 mmol) is added dropwise to the reaction solution, and warmed very slowly to r.t.. After stirring overnight at r.t., the reaction is quenched by addition of 60 mL of saturated NH 4 CI and extracted with 3X150 mL of ether. The combined organic layers is concentrated.
  • Ozone gas is bubbled though the solution for about 10 min or until the solution is turned very light blue color.
  • the nitrogen gas is bubbled though the solution for 15 min to remove excess ozone in the solution.
  • To the cool solution is added Zn dust(0.43 g. 6.6 mmol) and HCI(0.5 mL, 37%), and stirred at r.t. for 20 min. After filtration the solution is diluted with 50 mL of CH 2 CI 2 and washed with saturated NaHCO 3 (10 mL) and 2 x 20 ml of water. After dried and concentrated, a colorless liquid(1.0 g) is obtained without further purification for next step reaction. (NMR and MS data confirmed, U-4117-51 - 30).
  • the residue is purified by flash chromatography (silica gel; Hexane/EtOAc 4:1) to provide a yellow oil.
  • the yellow oil is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 h.
  • the mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate.
  • the solution is extracted with dichloromethane (3x50 mL).
  • the organic extracts are combined, dried and concentrated under vacuum to provide1.04 g (68% two steps) of the title compound E which is used in the next step without further purification or characterization.
  • Example 4 Compound 32 is prepared as follows:
  • an ELISA and a cell based assays are utilized.
  • Elisa Compounds are incubated with GST-BIR3 fusion protein and biotinylated SMAC peptide (AVPFAQK) in stretavidin-coated 96 well plates.
  • AVPFAQK biotinylated SMAC peptide
  • XIAP BIR3 Smac Elisa a GST-BIR3 fusion containing amino acids 248-358 from XIAP is used.
  • CIAP1 BIR3 Smac Elisa a GST-BIR3 fusion containing amino acids 259-364 from CIAP1 is used. Following a 30 minute incubation, wells are extensively washed.
  • the remaining GST-BIR3 fusion protein is monitored by ELISA assay involving first, incubation with goat anti-GST antibodies followed by washing and incubation with alkaline phosphatase conjugated anti-goat antibodies. Signal is amplified using Attophos (Promega) and read with Cytoflour Ex 450nm/40 and Em 580nm.
  • IC 50 S correspond to concentration of compound which displaces half of GST-BIR3 signal.
  • the IC 50 for non-biotinylated Smac is 400 nM.
  • the IC 50 values of compounds listed in Table 1 in the described ELISA assays ranged from 0.005 - 10 ⁇ M.
  • the ability of compounds to inhibit tumor cell growth in vitro is monitored using the CellTiter 96 ® AQ ue0 u s Non-Radioactive Cell Proliferation Assay (Promega).
  • This assay is composed of solutions of a novel tetrazolium compound [3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine methosulfate) PMS.
  • MTS is bioreduced by cells into a formazan product, the absorbance of which is measured at 490nm.
  • Tablets 1 comprising compounds of the formula (I)
  • Tablets comprising, as active ingredient, 50 mg of any one of the compounds of formula (I) mentioned in the preceding Examples 9-194 of the following composition are prepared using routine methods:
  • the active ingredient is combined with part of the wheat starch, the lactose and the colloidal silica and the mixture pressed through a sieve.
  • a further part of the wheat starch is mixed with the 5-fold amount of water on a water bath to form a paste and the mixture made first is kneaded with this paste until a weakly plastic mass is formed.
  • Example 197 The dry granules are pressed through a sieve having a mesh size of 3 mm, mixed with a pre-sieved mixture (1 mm sieve) of the remaining corn starch, magnesium stearate and talcum and compressed to form slightly biconvex tablets.
  • a sieve having a mesh size of 3 mm mixed with a pre-sieved mixture (1 mm sieve) of the remaining corn starch, magnesium stearate and talcum and compressed to form slightly biconvex tablets.
  • Tablets 2 comprising compounds of the formula (I)
  • Tablets comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) of Examples 9-194 are prepared with the following composition, following standard procedures:
  • Capsules comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) given in Examples 9-194, of the following composition are prepared according to standard procedures:
  • Manufacturing is done by mixing the components and filling them into hard gelatine capsules, size 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).

Description

INHIBITORS OF IAP
The present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs). The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
BACKGROUND
Programmed cell death plays a critical role in regulating cell number and in eliminating stressed or damaged cells from normal tissues. Indeed, the network of apoptotic signaling mechanisms inherent in most cell types provides a major barrier to the development and progression of human cancer. Since most commonly used radiation and chemo-therapies rely on activation of apoptotic pathways to kill cancer cells, tumor cells which are capable of evading programmed cell death often become resistant to treatment.
Apoptosis signaling networks are classified as either intrinsic when mediated by death receptor-ligand interactions or extrinsic when mediated by cellular stress and mitochondrial permeabilization. Both pathways ultimately converge on individual Caspases. Once activated, Caspases cleave a number of cell death-related substrates, effecting destruction of the cell.
Tumor cells have devised a number of strategies to circumvent apoptosis. One recently reported molecular mechanism involves the overexpression of members of the IAP (Inhibitor of Apoptosis) protein family. lAPs sabotage apoptosis by directly interacting with and neutralizing Caspases. The prototype lAPs, XIAP and clAP have three functional domains referred to as BIR 1 , 2 & 3 domains. BIR3 domain interacts directly with Caspase 9 and inhibits its ability to bind and cleave its natural substrate, Procaspase 3.
It has been reported that a proapoptotic mitochondrial protein, Smac (also known as DIABLO), is capable of neutralizing XIAP and/or clAP by binding to a peptide binding pocket (Smac binding site) on the surface of BIR3 thereby precluding interaction between XIAP and/or clAP and Caspase 9. The present invention relates to therapeutic molecules that bind to the Smac binding pocket thereby promoting apoptosis in rapidly dividing cells. Such therapeutic molecules are useful for the treatment of proliferative diseases, including cancer. In other words, Smac analogs would bind to BIR3 domain of lAPs and will remove the lAP's inhibition of activated Caspase 9 which would then go on to induce apoptosis.
Summary of the Invention
The present invention relates generally to novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs). The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action rely on the inhibition of the Smac/IAP interaction, and more particularly useful in therapies for the treatment of proliferative diseases, including cancer.
DETAILED DESCRIPTION
The present invention relates to compounds of the formula (1)
Figure imgf000004_0001
wherein
Ri is H; C1-C4 alkyl; Cι-C4 alkenyl; C-ι-C4 alkynyl or C3-Cι0cycloalkyl which are unsubstituted or substituted;
R2 is H; C1-C4 alkyl; Cι-C4 alkenyl; Cι-C alkynyl or C3-Cι0cycloalkyl which are unsubstituted or substituted;
R3 is H; -CF3; -C2F5; C C4 alkyl; C C4 alkenyl; d-C4 alkynyl; -CH2-Z or R2 and R3 together with the nitrogen form a het ring;
Z is H; -OH; F; Cl; -CH3; -CF3; -CH2CI; -CH2F or -CH2OH;
R4 is C1-C16 straight or branched alkyl; C-1-C16 alkenyl; C1-C-16 alkynyl; or -C3- C10cycloalkyl; -(CH2)ι-6-Zι; -(CH2)o-6-aryl; and -(CH2)o-6-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
Zi is -N(R8)-C(O)-C1-C10alkyl; -N(R8)-C(O)-(CH2)ι-6-C3-C7cycloalkyl; -N(R8)-C(O)- (CH2)o-6-phenyl; -N(R8)-C(O)-(CH2)ι-6-het; -C(O)-N(R9)(Rι0); -C(O)-O-Cι-C10alkyl; - C(O)-O-(CH2)ι-6-C3-C7cycloalkyl; -C(O)-O-(CH2)o-6-phenyl; -C(O)-O-(CH2)ι-6-het; -O- C(O)-C C10alkyl; -O-C(O)-(CH2)ι-6-C3-C7cycloalkyl; -O-C(O)-(CH2)o-6-phenyl; -O- C(O)-(CH2)ι-6-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted; het is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1 , 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon or nitrogen atom;
R8 is H; -CH3; -CF3 ; -CH2OH or -CH2CI;
R9 and R10 are each independently H; CrC-talkyl; C3-C7cycloalkyl; -(CH2)ι-6-C3- C7cycloalkyl; -(CH2)o-6-phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or R9 and R10 together with the nitrogen form het;
R5 is H; C-i-Cio-alkyl; aryl; phenyl; C3-C cycloalkyl; -(CH2)ι-6-C3-C7cycloalkyl; -Cr
C10alkyI-aryl; -(CH2)o-6-C3-C7cycloalkyl-(CH2)o-6-phenyl; -(CH2)o-4CH-((CH2)ι-4- phenyl)2; -(CH2)o-6-CH(phenyl)2; -indanyl;
Figure imgf000005_0001
-C(O)-(CH2)ι-6-C3-C7- cycloalkyl; -C(O)-(CH2)o-6-phenyl; -(CH2)o-6-C(O)-phenyl; -(CH2)0-6-het; -C(O)-(CH2)ι- 6-het; or R5 is a residue of an amino acid, wherein the alkyl, cycloalkyl, phenyl and aryl substituents are unsubstituted or substituted;
U is as shown in structure II:
Figure imgf000005_0002
wherein n = 0-5;
X is -CH or N;
Ra and Rb are independently an O, S, or N atom or C0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
O, S or N, and where the alkyl may be unsubstituted or substituted;
Rd is selected from: (a) -Re - Q - (Rf)p(Rg)q; or (b) AP,-D- Ar2; Re is H or Re and Rd may together form a cycloalkyl or het; where if Rd and Re form a cycloalkyl or het, R5 is attached to the formed ring at a C or N atom; p and q are independently 0 or 1 ;
Re is d-a alkyl or alkylidene, and Re which may be unsubstituted or substituted; Q is N, O, S, S(O), or S(O)2; An and Ar2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H; -d-C10alkyr, d-Cioalkylaryl; -OH; -O-d- Cioalkyl; -(CH2)o-6-C3-C7cycloalkyl; -O-(CH2)o-6-aryl; phenyl; aryl; phenyl-phenyl; - (CH2)ι-6-het; -O-(CH2)ι-6-het; -0R11 ; -C(O)-R1 i ; -C(O)-N(R11)(R12); -N(Rn)(R12); -S- R11; -S(O)-Rn; -S(O)2-Rnl -S(O)2-NRnR12; -NRn-S(O)2- R12; S-Cι-Cι0alkyl; aryl-d- C4alkyl; het-d-C4-alkyl wherein alkyl, cycloalkyl, het and aryl are unsubstituted or substituted; -SO2-C1-C2alkyl; -SO2.C1.C2alkylphenyl; -O-d-C4alkyl; or Rg and Rf form a ring selected from het or aryl;
D is -CO-; -C(O)-d-7 alkylene or arylene; -CF2-; -O-; -S(O)r where r is 0-2; 1 ,3dioaxolane; or Cι-7 alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-d-Cδalkyl, -S-d- Cβalkyl or -CF3; or D is -N(Rh) wherein Rh is H; d.7 alkyl (unsub or substituted); aryl; -O(C1.7cycloalkyl) (unsub or substituted); C(O)-d-C10alkχl; C(O)-Co-C10alkyl- aryl; C-O-Cι-C10alkyl; C-O-Co-Cι0alkyl-aryl or SO2-C1-Cι0-alkyl; SO2-(Co-Cι0- alkylaryl);
Re, R7, R'β and R'7 are each independently H; -Cι-C10 alkyl; -C1-C10 alkoxy; aryl-d- C10 alkoxy; -OH; -O-Cι-Cι0alkyl; -(CH2)o-6-C3-C7cycloalkyl; -O-(CH2)o-6-aryl; phenyl; - (CH2)ι-6-het; -O-(CH2)ι-6-het; -ORn; -C(O)-R1i ; -C(O)-N(Rn)(R12); -N(Rn)(Rι2); -S- Rn; -S(O)-Rn; -S(O)2-Rn; -S(O)2-NRnR12; -NRn-S(O)2- R12; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; and R6ι R7ι R'6 and R' can be united to form a ring system; R11 and Rι2 are independently H; d-Cio alkyl; -(CH2)o-6-C3-C7cycloalkyl; -(CH2)o-6-
Figure imgf000007_0001
-C(O)-d-C10alkyl; -C(O)-(CH2)ι-6-C3-C7cycloalkyl; -C(O)-O-(CH2)o-6- aryl; -C(O)-(CH2)o-6-O-fluorenyl; -C(O)-NH-(CH2)o-6-aryl; -C(O)-(CH2)0-6-aryl; -C(O)-
(CH2)i-6-het; -C(S)-d-C10alkyl; -C(S)-(CH2)1-6-C3-C7cycloalkyl; -C(S)-O-(CH2)0-6-aryl;
-C(S)-(CH2)o-6-0-fluorenyl; -C(S)-NH-(CH2)0-6-aryl; -C(S)-(CH2)0-6-aryl; -C(S)-(CH2)ι-6- het; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or R-u and R12 are a substituent that facilitates transport of the molecule across a cell membrane; or
R11 and R12 together with the nitrogen atom form het; wherein the alkyl substituents of Rn and R12 may be unsubstituted or substituted by one or more substituents selected from Cι-Cι0alkyl, halogen, OH, -O-Cι-C6alkyl, -S-
Cι-C6alkyl or -CF3; substituted cycloalkyl substituents of R-π and R12 are substituted by one or more substituents selected from a Cι-Cιo alkene; d-C6alkyl; halogen; OH; -O-Cι-C6alkyl; -
S-Cι-C6alkyl or -CF3; and substituted phenyl or aryl of Rn and R12 are substituted by one or more substituents selected from halogen; hydroxy; C1-C4 alkyl; d-C4 alkoxy; nitro; -CN; -O-C(O)-Cι- dalkyl and -C(O)-O-d-C4-aryl, or pharmaceutically acceptable salts thereof.
The present invention also related to the use of compound of formula I in the treatment of proliferative diseases, especially those dependent on the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs), or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of compounds of formula (I) in the treatment of said diseases, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said diseases, compounds of formula (I) for use in the treatment of said diseases.
The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated: "Aryl" is an aromatic radical having 6 to 14 carbon atoms, which may be fused or unfused, and which is unsubstituted or substituted by one or more, preferably one or two substituents, wherein the substituents are as described below. Preferred "aryl" is phenyl, naphthyl or indanyl.
"Het" refers to heteroaryl and heterocyclic rings and fused rings containing aromatic and non-aromatic heterocyclic rings. "Het" is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1 , 2 or 3 heteroatoms selected from N, O, and S. Suitable het substituents include unsubstituted and substituted pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1 ,4-diazapane, 1 ,4-oxazepane, 1 ,4-oxathiapane, furyl, thienyl, pyrrole, pyrazole, triazole, 1 ,2,3- triazole, tetrazolyl, oxadiazole, thiophene, imidazol, pyrrolidine, pyrrolidone, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, pyrazine, quinoline, isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole, benzofuran, benzothiofuran, benzindole, benzoxazole, pyrroloquinoline, and the like. The het substituents are unsubstituted or substituted on a carbon atom by halogen, especially fluorine or chlorine, hydroxy, C1-C4 alkyl, such as methyl and ethyl, d-C4 alkoxy, especially methoxy and ethoxy, nitro, -O-C(O)-Cι-C4alkyl or -C(O)-O-d-C4alkyl or on a nitrogen by d-C4 alkyl, especially methyl or ethyl, -O-C(O)-Cι:C4alkyl or -C(O)-O- Cι-C alkyl, such as carbomethoxy or carboethoxy.
When two substituents together with a commonly bound nitrogen are het, it is understood that the resulting heterocyclic ring is a nitrogen-containing ring, such as aziridine, azetidine, azole, piperidine, piperazine, morphiline, pyrrole, pyrazole, thiazole, oxazole, pyridine, pyrimidine, isoxazolyl, and the like.
Halogen is fluorine, chlorine, bromine or iodine, especially fluorine and chlorine. Unless otherwise specified "alkyl" includes straight or branched chain alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and branched pentyl, n-hexyl and branched hexyl, and the like.
A "cycloalkyl" group means C3 to Ciocycloalkyl having 3 to 8 ring carbon atoms and may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. Preferably, cycloalkyl is cycloheptyl. The cycloalkyl group may be unsubstituted or substituted with any of the substituents defined below, preferably halo, hydroxy or Cι-C4 alkyl such as methyl.
The amino acid residues include a residue of a standard amino acid, such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. The amino acid residues also include the side chains of uncommon and modified amino acids. Uncommon and modified amino acids are known to those of skill in the art (see for example G. B. Fields, Z. Tiam and G Barany; Synthetic Peptides A Users Guide, University of Wisconsin Biochemistry Center, Chapter 3, (1992)) and include amino acids such as 4-hydroxyproline, 5-hydroxylysine, desmosine, beta-alanine, alpha, gamma- and beta-aminobutric acid, homocysteine, homoserine, citrulline, omithine, 2- or 3-amino adipic acid, 6-aminocaproic acid, 2- or 3- aminoisobutric acid, 2,3-diaminopropionic acid, diphenylalanine, hydroxyproline and the like. If the side chain of the amino acid residue contains a derivatizable group, such as COOH, -OH or amino, the side chain may be derivatized by a substituent that reacts with the derivatizable group. For example, acidic amino acids, like aspartic and glutamic acid, or hydroxy substituted side chains, like those of serine or threonine, may be derivatized to form an ester, or amino side chains may form amide or alkylamino derivatives. In particular, the derivative may be a substituent that facilitates transport across a cell membrane. In addition, any carboxylic acid group in the amino acid residue, for example, an alpha carboxylic acid group, may be derivatized as discussed above to form an ester or amide. Substituents that facilitate transport of the molecule across a cell membrane are known to those of skill in the medicinal chemistry arts (see, for example, Gangewar S., Pauletti G. M.,Wang B., Siahaan T. J., Stella V. J., Borchardt R. T., Drug Discovery Today, vol. 2. p148-155 (1997) and Bundgaard H. and Moss J., Pharmaceutical Research, vol. 7, p 885 (1990)). Generally, such substituents are lipophillic substituents. Such lipophillic substituents include a C6-C30 alkyl which is saturated, monounsaturated, polyunsaturated, including methylene-interrupted polyene, phenyl, phenyl which substituted by one or two Cι-C8 alkyl groups, C5-C9 cycloalkyl, C5-C9 cycloalkyl which is substituted by one or two d-C8 alkyl groups, - Xrphenyl, -X^phenyl which is substituted in the phenyl ring by one or two Cι-C8 alkyl groups, X1-C5-C9 cycloalkyl or X1-C5-C9 cycloalkyl which is substituted by one or two Cι-C8 alkyl groups; where X1 is C1-C24 alkyl which is saturated, monounsaturated or polyunsaturated and straight or branched chain.
Unsubstituted is intended to mean that hydrogen is the only substituent.
Any of the above defined aryl, het, alkyl, cycloalkyl, or heterocyclic groups may be unsubstituted or independently substituted by up to four, preferably one, two or three substituents, selected from the group consisting of: halo (such as Cl or Br); hydroxy; lower alkyl (such as C1-C3 lower alkyl); lower alkyl which may be substituted with any of the substituents defined herein; lower alkenyl; lower alkynyl; lower alkanoyl; alkoxy (such as methoxy); aryl (such as phenyl or benzyl); substituted aryl (such as fluoro phenyl or methoxy phenyl); amino; mono- or disubstituted amino; amino lower alkyl (such as dimethylamino); acetyl amino; amino lower alkoxy (such as ethoxyamine); nitro; cyano; cyano lower alkyl; carboxy; esterified carboxy (such as lower alkoxy carbonyl e.g. methoxy carbonyl); n-propoxy carbonyl or iso-propoxy carbonyl; alkanoyl; benzoyl; carbamoyl; N-mono- or N,N-disubstituted carbamoyl; carbamates; alkyl carbamic acid esters; amidino; guanidine; urea; ureido; mercapto; sulfo; lower alkylthio; sulfoamino; sulfonamide; benzosulfonamide; sulfonate; sulfanyl lower alkyl (such as methyl sulfanyl); sulfoamino; substituted or unsubstituted sulfonamide (such as benzo sulfonamide); substituted or unsubstituted sulfonate (such as chloro-phenyl sulfonate); lower alkylsulfinyl; phenylsulfinyl; phenyl-lower alkylsulfinyl; alkylphenylsulfinyl; lower alkanesulfonyl; phenylsulfonyl; phenyl-lower alkylsulfonyl; alkylphenylsulfonyl; halogen-lower alkylmercapto; halogen-lower alkylsulfonyl; such as especially trifluoromethane sulfonyl; phosphono (-P(=O)(OH)2); hydroxy-lower alkoxy phosphoryl or di-lower alkoxyphosphoryl; substituted urea (such as 3-trifluoro-methyl-phenyl urea); alkyl carbamie acid ester or carbamates (such as ethyl-N-phenyl-carbamate) or -NR Rδ, wherein R4 and R5 can be the same or different and are independently H; lower alkyl (e.g. methyl, ethyl or propyl); or R and R5 together with the N atom form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms (e.g. piperazinyl, pyrazinyl, lower alkyl-piperazinyl, pyridyl, indolyl, thiophenyl, thiazolyl, n-methyl piperazinyl, benzothiophenyl, pyrrolidinyl, piperidino or imidazolinyl) where the heterocyclic ring may be substituted with any of the substituents defined herein.
Preferably the above mentioned alkyl, cycloalkyl, aryl or het groups may be substituted by halogen, carbonyl, thiol, S(O), S(O2), -OH, -SH, -OCH3, -SCH3> -CN, -SCN or nitro.
Where the plural form is used for compounds, salts, pharmaceutical preparations, diseases and the like, this is intended to mean also a single compound, salt, or the like.
It will be apparent to one of skill in the art when a compound of the invention can exist as a salt form, especially as an acid addition salt or a base addition salt. When a compound can exist in a salt form, such salt forms are included within the scope of the invention. Although any salt form may be useful in chemical manipulations, such as purification procedures, only pharmaceutically acceptable salts are useful for pharmaceutically products. Pharmaceutically acceptable salts include, when appropriate, pharmaceutically acceptable base addition salts and acid addition salts, for example, metal salts, such as alkali and alkaline earth metal salts, ammonium salts, organic amine addition salts, and amino acid addition salts, and sulfonate salts. Acid addition salts include inorganic acid addition salts such as hydrochloride, sulfate and phosphate, and organic acid addition salts such as alkyl sulfonate, arylsulfonate, acetate, maleate, fumarate, tartrate, citrate and lactate. Examples of metal salts are alkali metal salts, such as lithium salt, sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt, and zinc salt. Examples of ammonium salts are ammonium salt and tetramethylammonium salt. Examples of organic amine addition salts are salts with morpholine and piperidine. Examples of amino acid addition salts are salts with glycine, phenylalanine, glutamic acid and lysine. Sulfonate salts include mesylate, tosylate and benzene sulfonic acid salts.
In view of the close relationship between the compounds in free form and those in the form of their salts, including those salts that can be used as intermediates, for example in the purification or identification of the compounds, tautomers or tautomeric mixtures and their salts, any reference to the compounds hereinbefore and hereinafter especially the compounds of the formula I, is to be understood as referring also to the corresponding tautomers of these compounds, especially of compounds of the formula I, tautomeric mixtures of these compounds, especially of compounds of the formula I, or salts of any of these, as appropriate and expedient and if not mentioned otherwise.
Any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration. Substituents at a ring at atoms with saturated bonds may, if possible, be present in cis- (= Z-) or trans (= E-) form. The compounds may thus be present as mixtures of isomers or preferably as pure isomers, preferably as enantiomer-pure diastereomers or pure enantiomers.
Preferred embodiments according to the invention: In the following preferred embodiments, general expression can be replaced by the corresponding more specific definitions provided above and below, thus yielding stronger preferred embodiments of the invention.
Preferred is the USE of compounds of the formula I or pharmaceutically acceptable salts thereof, where the disease to be treated is a proliferative disease depending on binding of the Smac protein to inhibitor of Apoptosis Proteins (IAPS).
An embodiment of the present invention relates to compounds of the formula (I)
Figure imgf000013_0001
wherein
Ri is H; C1-C4 alkyl; C1-C4 alkenyl; C1-C4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, -OH, -SH, -OCH3, -SCH3, -CN, -SCN and nitro;
R2 is H; d-C4alkyl; C1-C4 alkenyl; C1-C4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, -OH, -SH, -OCH3l -SCH3, -CN, -SCN and nitro;
R3 is H; -CF3; -C2F5; d-C4 alkyl; C C4 alkenyl; C1-C4 alkynyl; -CH2-Z or R2 and R3 together with the nitrogen form a het;
Z is H; -OH; F; Cl; -CH3; -CF3; -CH2CI; -CH2F or -CH2OH; R4 is C1-C16 straight or branched alkyl; d-C-ι6 alkenyl; C1-C16 alkynyl; or -C3-C16 cycloalkyl; -(CH2)ι-6-Zι; -(CH2)0-6-phenyl; and -(CH2)0-6-het, wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
Z is -N(R8)-C(O)-d-C10alkyl; -N(R8)-C(O)-(CH2)1-6-C3-C7cycloalkyl; -N(R8)-C(O)- (CH2)o-6-phenyl; -N(R8)-C(O)-(CH2)ι-6-het; -C(O)-N(R9)(Rι0); -C(O)-O-d-C10alkyl; - C(O)-O-(CH2)ι-6-C3-C7cycloaIkyl; -C(O)-O-(CH2)o-6-phenyl; -C(O)-O-(CH2)ι-6-het; -O- C(O)-Cι-Cιoalkyl; -O-C(O)-(CH2)ι-6-C3-C7cycloalkyl; -O-C(O)-(CH2)o-6-phenyl; -O- C(O)-(CH2)ι-6-het, wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
het is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon atom by halogen, hydroxy, Cι-C4alkyl, Cι-C4 alkoxy, nitro, -O-C(O)-d- C4alkyl or -C(O)-O-C1-C4-alkyl or on a nitrogen by d-C4 alkyl, -O-C(O)-d-C4alkyl or -C(O)-O-d-C4alkyl;
R8 is H, -CH3, -CF3 , -CH2OH or -CH2CI;
Rg and R10 are each independently H; Cι-C alkyl; C3-C7cycloalkyl; -(CH2)ι-6-C3- C7cycloalkyl; -(CH2)0-6-phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or Rg and R10 together with the nitrogen form het;
R5 is H; Cι-Cιo-alkyl; C3-C7cycloalkyl; -(CH2)ι-6-C3-C7cycloalkyl; -d-doalkyl-aryl; -
(CH2)o-6-C3-C7cycloalkyl-(CH2)o-6-phenyl; -(CH2)o-4CH-((CH2)ι-4-phenyl)2; -(CH2)o-6- CH(phenyl)2; -(CH2)o-6-C(O)phenyl -indanyl;aryl -C(O)-d-Cιoalkyl;
Figure imgf000014_0001
C7cycloalkyl; -C(O)-(CH2)o-6-phenyl; -(CH2)o-6-het ; -C(O)-(CH2)ι-6-het; or R5 is a residue of an amino acid, wherein alkyl, cycloalkyl, phenyl and aryl are unsubstituted or substituted; U is a as shown in structure II:
Figure imgf000015_0001
wherein n = 0-5; X is -CH or N;
Ra and Rb are independently an O, S, or N atom or C0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
O, S or N, and where the alkyl may be unsubstituted or substituted;
Rd is selected from: (a) -Re - Q - (Rf)p(Rg)q; or (b) An-D- Ar2;
Re is H or Rd and Re together form cycloalkyl or het; where if Rd and Re form a cycloalkyl or heteroring, R5 is attached to the formed ring at a C or N atom; p and q are independently 0 or 1 ;
Re is C-ι-8 alkyl, or alkylidene, preferably methylidene, and Re rriay be unsubstituted or substituted;
Q is N, O, S, S(O), or S(O)2;
An and Ar2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H; -C1-C10 alkyl; d-Cι0alkylaryl; -OH; -O-d-
C10alkyl; -(CH2)0-6-C3-C7cycloalkyl; -O-(CH2)o-6-aryl; phenyl; aryl; phenyl-phenyl; -
(CH2)i-6-het; -O-(CH2)ι-6-het; -ORn; -C(0)-R11 ; -C(O)-N(Rn)(R12); -N(Rn)(R12); -S-
R11; -S(O)-Rn; -S(O)2-Rιι; -S(O)2-NRnRι2; -NR1 S(O)2- Rι2; S-d-d-alkyl; aryl-C
C4alkyl; het-Cι-C alkyl wherein alkyl, cycloalkyl, het and aryl are unsubstituted or substituted; -SO2-d-C2alkyl; -SO2.d-C2alkylphenyl; -O-C C alkyl; or Rg and Rf form a ring selected from het or aryl;
D is -CO-; -C(O)-d-7 alkylene or arylene; -CF2-; -O-; -S(O)r where r is 0-2; 1 ,3dioaxolane; or d- alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-d-Cβalkyl, -S-d- C6alkyl or -CF3; or D is -N(Rh) wherein Rh is H; d-7 alkyl (unsub or substituted); aryl; -O(d-7cycloalkyl) (unsub or substituted); C(O)-d-Cιoalkyl; C(O)-Co-C10alkyl- aryl; C-O-d-C10alkyl; C-O-C0-C10alkyl-aryl or SO2-C1-C10-alkyl; SO2-(C0-do- alkylaryl);
Rε, R7, R'β and R'7 are each independently H; -C1-C10 alkyl; -C1-C10 alkoxy; aryl-Ci- C 0 alkoxy; -OH; -O-d-C10alkyl; -(CH2)o-6-C3-C7cycloalkyl; -O-(CH2)0-6-aryl; phenyl; - (CH2)ι-6-het;
Figure imgf000016_0001
-0R11 ; -C(0)-R11 ; -C(O)-N(Rn)(R12); -N(Rn)(R12); -S- R11; -S(O)-Rn; -S(O)2-Rιι; -S(O)2-NRnR12; -NRn-S(O)2- R12; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; and R6, R7ι R'6 and R'7can be united to form a ring system;
R11 and R12 are independently H; C1-C10 alkyl; -(CH2)o-6-C3-C7cycloalkyl; -(CH2)o-6- (CH)0-i(aryl)1-2; -C(O)-d-C10alkyl; -C(O)-(CH2)ι-6-C3-C7cycloalkyl; -C(O)-O-(CH2)o-6- aryl; -C(O)-(CH2)o-6-O-fluorenyl; -C(O)-NH-(CH2)o-6-aryl; -C(O) (CH2)o-6-aryl; -C(O)-
Figure imgf000016_0002
-C(S)-Cι-Cιoalkyl; -C(S)-(CH2)1-6-C3-C7cycloalkyl; -C(S)-O-(CH2)0-6-aryl; -C(S)-(CH2)o-6-0-fluorenyl; -C(S)-NH-(CH2)o-6-aryl; -C(S)-(CH2)o-6-aryl; -C(S)-(CH2)ι-6- het; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or Rn and R12 are a substituent that facilitates transport of the molecule across a cell membrane; or R11 and R12 together with the nitrogen are het; aryl of R-n and R12 can be phenyl, naphthyl, or indanyl which is unsubstituted or substituted; alkyl of R-n and R12 may be unsubstituted or substituted by one or more substituents selected from a d-do alkene, halogen, OH, -O-d-C6alkyl, -S-d-Cδalkyl and -CF3; cycloalkyl of Rn and R12 may be unsubstituted or substituted by one or more selected from a C1-C10 alkene, one or more halogens, Cι-C6alkyl, halogen, OH, -O-
Cι-C6alkyl, -S-C C6alkyl or -CF3; and phenyl or aryl of Rn and R12 may be unsubstituted or substituted by one or more substituents selected from halogen, hydroxy, d-C4 alkyl, C1-C4 alkoxy, nitro,
-CN, -O-C(O)-C C4alkyl and -C(O)-O-d-C -aryl; or pharmaceutically acceptable salts thereof.
A further embodiment the present invention relates to the use of compound of formula I in the treatment of proliferative diseases, especially those dependent on the binding of the Smac protein to Inhibitor of Apoptosis Proteins (lAPs), or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of compounds of formula (I) in the treatment of said diseases, pharmaceutical preparations comprising compounds of formula (I) for the treatment of said diseases, compounds of formula (I) for use in the treatment of said diseases.
One embodiment of the present invention relates to compounds of the formula (I) wherein
Ri and R2 are independently H or substituted or unsubstituted Cι-C4alkyl;
R4 is d-C-16 straight or branched alkyl, or C3-Cι0cycloalkyl, wherein the alkyl or cycloalkyl may be unsubstituted or substituted;
R5 is H; Cι-C10alkyl; d-doalkyl-aryl; -C(O)-(CH2)o-6-Phenyl; -(CH2)o-6-C(O)- Phenyl; aryl; indanyl; naphthyl or R5 is a residue of an amino acid, wherein the alkyl or aryl substituents are unsubstituted or substituted;
U is as shown in structure II:
Figure imgf000017_0001
wherein n = 0-5;
X is -CH or N;
Ra and Rb are independently an O, S, or N atom or Co-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
O, S or N, and where the alkyl may be unsubstituted or substituted;
Rd is selected from (a) -Re - Q - (Rf)p(Rg)q; or (b) Arι-D- Ar2;
Re is H or Re and Rd together form cycloalkyl or het; where if Rd and Re form a cycloalkyl or heteroring, R5 is attached to the formed ring at a C or N atom; p and q are independently 0 or 1 ;
Re is C-ι-8 alkyl, or methylidene which may be unsubstituted or substituted;
Q is N, O, S, S(O), or S(O)2;
An and Ar2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H or substituted or unsubstituted Co-C10alkyl; C1-
Cioalkylaryl; aryl-d-C10alkyl; het-d-C10alkyl -C(O)-d-C4-alkyl-phenyl; -C(O)-d-C4- alkyl; -SO2-C1-C2alkyl; -SO2-C C2alkylphenyl; -O-d-C4-alky;
D is -C(O)-; d-7 alkylene or arylene; -O-, or -S(O)r where r is 0-2; where alkyl, alkylene or arylene which may be unsubstituted or substituted rvvith one or more halogens; -OH; -O-d-C6alkyl; -S-C C6alkyl or -CF3; or D is NRh wherein Rh is H; C1-7 alkyl (unsubtituted or substituted); aryl; -OCι-7 cycloalkyl (unsubstituted or substituted); -CO-C0.ιo alkyl or aryl or SO2-C0-ιo -alkyl or aryl; and R6> Rγ, R'β and R'7 are each independently H, -d-Cio alkyl, or -OH, alkoxy, or aryloxy; or pharmaceutically acceptable salts thereof.
In a further embodiment, U is a bicyclic saturated or unsaturated ring system, consisting of all carbon skeleton or with one or more heteroatoms such as O, N, S but preferably as shown in structure III:
Figure imgf000019_0001
wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R6, R7, R& and R7';
X is CH or N;
V is O, F2, Cl2, Br2, l2, S, YH, H2) NH, or d-C4 alkyl;
W is -CH, or -N; n is 0-3; and m is 0-3.
In a preferred embodiment the ring atoms may be substituted with subsituents independently selected from halo, H, OH, lower alkyl or lower alkoxy, wherein alkyl or alkoxy are unsubstituted or substituted by halogen, OH, lower alkyl or lower alkoxy.
In a further embodiment, U of formula II or III together with R5 farm a fused ring system.
Especially preferred is a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H; methyl; ethyl; chloromethyl; diehloromethyl or trifluoromethyl;
R4 is -Cι-C alkyl; -C3-C7 cycloalky; -(CH )ι-6cycloalkyl; or -(CH )o-6aryl. R4 is particularly ethyl; propyl; isopropyl; t-butyl; cyclopentyl; or cyclohexyl; -CH2- cyclopentyl; -CH2-cyclohexyl or -CH2-phenyl. R5 is -d-dalkyl-phenyl; -C(O)-d-C4alkyl-phenyl; -C1-C4alkyI-C(O)-pheny or aryl; R5 is particularly phenylmethyl, phenylethyl and phenylpropyl; indanyl, naphthyl; -C(O) -
CH2-phenyl or -CH2-C(O)-phenyl;
R6 and R are H or methyl;
U has the structure of formula III:
Figure imgf000020_0001
wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for Re, R7, Re- and R7';
X is N;
V is O or H2;
W is -N; n is 1; and m is 1 or 2.
Especially preferred is a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is H;
R is d-C alkyl; C3-C7 cycloalkyl; C1-C7 cycloalkyl-C1.C7alkyl; phenyl-Cι.C alkyl or aryl. R is particularly methyl; ethyl; butyl; isopropyl; t-butyl; or cyclohexyl; -CH2- cyclopentyl; -CH2-cyclohexyl; -CH -cyclopropyl; phenyl or -CH2-phenyl;
R5 is -d-dalkyl-phenyl; -C(O)-d-C4alkyl-phenyl; -C C4alkyl-C(O)-pheny or aryl. R5 is particularly phenylethyl; indanyl, naphthyl; -C(O) -CH2-phenyl; -CH2 -C(O)-phenyl or (CF3O)phenylethyl;
R6, R'e. R and R are H; U has the structure of formula III wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R6, R7, Rβ' and R7';
X is N;
V is O or H2;
W is -N; n is 1 ; and m is 1 or 2.
Another embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H;
U has the structure of formula II wherein
X is N;
Re, R'e, Ry, and R'7 are H; n is O;
Re is H;
An and Ar2 are substituted or unsubstituted phenyl or het particularly tetrazolyl, 1 ,
2,3-triazole, pyrazole, oxazole, pyrrolyl, triazine, pyrimidine, imidazol, oxadiazol; and and D is Cι alkyl which may optionally be substituted with halo, especially F.
Another embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is CrC4alkyl; C3-C7 cycloalkyl; C1-C7 cycloalkyl-d-C7alkyl; phenyl-d-C7alkyl or aryl. R4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH2- cyclopentyl, -CH2-cyclohexyl; -CH2-cyclopropyl; phenyl or -CH2-phenyl;
R5 is H; U has the structure of formula II wherein
X is N;
Re, R'e, R7, and R'7 are H; or R6 is -C(O)-C1-C alkyl-phenyl and R'6, R7. and R'7 are
H; n is O;
Re is H;
An and Ar2 are substituted or unsubstituted phenyl or het, particularly triazine, pyrimidine, pyridine, oxazole, 2,4-difluorophenyl, Cl-phenyl or fluorophenyl; and D is
N(Rh), where Rh is H, Me, -CHO, -SO2, -C(O), -CHOH, -CF3 or -SO2CH3.
Another embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-C4alkyl; C3-C7cycloa!kyl; Cι.C7cycloalkyl- Cι.C7alkyl; phenyl-Cι-C7alkyl or aryl. R is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH2- cyclopentyl, -CH2-cyclohexyl; -CH2-cyclopropyl; phenyl or -CH2-phenyl;
R5 is H;
U has the structure of formula II wherein
X is N;
Re, R'e, R7, and R'7 are H; n is O;
Rc is H;
A and Ar2 are substituted or unsubstituted phenyl or het particularly pyrimidine, pyridine, oxazole, 2-methyloxazole; and D is -O-.
Another embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl or C3-C7cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl; R5 is H;
U has the structure of formula II wherein X is N;
Re, R'e, R7, and R'7 are H; n is O; Re is H;
An and Ar2 are substituted or unsubstituted phenyl or het; and D is S, S(O), or S(O)2.
Another embodiment is directed to a compound of formula (I) wherein R-i and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl; R4 is Ci-dalkyl or C3-C cycloalkyI particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl; R5 is H;
U has the structure of formula II wherein X is N;
Re, R'e, R7, and R'7 are H; n is O; Re is H;
Ari and Ar2 are substituted or unsubstituted phenyl or het, particularly oxazole, thaizole and ozadiazole; and D is C(O), or 1 ,3-dioxolane.
Another embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl or C3-C7cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H or phenyl C Cιoalkyl such as phenylethyl;
U has the structure of formula II wherein X is N;
Re, R'e, R7, and R'7 are H; n is O;
Re and Rd are a heterocyclic ring, particularly pyrrolidine; pyrrolidin-2-one; or pyrrolidin-3-one.
Another embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R is d-C4alkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H, indanyl or phenyl;
U has the structure of formula II wherein
X is N;
Q is O;
Re, R'e, R7, and R'7 are H; n is O;
Re is d alkyl; and p and q are 0.
A further embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-C alkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H, indanyl or phenyl;
U has the structure of formula II wherein
X is N;
Q is N;
Re, R'e, R7, and R'7 are H; n is O; Re is Ci alkyl; and
Rg is H Cι-C8 alkyl, methyl, ethyl, hexyl, heptyl, octyl; or CH CF3; or aryl-Cι-C4 alkyl particularly phenylethyl, furanylethyl; d-dcycloalkyl particularly cyclohexyl; ethylphenyl; -C(O)-d-C4aIkyl-phenyl; -C(O)-C1-C4alkyl; -C1-C4alkyl-aryl particularly -
CH2-phenyl; -CH2-thiophene, -CH2-furan, -CH2-pyrrolidinyl, -CH2-imidazole, -CH2- triazole, -CH2-imidazole; and Rf is d-C2 alkyl; d-C2alkylphenyl; -SO2-C1-C2alkyl; -SO2-C C2alkylphenyl; -O-
CrC alkyl particularly O-ethyl; phenyl-phenyl, 1 ,2,3,4-tetrahydronapthalene and indanyl.
A further embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-C alkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H, indanyl or phenyl;
U has the structure of formula II wherein
X is N;
Q is N;
Re, R'e, R7, and R'7 are H; n is O;
Re is C1 alkyl; and
Rg and Rf form a ring selected from het or aryl particularly 2,3,4,5- tetrahydrobenzo[c]azepine; 1 ,2,3,4 tetrahydroquinoline; indanyl which may be substituted with Cι-C4alkylphenyl
A further embodiment is directed to a compound of formula (I) wherein
R-i and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-C4alkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl; R5 is phenyl;
U has the structure of formula II wherein
X is N;
Q is O, S, S(O) or S(O)2;
R6> R'6ι R7> and R'7 are H; n is O;
Re is Ci alkyl; q is 0;
Re is H; and Rf is C2 alkyl.
A further embodiment is directed to a compound of formula (I) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is phenyl;
U has the structure of formula II wherein
X is N;
Q is N;
Re, R'e, R7, and R'7 are H; n is O;
Re is CH; q is 0;
Re is H; and Rf is OC1 alkyl.
In a particularly important embodiment of the present invention, R3 and R4 have the stereochemistry indicated in formula IV, with the definitions of the variable substituents and preferences described herein above also applying to compounds having the stereochemistry indicated in formula IV.
Figure imgf000027_0001
Especially preferred is a compound with the stereochemistry of formula (IV) wherein Ri and R3 are preferably methyl or ethyl;
R2 is H, methyl, ethyl, or substituted methyl especially chloromethyl, diehloromethyl and trifluoromethyl; preferably R2 is H or unsubstituted methyl;
R4 is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is -Cι-C -alkyl-phenyl, particularly phenylmethyl, phenylethyl and phenylpropyl, indanyl, naphthyl; and
Re and R7 are H or methyl.
The preferred stereochemistry for U is as shown in Figure V
Figure imgf000027_0002
In a particular embodiment of the present invention, one or both of R6, R7, Res and Ry is H. If one of R6, R7, R&, and R7> is other than H, it is especially hydroxyl or phenoxy. Synthetic Procedure
Abbreviations:
CH2CI2 methylene chloride
CH3CN acetonitrile
DIBAL diisobutylalumϊnium hydride
DIPEA diisopropylethylamine
DME ethylene glycol dimethyl ether
DMF N, /V-dimethylformamide
DTBB 4,4'-di-tert-butylbiphenyl
EtOAc ethyl acetate
HBTU O-benzyltriazol-1-yl-Λ/,Λ/,/V',ry-tetramethyIuronium hexafluorophosphate
HOBt 1-hydroxhbenzotriazole
HPLC high pressure liquid chromatography
KOTMS potassium trimethysilanoate.
MeOH methanol
MgSO4 magnesium sulfate
MnO2 manganese dioxide
Na2CO3 sodium carbonate
NaHCO3 sodium bicarbonate
NaOH sodium hydroxide
Tetrakis tetrakis(triphenylphosphine)palladium(0)
TFA trifluoroacetic acid
THF tetrahydrofuran
The compounds of formula (I) may be prepared as depicted below in scheme 1 (for compound # 9 - 25, 29 - 31):
General synthesis scheme for compounds of formula 1 where W=N and X and X' are independently selected from the subsituents defined above for Re.
KOTMS is defined as potassium trimethysilanoate. Step A
Figure imgf000029_0001
PG = benzyl or benzylic protecting group
StepB NH2-R5 Br AP ^ CH,CN, Na2C0, R -N ^ n = 0,1 or 2 StepC
1) KOTMS 2) PivCI 3) amine
Figure imgf000029_0002
Figure imgf000029_0003
Figure imgf000029_0004
separate diastereomers
Figure imgf000029_0005
StepF
Figure imgf000030_0001
Scheme 1
Step A: This step involves the formation of an aziridine ring via standard base mediated conditions.
Step B: This step involves the formation of a secondary amine via the reaction of an alkyl bromide with excess amine in the presence of a base.
Step C: This step involves the coupling of a secondary amine with an activated derivative of the aziridine methyl ester to form an amide substituted aziridine.
Step D: This step involves the intramolecular cycloaddition of the aziridine to the tethered alkene through a thermally accessible azomethine ylide intermediate.
Step E: This step involves the reduction of the amide to an amine via standard reduction conditions employing DIBAL-H. Step F: This step involves the removal of the benzylic protecting group using standard palladium conditions under a hydrogen atmosphere.
Step G: This step involves coupling of the scaffold with a f-Boc protected natural or unnatural amino acid using standard peptide coupling conditions followed by the removal of the f-Boc group with TFA.
Step H: This step involves the coupling of the amine generated in the preceding step with a f-Boc protected or tertiary natural or unnatural amino acid using standard peptide coupling conditions followed by the removal of the f-Boc group with TFA if applicable. The product is then purified by high-performance liquid chromatography (HPLC).
The compounds of formula (I) may be prepared as depicted below in scheme 2 (for compound # 26 - 28):
Figure imgf000032_0001
68% B
D Scheme 2
The compounds of formula (I) may be prepared as depicted below in scheme 3 (for compound # 32 - 33):
Figure imgf000033_0001
Figure imgf000033_0002
Figure imgf000033_0003
Scheme 3
The compounds of formula (I) may be prepared as depicted below in scheme 4 (for compound # 34- 35):
Figure imgf000033_0004
Scheme 4 Compounds 36-38 can be prepared analogously to the preparation of compounds 34-35 according to Scheme 4.
As discussed above, the compounds of the present invention are useful for treating proliferative diseases. Thus, the present invention further relates to a method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of the invention to a mammal, preferably a human, in need of such treatment.
A proliferative disease is mainly a tumor disease (or cancer) (and/or any metastases). The inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other chemotherapeutics; or (iii) a tumor that is refractory to treatment with other chemotherapeutics due to multidrug resistance.
In a broader sense of the invention, a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
Where a tumor, a tumor disease, a carcinoma or a cancer are mentioned, also metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis. The inventive compound is selectively toxic or more toxic to rapidly proliferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
The compounds of the present invention may be administered alone or in combination with other anticancer agents, such as compounds that inhibit tumor angiogenesis, for example, the protease inhibitors, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors and the like; cytotoxic drugs, such as antimetabolites, like purine and pyrimidine analog antimetabolites; antimitotic agents like microtubule stabilizing drugs and antimitotic alkaloids; platinum coordination complexes; anti-tumor antibiotics; alkylating agents, such as nitrogen mustards and nitrosoureas; endocrine agents, such as adrenocorticosteroids, androgens, anti-androgens, estrogens, anti-estrogens, aromatase inhibitors, gonadotropin-releasing hormone agonists and somatostatin analogues and compounds that target an enzyme or receptor that is overexpressed and/or otherwise involved a specific metabolic pathway that is upregulated in the tumor cell, for example ATP and GTP phosphodiesterase inhibitors, histone deacetylase inhibitors, protein kinase inhibitors, such as serine, threonine and tyrosine kinase inhibitors, for example, Abelson protein tryosine kinase and the various growth factors, their receptors and kinase inhibitors therefore, such as, epidermal growth factor receptor kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors and platelet-derived growth factor receptor kinase inhibitors and the like; methionine aminopeptidase inhibitors, proteasome inhibitors, and cyclooxygenase inhibitors, for example, cyclooxygenase-1 or -2 inhibitors.
The present invention further relates to a method of promoting apoptosis in rapidly proliferating cells, which comprises contacting the rapidly proliferating cells with an effective apoptosis promoting amount of a non-naturally-occurring compound that binds to the Smac binding site of XIAP and/or clAP proteins. Preferably, the non- naturally-occurring compound a compound of present formula 1 or IV.
The present invention further relates to a method of treating or inhibiting myeloma, especially multiple myeloma. The term "myeloma" as used herein relates to a tumor composed of cells of the type normally found in the bone marrow. The term "multiple myeloma" as used herein means a disseminated malignant neoplasm of plasma cells which is characterized by multiple bone marrow tumor foci and secretion of an M component (a monoclonal immunoglobulin fragment), associated with widespread osteolytic lesions resulting in bone pain, pathologic fractures, hypercalcaemia and normochromic normocytic anaemia. Multiple myeloma is incurable by the use of conventional and high dose chemotherapies. The invention relates to a method of treating myeloma, especially myeloma which is resistant to conventional chemotherapy.
Pharmaceutical Compositions The invention relates also to pharmaceutical compositions comprising a compound of formula I, to their use in the therapeutic (in a broader aspect of the invention also prophylactic) treatment or a method of treatment of a kinase dependent disease, especially the preferred diseases mentioned above, to the compounds for said use and to pharmaceutical preparations and their manufacture, especially for said Uses.
The present invention also relates to pro-drugs of a compound of formula I that convert in vivo to the compound of formula I as such. Any reference to a compound of formula 1 is therefore to be understood as referring also to the corresponding pro-drugs of the compound of formula I, as appropriate and expedient.
The pharmacologically acceptable compounds of the present invention may be present in or employed, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of a compound of the formula I, or a pharmaceutically ac- ceptable salt thereof, as active ingredient together or in admixture with one or more inorganic or organic, solid or liquid, pharmaceutically acceptable carriers (carrier materials).
The invention relates also to a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to cells or cell lines derived from a warm-blooded animal, especially a human, e.g. lymphocytes), for the treatment of (this, in a broader aspect of the invention, also includes the prevention of (= prophylaxis against)) a disease that responds to inhibition of protein kinase activity, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof, preferably which is effective for said inhibition, together with at least one pharmaceutically acceptable carrier.
The pharmaceutical compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (especially a human), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
The invention relates also to a method of treatment for a disease that responds to inhibition of a protein kinase and/or a proliferative disease, which comprises administering a (against the mentioned diseases) prophylactically or especially therapeutically effective amount of a compound of formula I according to the invention, or a tautomer thereof or a pharmaceutically acceptable salt thereof, especially to a warm-blooded animal, for example a human, that, on account of one of the mentioned diseases, requires such treatment. The dose of a compound of the formula I or a pharmaceutically acceptable salt thereof to be administered to warm-blooded animals, for example humans of approximately 70 kg body weight, preferably is from approximately 3 mg to approximately 10 g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1000 mg /person/day, divided preferably into 1-3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
The pharmaceutical compositions comprise from approximately 1 % to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
Combinations A compound of the formula I may also be used to advantage in combination with other antiproliferative agents. Such antiproliferative agents include, but are not limited to aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active agents; alkylating agents; histone deacetylase inhibitors; compounds which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; agents used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors; temozolomide (TEMODAL®); and leucovorin.
The term "aromatase inhibitor" as used herein relates to a compound which inhibits the estrogen production, i.e. the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to steroids, especially atamestane, exemestane and formestane and, in particular, non-steroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane can be administered, e.g., in the form as it is marketed, e.g. under the trademark AROMASIN. Formestane can be administered, e.g., in the form as it is marketed, e.g. under the trademark LENTARON. Fadrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark AFEMA. Anastrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark ARIMIDEX. Letrozole can be administered, e.g., in the form as it is marketed, e.g. under the trademark FEMARA or FEMAR. Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g. under the trademark ORIMETEN. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g. breast tumors.
The term "antiestrogen" as used herein relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term indydes, but is not limited to tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen can be administered, e.g., in the form as it is marketed, e.g. under the trademark NOLVADEX. Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g. under the trademark EVISTA. Fulvestrant can be formulated as disclosed in US 4,659,516 or it can be administered, e.g., in the form as it is marketed, e.g. under the trademark FASLODEX. A combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g. breast tumors. The term "anti-androgen" as used herein relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g. as disclosed in US 4,636,505.
The term "gonadorelin agonist" as used herein includes, but is not limited to abarelix, goserelin and goserelin acetate. Goserelin is disclosed in US 4,100,274 and can be administered, e.g., in the form as it is marketed, e.g. under the trademark ZOLADEX. Abarelix can be formulated, e.g. as disclosed in US 5,843,901.
The term "topoisomerase I inhibitor" as used herein includes, but is not limited to topo- tecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound A1 in WO99/ 17804). Irinotecan can be administered, e.g. in the form as it is marketed, e.g. under the trademark CAMPTOSAR. Topotecan can be administered, e.g., in the form as it is marketed, e.g. under the trademark HYCAMTIN.
The term "topoisomerase II inhibitor" as used herein includes, but is not limited to the anthracyclines such as doxorubicin (including liposomal formulation, e.g. CAELYX), daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and losoxantrone, and the podophillotoxines etoposide and teniposide. Etoposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark ETOPOPHOS. Teniposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark VM 26-BRISTOL. Doxorubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ADRIBLASTIN or ADRIAMYCIN. Epirubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark FARMORUBICIN. Idarubicin can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZAVEDOS. Mitoxantrone can be administered, e.g. in the form as it is marketed, e.g. under the trademark NOVANTRON.
The term "microtubule active agent" relates to microtubule stabilizing, microtubule destabilizing agents and microtublin polymerization inhibitors including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca alkaloids, e.g., vinblastine, especially vin- blastine sulfate, vincristine especially vincristine sulfate, and vinorelbine, discodermo- lides, cochicine and epothilones and derivatives thereof, e.g. epothilone B or D or derivatives thereof. Paclitaxel may be administered e.g. in the form as it is marketed, e.g. TAXOL. Docetaxel can be administered, e.g., in the form as it is marketed, e.g. under the trademark TAXOTERE. Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark VINBLASTIN R.P.. Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g. under the trademark FARMISTIN. Discodermolide can be obtained, e.g., as disclosed in US 5,010,099. Also included are Epothilone derivatives which are disclosed in WO 98/10121 , US 6,194,181 , WO 98/25929, WO 98/08849, WO 99/43653, WO 98/22461 and WO 00/31247. Especially preferred are Epothilone A and/or B.
The term "alkylating agent" as used herein includes, but is not limited to, cyclophospha- mide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark CYCLO- STIN. Ifosfamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark HOLOXAN.
The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO 02/22577, especially N-hydroxy-3-[4-[[(2- hydroxyethyl)[2-(1 H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, N- hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2- propenamide and pharmaceutically acceptable salts thereof. It further especially includes Suberoylanilide hydroxamic acid (SAHA).
The term "antineoplastic antimetabolite" includes, but is not limited to, 5-Fluorouracil or 5-FU, capecitabine, gemcitabine, DNA demethylating agents, such as 5-azacytidine and decitabine, methotrexate and edatrexate, and folic acid antagonists such as pemetrexed. Capecitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark XELODA. Gemcitabine can be administered, e.g., in the form as it is marketed, e.g. under the trademark GEMZAR. Also included is the monoclonal antibody trastuzumab which can be administered, e.g., in the form as it is marketed, e.g. under the trademark HERCEPTIN.
The term "platin compound" as used herein includes, but is not limited to, carboplatin, cis-platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark CARBOPLAT. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g. under the trademark ELOXATIN.
The term "compounds targeting/decreasing a protein or lipid kinase activity and further anti- angiogenic compounds" as used herein includes, but is not limited to: protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g.: a) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor-receptors (FGF-Rs); b) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the IGF-IR receptor, such as those compounds disclosed in WO 02/092599; c) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family; d) compounds targeting, decreasing or inhibiting the activity of the Axl receptor tyrosine kinase family; e) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor; f) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK and Ras/MAPK family members, or Pl(3) kinase family, or of the Pl(3)- kinase-related kinase family, and/or members of the cyclin-dependent kinase family (CDK) and are especially those staurosporine derivatives disclosed in US 5,093,330, e.g. midostaurin; examples of further compounds include e.g. UCN-01 , safingol, BAY 43-9006, Bryostatin 1, Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521 ; LY333531/LY379196; isochinoline compounds such as those disclosed in WO 00/09495; FTIs; PD184352 or QAN697 (a P13K inhibitor); g) compounds targeting, decreasing or inhibiting the activity of a protein-tyrosine kinase, such as imatinib mesylate (GLIVEC/GLEEVEC) or tyrphostin. A tyrphostin is preferably a low molecular weight (Mr < 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S-arylbenzenemalonirile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG- 50810; AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490; Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG 494; Tyrphostin AG 556, AG957 and adaphostin (4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester; NSC 680410, adaphostin); and h) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGF-R, ErbB2, ErbB3, ErbB4 as homo- or heterodimers), such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g. EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO 97/02266, e.g. the compound of ex. 39, or in EP 0 564 409, WO 99/03854, EP 0520722, EP 0 566 226, EP 0 787 722, EP 0 837 063, US 5,747,498, WO 98/10767, WO 97/30034, WO 97/49688, WO 97/38983 and, especially, WO 96/30347 (e.g. compound known as CP 358774), WO 96/33980 (e.g. compound ZD 1839) and WO 95/03283 (e.g. compound ZM105180); e.g. trastuzumab (HERCEPTIN), cetuximab, Iressa, Tarceva, CI-1033, EKB-569, GW-2016, E1.1 , E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO 03/013541.
Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g. unrelated to protein or lipid kinase inhibition e.g. thalidomide (THALOMID) and TNP-470. Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are e.g. inhibitors of phosphatase 1 , phosphatase 2A, PTEN or CDC25, e.g. okadaic acid or a derivative thereof.
Compounds which induce cell differentiation processes are e.g. retinoic acid, α- γ- or δ- tocopherol or α- γ- or δ-tocotrienol.
The term "cyclooxygenase inhibitor" as used herein includes, but is not limited to, e.g. Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2-aryl- aminophenylacetic acid, e.g. 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid, lumiracoxib.
The term "mTOR inhibitors" relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity such as sirolimus (Rapamune®), everolimus (Certican™), CCI-779 and ABT578.
The term "bisphosphonates" as used herein includes, but is not limited to, etridonic, clo- dronic, tiludronic, pamidronic, alendronic, ibandronic, risedronie and zoledronic acid. "Etridonic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark DIDRONEL. "Clodronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONEFOS. "Tiludronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark SKELID. "Pamidronic acid" can be administered, e.g. in the form as it is marketed, e.g. under the trademark AREDIA™. "Alendronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark FOSAMAX. "Ibandronic acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONDRANAT. "Risedronie acid" can be administered, e.g., in the form as it is marketed, e.g. under the trademark ACTONEL. "Zoledronic acid" can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZOMETA. The term "heparanase inhibitor" as used herein refers to compounds which target, decrease or inhibit heparin sulphate degradation. The term includes, but is not limited to, PI-88.
The term "biological response modifier" as used herein refers to a lymphokine or inter- ferons, e.g. interferon γ.
The term "inhibitor of Ras oncogenic isoforms", e.g. H-Ras, K-Ras, or N-Ras, as used herein refers to compounds which target, decrease or inhibit the oncogenic activity of Ras e.g. a "famesyl transferase inhibitor", e.g. L-744832, DK8G557 or R115777 (Zamestra).
The term "telomerase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g. telomestatin.
The term "methionine aminopeptidase inhibitor" as used herein refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are e.g. bengamide or a derivative thereof.
The term "proteasome inhibitor" as used herein refers to compounds which target, de- crease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include e.g. PS-341 and MLN 341.
The term "matrix metalloproteinase inhibitor" or ("MMP inhibitor") as used herein includes, but is not limited to collagen peptidomimetie and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g. hydroxamate peptidomimetie inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551) BMS-279251 , BAY 12-9566, TAA211 , MMI270B or AAJ996.
The term "agents used in the treatment of hematologic malignancies" as used herein includes, but is not limited to FMS-like tyrosine kinase inhibitors e.g. compounds tar- geting, decreasing or inhibiting the activity of Flt-3; interferon, 1-b-D- arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors e.g. compounds which target, decrease or inhibit anaplastic lymphoma kinase.
The term "compounds which target, decrease or inhibit the activity of Flt-3" are especially compounds, proteins or antibodies which inhibit Flt-3, e.g. PKC412, midostaurin, a staurosporine derivative, SU11248 and MLN518.
The term "HSP90 inhibitors" as used herein includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteasome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90 e.g.,17-allylamino,17-demethoxygeldanamycin (17AAG), a geldanamycin derivative; other geldanamycin related compounds; radicicol and HDAC inhibitors.
The term "antiproliferative antibodies" as used herein includes, but is not limited to trastuzumab (Herceptin™), Trastuzumab-DM1 , erlotinib (Tarceva™), bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553 (anti-CD40) and 2C4 Antibody. By antibodies is meant e.g. intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity.
For the treatment of acute myeloid leukemia (AML), compounds of formula I can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of formula I can be administered in combination with e.g. farnesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP-16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412. The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications).
The above-mentioned compounds, which can be used in combination with a compound of the formula I, can be prepared and administered as described in the art such as in the documents cited above.
A compound of the formula I may also be used to advantage in combination with known therapeutic processes, e.g., the administration of hormones or especially radiation.
A compound of formula I may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
By "combination", there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula I and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g. synergistic, effect, or any combination thereof.
Examples
The following examples are intended to illustrate, but not further limit, the invention.
Example 1
N-[1-cyclohexyl-2-oxo-2-(6-phenethyl-octahydro-pyrrolo[2,3-c]pyridin-1-yl)-ethyl]-2- methylamino-propionamide (9); Compound 9 according to Formula I is prepared according to the procedure set forth in Scheme 5.
Figure imgf000048_0001
about 1:1 ratio, separable
Figure imgf000048_0002
Scheme 5
1-(1-Naphthalen-1-yl-ethyl)-aziridine-2-carboxylic acid methyl ester (1). To a solution of (S)-(-)-1-(1-naphthyl)ethylamine (20.8 g, 120 mmol) in acetonitrile (HPLC grade, 600 mL) is added K2CO3 (52.7 g, 360 mmol) and methyl 2,3- dibromopropionate (30 g, 120 mmol). The solution is stirred overnight at room temperature. The solution is evaporated to dryness, then H2O/EtOAc (1 :1) (600 mL) is added, and the mixture is extracted with EtOAc (4x100 mL). The organic extracts are combined, dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; Hexane/EtOAc 1 :2) to provide 24 g (78%) of the title compound as a mixture of two diastereomers in an equimolecular ratio. M+H+= 256.10.
But-3-enyl-phenethyl-amine (2). To a solution of 2-phenylethylamine (72 mL, 570 mmol) is added K2CO3 (82 g, 570 mmol) and 4-bromo-1-butene (25 g, 185 mmol). The solution is stirred overnight at room temperature. The solution is evaporated to dryness and H2O/EtOAc (1 :1) (600 mL) is added. The mixture is extracted with EtOAc (4x150 mL). The organic extracts are combined, dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; Hexane/EtOAc 1 :8) to provide 20 g (62%) of the title compound. M+H+= 176.10.
1 -(1 -Naphthalen-1 -yl-ethyl)-aziridine-2 -carboxylic acid but-3-enyl-phenethyl- amide (3). To a solution of 1 (12.6 g, 49.75 mmol) in THF (200 mL) is added KOTMS ( 6.38 g, 49.75 mmol). The mixture is stirred overnight at room temperature. The mixture is concentrated and the residue dissolved in dichloromethane (200 mL) and cooled to 0° C. Trimethylaeetyl chloride (5.94 g, 49.25 mmol) is added slowly and the mixture is warmed to room temperature over 2 hours. The mixture is cooled to -78° C, 2 (8.63 g, 49.25 mmol) is added and stirring continued at -78°C for 1.5 h. Saturated sodium bicarbonate (100mL) is added and the mixture is allowed to warm to rt. The mixture is extracted with EtOAc (4x100 mL) and the organic extracts are combined, dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; Hexane/EtOAc 1 :8) to provide 15 g (76%) of the title compound as a mixture of two diastereomers in an equimolecular ratio. M+H+= 399.37.
1-(1-NaphthaIen-1-yl-ethyl)-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridin-7-one (4). A solution of 3 (15 g, 58.7 mmol) in o-dichlorobenzene (100 mL) is heated at 250° C for 1200 s in a microwave reactor. The mixture is purified by flash chromatography (silica gel; Hexane/EtOAc 1 :1 ; second spot) to provide 5 g (33%) of the title compound as an enantiomerically pure compound. M+H+= 399.32.
1 -(1 -Naphthalen-1 -yl-ethyl)-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridine (5). To a solution of 4 (4.8 g, 12 mmol) in THF (100 mL) is added slowly 1 M DIBAL in toluene, (50 mL, 50 mmol) at -78°C. The mixture is stirred at room temperature for 1 hour and quenched with 20 mL of water. The solvent is evaporated, the residue is diluted with 100 mL of 1 :1 saturated Rochells salt/15% NaOH, and this extracted with EtOAc (4x50 mL). The organic extracts are combined, dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; Hexane/EtOAc 1 :9) to provide 2.3 g (48%) of the title compound. M+H+= 385.26.
6-Phenethyl-octahydro-pyrrolo[2,3-c]pyridine (6). To a solution of 5 (2.3 g, 6 mmol) in MeOH/CH2CI2 (1 :1 ; 200 mL) is added Pd(OH)2 (300 mg). The mixture is agitated under 50psi. hydrogen atmosphere for 10 h. The mixture is filtered through a celite pad, the filtrate is concentrated and the residue is used directly in the next step without further purification. M+H+= 231.17.
Compound (7). To a solution of 6 in dichloromethane (25 mL) is added sequentially diisopropylethylamine (4.17 mL, 24 mmol), f-Boc-L-cyclohexylglycine (1.54 g, 6 mmol), and a solution of 0.45 M HOBt/HBTU in DMF (16 mL, 7.19 mmol). The mixture is stirred overnight at room temperature, then diluted with EtOAc (200 mL) and washed sequentially with 1 M aq. citric acid (50 mL), water (50 mL), aq. Sat. NaHCO3 (50 mL) and brine (2x50 mL). The organic layer is dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; Hexane/EtOAc 1 :9) to provide a yellow oil. The yellow oil is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 h. The mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate. The solution is extracted with dichloromethane (3x50 mL). The organic extracts are combined, dried and concentrated under vacuum to provide1.75 g (79% two steps) of the title compound which is used in next step without further purification or characterization.
Compound (9). To a solution of 7 (1.75 g, 4.74 mmol) in dichloromethane (25 mL) is added sequentially diisopropylethylamine (3.30 mL, 19 mmol), f-Boc-tV-methyl-L- alanine (0.97 g, 4.74 mmol), and a solution of 0.45 M HOBt/HBTU in DMF (13 mL, 5.691 mmol). The mixture is stirred overnight at room temperature. The mixture is diluted with EtOAc (200 mL) and washed sequentially with 1 M citric acid (50 mL), water (50 mL), aq. Sat. NaHCO3 (50 mL) and brine (2x50 mL). The organic layer is dried and concentrated under vacuum. The residue is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 hours. The mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate. The solution is extracted with dichloromethane (3x50 mL). The organic extracts are combined, dried and concentrated under vacuum. The residue is purified by HPLC (C-18 silica gel, 20%) CH3CN/H2O in 0.5%TFA) to providel g (36% two steps) of the title compound as TFA salt. M+H+= 455.39.
Example 2 (S)-N-((S)-1-Cyclohexyl-2-{(2S,3R)-2-[(ethyl-phenethyl-amino)-methyl]- 3-methyl-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide (23)
Figure imgf000051_0001
TFA / CHJCI.
Figure imgf000051_0002
thrS But-3-enyl-((S)-1-phenyl-ethyl)-amine (A): To a solution of S-(-)-1 -phenyl ethylamine (15.75 g.130 mmol) in 150 mL of DMF at 0 °C is added K2CO3 (53.9 g, 390 mmol) in small portions. After stirring at 0 °C for 10 min, 4-bromobutene (13.5 g, 100 mmol) is added dropwise and followed by Nal (58.5 g, 390 mmol) in small portions. The reaction mixture, a white suspension, is heated to 95 °C and stirred overnight/16 hrs. The solution is cooled to RT and diluted with 200 mL of ether, and washed with 3 x 100 ml of water. The organic layer is dried over Na2SO4 and concentrated. The crude product is purified by distillation ( 65~70 °C under high vacuum) to yield a colorless liquid(13.5g, 76.7%). (NMR and MS data confirmed, U- 4117-28-23).
[But-3-enyl-((S)-1-phenyl-ethyl)-amino]-acetic acid ethyl ester (B): To a solution of But-3-enyl-((S)-1-phenyl-ethyl)-amine (6.37 g,36.4 mmol) in 150 mL of DMF at 0 °C is added K2CO3 (10.0 g, 72.8 mmol) in small portions. After stirring at 0 °C for 10 min, ethylbromoacetate (8.35 g, 54.6 mmol) izs added slowly. The reaction mixture, a white suspension, is stirred at r.t. overnight/16 hrs. The solution is diluted with 200 mL of ether, and washed with 3 x 100 ml of water. The crude product is purified by chromatography (hexane/CH2CI2: 50/50) to give a pale liquid(8.5 g, 94.5%). (NMR and MS data confirmed, U-4117-58).
(2S,3R)-3-But-3-enyl-1 -((S)-1 -pheny l-ethyl)-pyrrolidine-2-carboxylic acid ethyl ester (C): To a solution of diisopropylamine(3.6 g, 35.7 mmol) in THF(80 mL) at -40 °C is added BuLi(14.28 mL, 35.7 mmol, 2.5 M in hexane) slowly. The solution is warmed to 0 °C and stirred for 30 min to form an LDA solution. The LDA solution is cooled to -70 °C and added to a solution of [But-3-enyl-((S)-1-phenyl-ethyl)-amino]- acetic acid ethyl ester(7.8 g, 29.8 mmol) in THF(80 mL) slowly at -70 °C. The light yellowish reaction solution is stirred at -20 °C for 30 min to become a deep yellow solution, and then cooled to -70 °C. To the solution is added **ZnBr2 **(16.76 g, 74.5 mmol) in ether(50 mL) dropwise at -70 °C. After stirring at RT for 1.5hrs, the reaction solution is cooled to 0 °C and added a solution of CuCN(3.47 g, 38.74 mmol) and LiCI(3.29 g, 77.48 mmol) in THF(80 mL) slowly. After stirring at 0 °C for 10 min, allyl bromide(7.26 g, 60 mmol) is added dropwise to the reaction solution, and warmed very slowly to r.t.. After stirring overnight at r.t., the reaction is quenched by addition of 60 mL of saturated NH4CI and extracted with 3X150 mL of ether. The combined organic layers is concentrated. The crude product is purified by chromatography (hexane/EtOAc: 85/15) to give a colorless liquid(7.4g, 82.6%). (NMR and MS data confirmed, U-4117-40-19, U-4117-34-35). ** ZnBr2** is dried at 150 °C under high vacuum for 1 hour before used**
(2S,3R)-1-((2E,4Z)-(S)-1)2-DimethyI-hexa-254-dienyl)-3-(3-oxo-propyl) pyrrolidine-2-carboxylic acid ethyl ester (D): (2S,3R)-3-But-3-enyl-1-((S)-1- phenyl-ethyl)-pyrrolidine-2-carboxylic acid ethyl ester(1.0 g, 3.32 mmol) is dissolved in EtOH(10 mL) with HCI(0.5 mL, 37%), and cooled to -70 °C. Ozone gas is bubbled though the solution for about 10 min or until the solution is turned very light blue color. The nitrogen gas is bubbled though the solution for 15 min to remove excess ozone in the solution. To the cool solution is added Zn dust(0.43 g. 6.6 mmol) and HCI(0.5 mL, 37%), and stirred at r.t. for 20 min. After filtration the solution is diluted with 50 mL of CH2CI2 and washed with saturated NaHCO3(10 mL) and 2 x 20 ml of water. After dried and concentrated, a colorless liquid(1.0 g) is obtained without further purification for next step reaction. (NMR and MS data confirmed, U-4117-51 - 30).
(2S,3R)-3-(3-Phenethylamino-propyl)-1-((S)-1-phenyl-ethyl)-pyrrolidine-2- carboxylic acid ethyl ester (E): To a solution of (2S,3R)-1-((2E,4Z)-(S)-1 ,2- Dimethyl-hexa-2,4-dienyl)-3-(3-oxo-propyl) pyrrolidine-2-carboxylic acid ethyl ester(1.g, crude) in EtOH(10 mL) is added phenethylamine(0.44 g, 3.65 mmol) at r.t.. After stirring at r.t. for 30 min, NaBH3CN(0.3 g, 4.87 mmol) is added in one portion, After stirring at r.t. for 1.5 Hrs, the reaction solution is diluted with 50 mL of ether and washed with 20 mL of brine. The ether layer is concentrated and the crude product is purified by chromatography (CH2CI2/MeOH: 97/3) to give a pale liquid (405 mg, 30.0%). (NMR and MS data confirmed, U-4117-52-20). (3aS,7aS)-6-Phenethyl-1-((S)-1-phenyl-ethyl)-octahydro-pyrrolo[2,3-c]pyridin-7- one (F): (2S,3R)-3-(3-Phenethylamino-propyl)-1 -((S)-1 -phenyl-ethyl)-pyrrolidine-2- carboxylic acid ethyl ester(340 mg, 0.83 mmol) is dissolved in 20 mL of MeOH/KOH/H2O(10 mL/5 g/5 mL). After stirring at 80 °C for 2 hrs, the solution is cooled to 0 °C and neutralized by addition of HCI (37%) to pH = 5. After concentration the crude product is dissolved in 1 mL of CH2CI2, and filtered through a short silica gel plug and eluted with CH2CI2/MeOH(93/7) to give a pale glassy solid (250 mg, 78.9%) as the acid. (NMR and MS data confirmed, U-4117-60-22):
To a solution(0.05-0.1 M) of acid (1 equivalent) in DMF at r.t. is added diisopropylethylamine(5 equivalents). After stirring at r.t. for 20min, a solution(0.05~0.1 M) of HOBT(1.2 equivalents) and HBTU(1.2 equivalents) in DMF is added to the reaction mixture, and continued to be stirred for 1.5 h (or monitored by TLC). The reaction solution is diluted with ether(1X5~10 times by volume of the solution), and washed with water( twice X3 by volume of the solution). The combined organic solution is concentrated. The crude product is diluted with CH2CI2 and dried over Na2SO , and purified by chromatography(CH2Cl2/MeOH:97/3) to give pure product (70-95% yield). (NMR and MS data confirmed, U-4117-102).
Procedure for compound F:
A solution of(2S,3R)-3-(2-Phenethylamino-ethyl)-1 -((S)-1 -phenyl-ethyl)-pyrrolidine-2 carboxylic acid methyl ester(400 mg, 1.05 mmol) and 2-hydroxyl pyridine(100 mg, 1.05 mmol) in THF(10 mL) is stirred at 40 °C for 24 hrs. The reaction is diluted with 50 mL of ether and washed with 2 x 120 mL of water. After dried and concentrated to give a pale liquid(350 mg, LC/MS shown a clean product only.) without further purification for next step reaction.
(3aR,8aS)-7-Phenethyl-1-((S)-1-phenyl-ethyl)-decahydro-pyrrolo[2,3-c]a zepine (G): To a solution(0.02M) of lactam (1 equivalent) in THF at - 20 °C is added a solution(0.02M) of LiAIH4(2 equivalent) in THF slowly. After stirring at r.t. for 1.5 hrs, the solution is diluted with ether(1x5 times by volume of the solution) and washed with water(twice 2 times by volume of the solution), dried and concentrated. The crude product is purified by Chromatography (CH2CI2/MeOH:97/3) to give product(yield 70-90%). (NMR and MS data confirmed, U-4117-104).
(3aR,8aS)-7-PhenethyI-decahydro-pyrrolo[2,3-c]azepine (H): A solution/suspension of reactant (<1 g) and Pd 10% on carbon ( 20% by weight) in MeOH (10 mL, with 2 drops of acetic acid) in a 1000ml round flask is vigorously stirred at r.t. under hydrogen gas (at atmosphere pressure) from a balloon for 4-8 hrs. After degassed by house vacuum for 10 min, the reaction mixture is filtered to remove catalyst and concentrated. The crude product is diluted with CH2CI2/H2O(8/2, reasonable amount) and neutralized with 10% NH4OH to pH = 7-8. After dried and concentrated to give product (80% -quantitative yield) without purification for the next step reaction. (NMR and MS data confirmed, U-4117-105).
(S)-N-((S)-1-Cyclohexyl-2-{(2S,3R)-2-[(ethyl-phenethyl-amino)-methyl]- 3-methyl-pyrroIidin-1-yl}-2-oxo-ethyl)-2-methylamino-propjonamide (compound 23): Prepared from compound H following the procedures established in Scheme 5.
Example 3
Figure imgf000056_0001
Scheme 6
Diphenethylamine (D). To a solution of phenylacetaldehyde (6.0 g, 50 mmol) and 2- phenylethylamine in THF (200 mL) is added sodium triacetoxy-borohydride drop wise. The solution is stirred under nitrogen overnight at room temperature. The solution is quenched with aq. saturated sodium bicarbonate (200 mL), and extracted with EtOAc (4x100 mL). The organic extracts are combined, dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; EtOAc/ MeOH 9:1) to provide 1.25 g (11%) of the compound D as a clear oil. M+H+= 226.10. Diphenethyl-(S)-1-pyrrolidin-2-ylmethyl-amine (E). To a solution of (S)-2-Formyl- pyrrolidine-1 -carboxylic acid tert-butyl ester (1.0 g, 5.0 mmol) and D (1.125 g, 5.0 mmol) in THF (40 mL) is added sodium triacetoxyborohydride drop wise. The solution is stirred under nitrogen overnight at room temperature. The solution is quenched with aq. saturated sodium bicarbonate (40 mL). The mixture is extracted with EtOAc (4x50 mL). The organic extracts are combined, dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; Hexane/EtOAc 4:1) to provide a yellow oil. The yellow oil is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 h. The mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate. The solution is extracted with dichloromethane (3x50 mL). The organic extracts are combined, dried and concentrated under vacuum to provide1.04 g (68% two steps) of the title compound E which is used in the next step without further purification or characterization.
Compound (F). To a solution of f-Boc-L-cyclohexylglycine (0.868 g, 3.38 mmol) in DMF (20 mL) is added diisopropylethylamine (1.83 mL, 16.9 mmol). The mixture is stirred for 20 minutes at room temperature. Then a solution of E, HOBt (516 mg, 3.82 mmol) and HBTU (1.448 g, 3.82 mmol) in DMF (30 mL) is added. The mixture is stirred overnight at room temperature, and then diluted by ether (200 mL) and washed sequentially with aq. 1 M citric acid (50 mL), water (50 mL), satd. aq. NaHCO3 (50 mL) and brine (2x50 mL). The organic extract is dried and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; Hexane/EtOAc 2:3) to provide a yellow oil. The yellow oil is dissolved in dichloromethane (20 mL), TFA (10 mL) is added and the mixture is stirred at room temperature for 3 hours. The mixture is concentrated and the residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate. The solution is extracted with dichloromethane (3x50 mL). The organic extracts are combined, dried and concentrated under vacuum to provide 780 mg (52% two steps) of the title compound F which is used in the next step without further purification or characterization.
Compound 26. To a solution of f-Boc-Λ/-methyl-L-alanine (354 mg, 1.75 mmol) in DMF (20 mL) is added diisopropylethylamine (0.938 mL, 8.75 mmol). The mixture is stirred for 20 minutes at room temperature. Then a solution of F, HOBt (267 mg, 1.98 mmol) and HBTU (751 mg, 1.98 mmol) in DMF (30 mL) is added. The mixture is stirred for 3 h at room temperature, and then diluted by ether(200 mL) and washed sequentially with 1 M citric acid (50mL), water (50 mL), satd. aq. NaHCO3 (50 mL) and brine (2x50 mL). The organic extract is dried and concentrated under vacuum. The residue is dissolved in dichloromethane (20 mL) and TFA (10 mL) is added. The mixture is stirred at room temperature for 3 h and concentrated. The resulting residue is dissolved in dichloromethane (100 mL) and neutralized with saturated sodium bicarbonate. The solution is extracted with dichloromethane (3x50 mL). The organic extracts are combined, dried and concentrated under vacuum. Portion of the residue is purified by HPLC (C-18 silica gel, 30% CH3CN/H2O in 0.5%TFA) to provide 120 mg of compound 26 as TFA salt. M+H+ = 533.47.
Example 4 Compound 32 is prepared as follows:
Figure imgf000059_0001
Figure imgf000059_0002
chiral separation
Scheme 7
Compound I. Compounds G (122 mg,1 mmole) and H (226 mg,1 mmole) are dissolved in 5 mL DME. To this a mixture of 1 mL 2 N aq. Na2CO3 and 50 mg Tetrakis is added. The resulting mixture is degassed for 5 minutes, stirred at 90 °C for 6 h, cooled down to room temperature, and concentrated. Trje residue is purified by flash chromatography (ethyl acetate/hexane) to provide I as an amber oil (204 mg, 90%). The crude product is used directly in next reaction without further purification or characterization.
Compound J. LAH (38 mg) is added to a solution of I (226 mg,1 mmole) in 5 mL THF 0 °C. The temperature of the mixture is allowed to warm to room temperature and further stirred overnight. The reaction is quenched by following the Fisher method, filtered and concentrated to provide J as a colorless oil (183 mg, 92%) and is used directly in next reaction without further purification or characterization. Compound K. The suspension of compound J (198 mg, 1 mmole) and MnO2 (870 mg, 10 mmole) in 15 mL chloroform is stirred overnight. Filtering and concentration yielded product K as a colorless oil (192 mg, 98%). 1H NMR (CDCI3 ) δ 9.96 (s, 1 H), 7.72 (s,2H), 7.47 (s, 2H), 7.15-7.35 (m,5H), 4.07 (s, 2H)
Compound L. A mixture of 3-chloropropylamine hydrochloride ( 140 mg, 1.1 mmol), aldehyde K (196 mg, 1.0 mmol), and sodium carbonate (212 mg, 2 mmol) in water (10 mL) is stirred overnight at room temperature. The resulting solution is extracted with ethyl acetate (3 x 20 mL), separated, dried over Na2SO4 and evaporated in vacuum (15 Torr) to give an essentially pure oily residue (270 mg) which is used for the next reaction without further purification. (M +H+ 272, calc. 272)
Compound M. Imine L (271 mg,1 mmol) is added to a blue suspension of lithium powder (75 mg, 10 mmol) and a catalytic amount of DTBB (30 mg, 0.10 mmol; 5% molar) in THF (5 mL) at -78 °C. The resulting mixture is stirred for 2 h at same temperature. Reaction is quenched with water (20 mL) allowing the temperature to rise to 20 °C. The resulting solution is purified by successively acid-base extraction with 2 M hydrochloric acid (3 x 15 mL) and 4 M sodium hydroxide (3 x 20 mL). The final solution is extracted with ethyl acetate (3 x 20 mL), separated, dried over Na2SO4 and evaporated to give pure compound M, ( 214 mg, 90%); (M +H+ 238, calc. 238)
Compound O. A mixture of compound M (237 mg,1 mmole) , compound N (257 mg,1 mmole), HBTU (460 mg,1.2 mmole), HOBT (170 mg, 1.1 mmole), DIPEA (512 mg, 3 mmole) and 5 mL DMF is stirred overnight. The mixture is diluted with ether (25 mL), washed with water, brine, dried over MgSO , filtered, and concentrated. The resulting residue is treated with 2 mL of CH CI2/TFA (1/1), stirred for 2 h, concentrated to provided product O as a pale yellow solid (320 mg, 85%); (M +H+ 377, calc. 377). Compound 32. A mixture of compound O (376 mg, 1 mmole), t-Boc-N- methylalanine P (203 mg,1 mmole), HBTU (460 mg,1.2 mmole), HOBT (170 mg, 1.1 mmole), DIPEA (512 mg, 3 mmole) and 5 mL DMF is stirred overnight. The mixture is diluted with ether (25 mL), washed with water, brine, dried over MgSO4, filtered, and concentrated. The resulting residue is treated with 2 mL of CH2CI2 /TFA (1/1), stirred for 2 h and concentrated under vacuum. Column chromatography provided compound 32 as a pale yellow solid, (397 mg, 86%). (M +H+ 462, calc. 462).
Example 5 (S)-N-{(S)-1-Cyclohexyl-2-[(S)-2-(indan-2-yIoxymethyl)-pyrrolidin-1-yl]-2-oxo-ethyl}-2- methylamino-propionamide (34)
(S)-2-Methanesulfonyloxymethyl-pyrrolidine-1 -carboxylic acid tert-butyl ester, (P). A flame dried flask charged with (S)-2-Hydroxymethyl-pyrrolidine-1- carboxylic acid ferf-butyl ester (1 g, 5 mmol), dichloromethane (DCM) ( 20 mL) and triethylamine (0.70 mL, 5.2 mmol) is cooled to 0°C under N2 is added a solution of methanesulfonychloride (0.38 mL, 5 mmol) in DCM (5 mL) dropwise over 10 minutes. The reaction is stirred for 1 hour . After addition of DCM (100 mL), the reaction mixture is washed with brine, dried and concentrated in vacuo. The residue is purified by chromatography on Siθ2 (5% EtOAc/Hexanes) to give 1.38 g of methanesulfonate ester (P) as a clear colorless oil: LCMS (ES) 280.10 (MH+).
(S)-2-(lndan-2-yloxymethyl)-pyrrolidine-1 -carboxylic acid terf-butyl ester, (Q).
Sodium hydride (60%) (0.6 g, 14.4 mmol) is added to a flame dried flask charged with indan-2-ol (0.965 g, 7.2 mmol) and N,N'-dimethylformamide (DMF) (20 mL), cooled to 0°C under N2 and stirred for 30 minutes. A solution of (S)-2- Methanesulfonyloxymethyl-pyrrolidine-1 -carboxylic acid fetf-butyl ester (P) (1 g, 3.6 mmol) in DMF (5 mL) is added dropwise to the reaction mixture in such a manner as to maintain 0°C. The reaction is stirred at 60 °C for one hour, cooled to 0°C, quenched with brine, diluted with EtOAc, washed repeatedly with brine (6X), dried and concentrated in vacuo. The residue is purified by chromatography on SiO2 (5% EtOAc/Hexanes) to give 0.20 g of indanyl ether (Q) as a clear colorless oil: LCMS (ES) 340.17 (MNa+).
(S)-N-{(S)-1-Cyclohexyl-2-[(S)-2-(indan-2-yloxymethyl)-pyrrolidin-1-yl]-2-oxo- ethyl}-2-methylamino-propionamide, (34). ((S)-1 -{(S)-1 -Cyclohexyl-2-[(S)-2- (indan-2-yloxymethyl)-pyrroIidin-1-yl]-2-oxo-ethylcarbamoyl}-ethyl)-methyl-carbamic acid tetf-butyl ester (Q) (0.54 g, 1 mmol) is dissolved in DCM (8mL) and treated with trifluoroacetic acid (4 mL) for 45 minutes. The reaction mixture is concentrated in vacuo, purified by preparative reverse-phase hplc to give 0.096 g of the methylamine (34) as a clear gum: LCMS (ES) 442.26 (MH+).
Example 6
Figure imgf000062_0001
HOBt, HBTU, DIPEA TFA CH2CI2 oγ Cf°xyQ -C H >— NHBoc
Figure imgf000062_0002
1-Bromo-3-phenoxy-benzene (A) A mixture of dibromobenzene (3g, 12.75mmol), phenol (1g, 10.6mmol), copper(l) oxide (152mgs, 1mmol), and cesium carbonate (3.46g, 10.6mmoi) in 8mL of NMP is heated at 195°C for 20 minutes in a microwave. The heterogeneous mixture is filtered through a bed of Celite and the residue is washed with EtOAc (1 x 20mL). The filtrate is diluted with 1 N NaOH (200mL) and extracted with EtOAc (3 x 100mL). The organics were combined, dried over Na2SO , filtered and concentrated under reduced pressures to give crude product as a yellow oil which is purified by column chromatography (100% hexanes) to give 1- bromo-3-phenoxy-benzene as a colorless oil (1.4g, 53%). LCMS m/z 250 (M+1).
5-(3-Phenoxy-phenyl)-3,4-dihydro-2H-pyrrole (B): To a cold solution (-78°C) of 1- bromo-3-phenoxy-benzene (10.13g, 40.6mmol) in anhydrous THF (100mL) and under nitrogen is added n-BuLi (1.6M, 44.7mmol, 27mL). The mixture is allowed to stir for 30 minutes before being added to a cold solution (-78°C) of 1-(fetf- Butoxycarbonyl)-2-pyrrolidionone in anhydrous THF (50mL) under nitrogen via cannula. The resulting mixture is allowed to warm to room temperature overnight before being quenched with water (200mL) and extracted with EtOAc (3 x 100mL). The organics were collected, dried over Na2SO , filtered and concentrated under reduced pressures. The residue is dissolved in CH2CI2 (20mL) and TFA (10mL) is added with stirring. The mixture is stirred for 30 minutes and quenched over ice cold sat. NaHCO3, extracted with CH2CI2 (3 x 100mL) and the organics were combined, dried over Na SO , filtered and concentrated under reduced pressures. The residue is purified by silica gel column chromatography (20% EtOAc/Hexanes) to give 5-(3- phenoxy-phenyl)-3,4-dihydro-2H-pyrrole as light yellow oil (6.1g, 63%). LCMS m/z 238 (M+1).
(S)-2-(3-Phenoxy-phenyI)-pyrrolidine (C): To oven dried round bottom flask is added S,S-EBTHITiF2 (100mgs, 0.3mmol) and diluted with THF (5mL). The flask is sealed and purged with argon. To the yellow solution is added phenylsilane (4.6mL, 37.5mmol), pyrrolidine (100uL, 1.1mmol), and anhydrous methanol (100uL, 1.1 mmol). The resulting yellow mixture is stirred for 45minutes until green color persisted. A solution of 5-(3-phenoxy-phenyl)-3,4-dihydro-2H-pyrrole (1.2g, 5.05mmol) in THF (2mL) is added to the catalyst and the mixture is stirred for 8 hrs. The reaction is carefully quenched with 10% HCI (100mL) until gas evolution subsided and the pH~2. The mixture is diluted with EtOAc (100mL) and the aqueous layer is removed, neutralized with 3M NaOH (50mL) until basic and extracted with EtOAc (3 x 100mL). The organics were combined, dried over Na2SO4, filtered and concentrated under reduced pressures. The solid residue is purifed by silica gel column chromatography (100% EtOAc) to give (S)-2-(3-phenoxy-phenyl)-pyrrolidine as a yellow solid (580mgs, 48%). LCMS m/z 240.1 (M+1).
{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolidin-1-yl]-ethyl}- carbamic acid tert-butyl ester (D): (S)-2-(3-phenoxy-phenyl)-pyrrolidine (1.2g, 5.02mmol) is added to a solution of Boc-L-α-cyclohexylglycine (1.42g, 5.2mmoI), HOBt (1.0g, 7.53mmol) and HBTU (2.86g, 7.53mmol) in 10mL of DMF. Hunig's base (3.6MI, 20mmol) is added and the mixture is stirred for 30 minutes. The mixture is diluted with brine (20mL) and extracted with EtOAc (3 x 10mL). The organics were combined, dried over Na2SO4, filtered, concentrated under reduced pressures and purified by silica gel column chromatography (20% EtOAc/Hexanes) to give {(S)-1 -cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolidine-1 -yl]-ethyl}- cabamic acid tert-butyl ester as a white powder (1.65 g, 66%). LCMS m/z 479.2 (M+1).
(S)-2-Amino-2-cyclohexyl-1-[(S)-2-(3-phenoxy-phenyl)-pyrrolidin-1-yI]-ethanone (E): To a solution of {(S)-1-cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolidine- 1-yl]-ethyl}-carbamic acid tert-butyl ester in CH2CI2 (20mL) is added TFA (10mL) and the mixture is stirred for 30 minutes. The mixture is concentrated under reduced pressures to give (S)-2-amino-2-cyclohexyl-1-[(S)-2-(3-phenoxy-phenyl)-pyrrolidin-1- yl]-ethanone as a TFA salt quantitavely (1.65g). LCMS m/z 379 (M+1).
((S)-1 -{(S)-1 -Cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrroIidin-1 -yl]- ethylcarbamoyl}-ethyl)-methyl-carbamic acid tert-butyl ester (F): To a solution of Boc-N-methyl-L-alanine (771mgs, 3.79mmol), HOBt (700mgs, 5.17mmol), and HBTU (2.0g, 5.17mmol) in DMF (10mL) is added (S)-2-amino-2-cyclohexyl-1-[(S)-2- (3-phenoxy-phenyl)-pyrrolidin-1-yl]-ethanone and DIPEA (3mL, 17.25mmol). The mixture is stirred for 30 minutes and diluted with brine (20mL) and extracted with EtOAc (3 x 10mL). The organics were combined, dried over Na2SO4, filtered, concentrated under reduced pressures and purified by silica gel column chromatography (50% EtOAc/Hexanes) to give the product ((S) 1-{(S)-1-cyclohexyl- 2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolodin-1-yl]-ethylcarbamoyl}-ethyl)-methyl- carbamic acis tert-butyl ester as a white powder (1.3g, 84%). LCMS m/z 564 (M+1).
(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolidin-1-yl]- ethyl}-2-methylamino-propionamide(45): To a solution of ((S) 1 -{(S)-1 -cyclohexyl- 2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolodin-1-yl]-ethylcarbamoyl}-ethyl)-methyl- carbamic acis tert-butyl ester (450mgs, 0.79mmol) in CH2CI2 (20mL) is added TFA (10mL) and stirred for 30 minutes. The mixture is concentrated under reduced pressures and purified by reverse phase column chromatography to give the product as a TFA salt (370mgs, 82%). LCMS m/z 464.1 (M+1).
Example 7
Figure imgf000066_0001
(S)-2-(1H-Tetrazol-5-yl)-pyrrolidine-1 -carboxylic acid tert-butyl ester (A). To a solution of (S)-2-Cyano-pyrrolidine-1 -carboxylic acid tert-butyl ester (500 mg, 2.55 mmol) in N, N-dimethyl-formamide (20 mL) is added sodium azfde (174 mg, 2.68 mmol) and ammonium chloride (150 mg, 2.81 mmol). The solution is stirred at 93°C over night. The solution is poured into 5% citric acid solution with ice, and the mixture is extracted with EtOAc. The organic extract is washed with brine, dried and "concentrated under vacuum. The crude oil is used directly in the next step without further purification. M+H+= 240.
(S)-2-(2-BenzyI-2H-tetrazol~5-yl)-pyrrolidine-1 -carboxylic acid tert-butyl ester (B). To a solution of crude compound A in N, N-dimethyl-formamide (5 mL) is added K CO (1.16 g, 8.4 mmol) and benzyl bromide (665 t/L, 5.6 mmol). The solution is stirred at room temperature for 1 hr. The mixture is diluted with EtOAc and washed with brine. The organic layer is dried and concentrated under vacuum. The residue is purified by flash column chromatography (Hexanes/EtOAc) to provide 404 mg of the title compound M+H+= 330, and 401 mg of the other region isomer (S)-2-(1- Benzyl-1 H-tetrazol-5-yl)-pyrrolidine-1 -carboxylic acid tert-butyl ester (C). M+H+= 330. Combined yield is 87% for 2 steps.
2-Benzyl-5-(S)-pyrrolidine-2-yl-2H-tetrazole (D). To a solution of compound B in DCM (5 mL) is added triethylsilane (479 t/L, 3.0 mmol) and then TFA (5 mL). The solution is stirred at room temperature for 1 hr and dried under vacuum. The crude oil is used directly in the next step without further purification. M+H+= 230.
{2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyI-2-oxo-ethyl}- carbamic acid tert-butyl ester (E). To a solution of (S)-tert-butoxycarbonylamino- cyclohexyl-acetic acid (123.8 mg, 0.48 mmol) in DMA (5 mL) is added HBTU (248.8 mg, 0.656 mmol), HOBt (88.6 mg, 0.656 mmol) and diisopropylethylamine (305 i/L, 1.75 mmol). The mixture is stirred at room temperature for 5 minutes. A solution of compound D in DCM (5mL) is added to the above mixture at 0°C. The reaction mixture is stirred at room temperature for 1 hour and concentrated under vacuum. The residue is diluted with EtOAc. The organic is washed with brine, citric acid(5%), brine, NaHCO3(Sat.) and brine. The organic layer is then dried and concentrated under vacuum. The residue is purified by flash column chromatography (Hexanes/EtOAc) to provide the title compound 190mg (92%). M+H+= 369.
2-Amino-1-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-2-cyclohexyl- ethanone; compound with trifluoro-acetic acid (F). To a solution of compound E in DCM (4 mL) is added TFA (4 mL) at 0°C. The solution is stirred at room temperature for 1 hr and dried under vacuum. The crude oil is used directly in the next step without further purification. M+H+= 369. ((S)-1 -{2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-py rroIidin-1 -y l]-1 -cyclohexyl-2-oxo- ethylcarbamoyl}-propyl)-methyl-carbamic acid tert-butyl ester (G). To a solution of (S)-2-(tert-butoxycarbonyl-methyl-amino)-butyric acid (53.0 mg, 0.24 mmol) in DMA (2 mL) is added HBTU (125.0 mg, 0.33 mmol), HOBt (44.6 mg, 0.33 mmol) and diisopropylethylamine (192 t/L, 1.1 mmol). The mixture is stirred at room temperature for 5 minutes. A solution of compound F in DCM (2 mL) is added to the above mixture at 0°C. The reaction mixture is stirred at room temperature for 1 hour and concentrated under vacuum. The residue is diluted with EtOAc. The organic is washed with brine, citric acid(5%), brine, NaHCO3(Sat.) and brine. The organic layer is then dried and concentrated under vacuum. The crude oil is used directly in the next step without further purification. M+H+= 554.
(S)-N-{2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo- ethyl}-2-methylamino-butyramide; compound with trifluoro-acetic acid (50). To a solution of compound G in DCM (2 mL) is added TFA (2 mL) at 0°C. The solution is stirred at room temperature for 1 hr and dried under vacuum. The crude oil is purified by HPLC to provide the title compound. M+H+= 467.
Example 8 c < -θ_Ph H,N' pyridine h TFA boc 98% Q b-oct"' X > "Ph
TFA
Figure imgf000069_0001
DIPEA, HOBt, HBTU Boc-N-methy-LI-alanine TFA
Figure imgf000069_0003
Figure imgf000069_0004
2-(Benzyloxyimino-methyl)-pyrrolidine-1 -carboxylic acid tert-butyl ester (A). To a solution of benzylhydroxylamine (2.64g, 16.56mmole) in dry pyridine (20ml) is added 2-formyl-pyrrolidine-1 -carboxylic acid tert-butyl ester (3.30g, 16.56mmole). The solution is stirred for three hours at room temperature. The reaction solution is quenched with water and extracted with dichloromethane. The organic layer is combined, dried, and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; from 50% to 50% of ethyl acetate in hexane) to provide 4.9g (98%) of the title compound. M+H+-Boc=205.1.
Pyrrolidine-2-carbaldehyde-O-benzyl-oxime (B). The solution of 2- (benzyloxyimino-methyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (1.50g, 4.92mmole) and TFA (10ml) in dichloromethane (10ml) is stirred for 2 hours at room temperature. Solvent is removed. The crude product is carried to next step without further purification. M+H+=205.1 {(S)-2-[BenzyloxyIimino-methyl-pyrrolidine-1-yl]-1-cyclohexyl-2-oxo-ethyl}- carbamic acid tert-butyl ester (C). The solution of boc-L-α-cyclohexylglycine (1.27g, 4.92mmo!e), 1-hydroxylbenzotriazole (0.99g, 7.38mmole), diisopropylethylamine (2.54g, 19.68mmole), and O-benzotriazole-N,N,N,N- tetramethyl-urounium hexafluorophosphate (2.80g, 7.38mmole) in dichloromethane (30ml) is stirred for 15 minutes at room temperature. A solution of pyrrolidine-2- carbaldehyde-O-benzyl-oxime (~1.00g, 0.49mmole) in dichloromethane is added. The reaction solution is stirred for three hours at room temperature and then quenched with saturated NaHCO3 aqueous. , extracted with dichloromethane. The organic layer is combined, dried, and concentrated under vacuum. The residue is purified by flash chromatography (silica gel; from 20% to 70% of ethyl acetate in hexane) to provide 1.81g (83% over 2 steps) of the title compound. M+H+=444.2
1-((S)-2-Amino-2-cyclohexyl-acetyl)-prroIidine-2-Carbaldehyde-O-benzyl-oxime (D). The solution of {(S)-2-[benzyloxylimino-methyl-pyrrolidine-1-yl]-1-cyclohexyl-2- oxo-ethyl}-carbamic acid tert-butyl ester (1.76g, 3.97mmole) and TFA (10ml) in dichloromethane (20ml) is stirred for a hour. Solvent is removed under vacuum. The residue is carried to next step without further purification. M+H+=344.2
((S)-1 -{(S)-2-[2-(Benzyloxy imino-methy l)-pyrrolidine-1 -y l]-1 -cyclohexyl-2-oxo- ethylcarbamoyl}-ethyl)-methyl-carbamic acid tert-butyl ester (E). The solution of Boc-L-α-cyclohexylglycine (0.81g, 3.87mmole), 1-hydroxylbenzotriazole (0.81g, 5.95mmole), , diisopropylethylamine (2.05g, 15.88mmole), and O-benzotriazole- N,N,N,N-tetramethyl-urounium hexafluorophosphate (2.35g, 5.95mmole) in dichloromethane is stirred for 15 minutes at room temperature. A solution of 1-((S)- 2-amino-2-cyclohexyl-acetyl)-prrolidine-2-carbaldehyde-O-benzyl-oxime (~1.40g, 3.97mmole) in dichloromethane is added. The reaction solution is stirred for three hours at room temperature and then quenched with saturated NaHCO3 aqueous and extracted with dichloromethane. The organic layer is combined, dried, and concentrated under vacuum. The residue is carried to next step without further purification. M+H+=529.4.
(S)-N-{2-[2-(Benzyloxyimino-methyl-pyrrolϊdine-1-yl]-1-cyclohexyl-2-oxo-ethyl}- 2-methylamino-propionamide(8). The solution of ((S)-1-{(S)-2-[2-(benzyloxyimino- methyl)-pyrrolidine-1-yl]-1-cyclohexyl-2-oxo-ethylcarbamoyl}-ethyl)-methyl-carbamic acid tert-butyl ester (~2.10g, 3.97mmole) and TFA (20ml) in dichloromethane (40ml) is stirred for a hour. Solvent is removed under vacuum. 1.36g of crude product is obtained. The crude product (0.66g) is purified by HPLC (C18 silica gel, from 10% to 70% of CH3CN /H2O in 0.1% TFA) to provide 0.058g of the title compound as TFA salt of isomeric mixtures. M+H+=429.4.
Examples 9 - 78
The following compounds are prepared by methods analogous to those described herein utilizing analogous starting materials:
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0002
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000078_0002
Figure imgf000078_0003
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000086_0002
Figure imgf000087_0001
Additional compounds within the scope of Formula I include:
Figure imgf000087_0002
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000107_0002
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000109_0002
Figure imgf000110_0001
Example 195 (S)-N-[(S)-1-Cyclohexyl-2-((R)-2-{6-[(2-fluoro-phenyl)-methyl-amino]-pyridin-2-yl}- pyrrolidin-1 -yl)-2-oxo-ethyl]-2-methylamino-propionamide (78)
Figure imgf000110_0002
4,4,N-Trimethoxy-N-methy l-buty ramide (1 )
To a solution of methyl 4,4-dimethoxy-butyrate(4.99 g, 30.8 mmol) and N,O- dimethylhydroxylamine HCI(4.65 g, 47.68 mmol) in 60 mL of THF at - 20 °C, is added isopropylmagnesiumchloride(46 mL, 92.28 mmol, 2.0M in THF) maintaining the temperature below - 20 °C. After stirring at - 10 °C for 30 min, the reaction mixture is quenched with 50 mL of water and extracted with 3 x 80 mL of EtOAc. The combined organic layers is dried over Na2SO and filtered through a short silica gel pluge. The solution is concentrated to give 4,4,N-Trimethoxy-N-methyl- butyramide(5.9 g, 99%) as pale liquid. M/Z=191.0
N-[1 -Eth-(Z)-ylidene-5,5-dimethoxy-2-oxo-pentyl]-acryIimidoyl bromide (2)
To a suspension of 2,6-dibromopyridine( 8.1 g, 34.03 mmol) in 80 mL of ether at - 70 °C, is added BuLi( 12.3 mL, 26.17 mmol, 2.5 M in Hexane) in on portion. After stirring at - 70 °C for 5 min, 4,4,N-Trimethoxy-N-methyl-butyramide(5.0 g, 26.17 mmol) is added to the solution dropwise. After stirring at - 70 °C for 1.5 hr, the reaction mixture is quenched with 120 mL of water and extracted with 3 x 130 mL of EtOAc. The combined organic layers is concentrated and purified by chromatography(Hexane/EtOAc:70/30) to give N-[1-Eth-(Z)-ylidene-5,5-dimethoxy-2- oxo-pentyl]-acrylimidoyl bromide(5.96 g, 60.5%) as light yellow liquid. M/Z=288.0
N-[1-Eth-(Z)-ylidene-2,5-dioxo-pentyl]-acrylimidoyl bromide (3)
To a solution of N-[1-Eth-(Z)-ylidene-5,5-dimethoxy-2-oxo-pentyl] aerylimidoyl bromide(7.0 g, 28.9 mmol) in a solution of acetone( 30 mL) and water(1.5 mL) at room temperature, is added Amberlyse-15(20 g). After mechanical shacking for 3 hr at room temperature, the reaction mixture is filtered. The resin beads were washed with acetone (contain 10% of Et3N). The combined organic layers were concentrated and purified by chromatography(Hexane/EtOAc : 70/30) to yield N-[1-Eth-(Z)-ylidene-2,5-dioxo-pentyl]- acrylimidoyl bromide(5.18 g, 88.1%) as light yellow liquid. M/Z=421, 243.9 [M+1]
2-Bromo-6-[(S)-1-((R)-1-phenyl-ethyl)-pyrroIidin-2-yl]-pyridine (4)
To a solution of N-[1-Eth-(Z)-ylidene-2,5-dioxo-pentyl]-acrylimidoyl bromide(1.0 g, 4.1 mmol) and R(+)-α-methylbenzylamine(0.5 g, 4.1 mmol) in 17 mL of CH2CI2 at- 70 °C, is added acetic acid(0.6mL) and sodium triacetoxyborohydride(1.74 g, 8.2mmol). After stirring at - 70 °C for 40 min, the dry ice bath is removed, and the reaction solution is warmed to room temperature. After stirring at room temperature overnight, the reaction mixture is quenched with 20 mL of water and extracted with 3 x 30 mL of CH2CI2. The combined organic layers were concentrated and purified by chromatography(Hexane/EtOAc : 70/30) to yield 2-Bromo-6-[(S)-1-((R)-1-phenyl-ethyl)- pyrrolidin-2-yl]-pyridine(0.86 g, 62.9%) as light yellow liquid. M/Z=332.7 [M+1]
(Z)-N-(2-Fluoro-phenyl)-N-methyI-N,-[i_[(S)-1-((R)-1-phenyI-ethyl)-pyrrolidin-2-yl3- prop-2-en-(E)-ylidene]-propenamidine (5)
To a solution of 2-Bromo-6-[(S)-1-((R)-1-phenyl-ethyl)-pyrrolidin-2-yl]-pyridine(86.5 g, 2.57mmol), 2-fluro-methyaniline(64.7 mg, 5.14 mmol) and 2-(di-cyclohexylphosphino)-bi- pheny(38.5 mg, 0.13 mmol) in 20 mL of toluene at room temperature, were added Pd2(dba)3(117.6 mg, 0.13 mmol). The reaction mixture is stirred at 80 °C for 2 hrs, and then cooled to room temperature. The reaction mixture is filtered through celite, and the filtrate is diluted with 50 mL of EtOAc and washed with 2 x 50 mL of water. The combined organic layers were concentrated and purified by chromatography (CH2CI2/MeOH : 97/3) to give (Z)-N-(2-Fluoro-phenyl)-N-methyl-N'-[1 -[(S)-1 -((R)-1 -phenyl-ethyl)-pyrrolidin-2-yl]- prop-2-en-(E)-ylidene]-propenamidine(870 mg, 90.3%) as pale solid. M/Z=376.0 [M+1]
(Z)-N-(2-Fluoro-phenyl)-N-methyl-N,-[1-[(S)-1-((R)-1-phenyl-ethyl)-pyrrolidin-2-yl]- prop-2-en-(E)-ylidene]-propenamidine (6)
(Z)-N-(2-Fluoro-phenyl)-N-methyl-N'-[1-[(S)-1-((R)-1-phenyl-ethyl)-pyrrolidin-2-yl]-prop-2- en-(E)-ylidene]-propenamidine(500 mg, 1.33 mmol) is dissolved in 10 mL of MeOH in a 500 mL round bottle flask with 300 mg of Pd/C. The reaction mixture is stirred under H2 gas( 1 atm) from a balloon for 24 hours. After degasing under vacuum, the reaction mixture is filtered to remove catalyst. The crude product is purified by reverse phase HPLC to give give (Z)-N-(2-Fluoro-phenyl)-N-methyl-N'-[1-[(S)-1-((R)-1-phenyl-ethyl)- pyrrolidin-2-yl]-prop-2-en-(E)-ylidene]-propenamidine (200 mg, 55.4%) as yellow oil. M/Z=272.07 [M+1]
[(S)-1 -Cyclohexyl-2-((S)-2-{1 -[(E)-(Z)-N-(2-fluoro-phenyl)-N-methyl-1 -imioxo- propenylimino]-aIlyI}-pyrrolidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester (7) To a solution of Boc-L-a-cyclohexyglycine(204 mg, 0.79 mmol) in 5 mL of DMF at room temperature, is added diisopropylethylamine (0.58 mL, 3.3 mmol) slowly. After stirring at room temperature for 20 minutes, a solution of HOBT(116 mg, 0.86 mmol) and HBTU(325 mg, 0.86 mmol) in DMF (5 mL) is added to the reaction mixture, and the solution is transferred to another flask contained (Z)-N-(2-Fluoro-phenyl)-N-methyl-N'-[(S)-1- pyrrolidin-2-yl-prop-2-en-(E)-ylidene]-propenamidine(180 mg, 0.66 mmol). After stirring for 1 hr, the reaction solution is diluted with EtOAc (50 mL), and washed with water ( 3 x 20 mL). The combined organic layers is concentrated. The crude product is diluted with CH2Cl2 (10 mL) and dried over Na2SO4, and purified by chromatography (CH2CI2/MeOH:97/3) to give [(S)-1-Cyclohexyl-2-((S)-2-{1-[(E)-(Z)-N-(2-fluoro-phenyl)-N- methy!-1 -imioxo-propenylimino]-allyl}-pyrrolidin-1 -yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester (320 mg,94.5%) as pale gum. M/Z=511.14[M+1]
(Z)-N'-[1-[(S)-1-((S)-2-Amino-2-cyclohexyl-acetyl)-pyrrolidin-2-yl]-prop-2-en-(E)- ylidene]-N-(2-fluoro-phenyl)-N-methyl-propenamidine (8)
To a solution of [(S)-1-Cyclohexyl-2-((S)-2-{1-[(E)-(Z)-N-(2-fluoro-phenyl)-N-methyl- 1 -imioxo-propenylimino]-allyl}-pyrrolidin-1 -yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester (320 mg, 0.63 mmol) in CH2CI2 ( 3 mL) at -20 °C is added TFA (5 ML, pre- cooled to -20 °C) slowly. After stirring at 0 °C for 30 min, the reaction mixture is concentrated to remove most of TFA. The residue is dissolved in 20 mL of CH2CI2, and neutralized with 10% NH4OH to PH=8. The solution is dried over Na2SO and concentrated to give (Z)-N'-[1-[(S)-1-((S)-2-Amino-2-cyc lohexyl-acetyl)-pyrrolidin-2-yl]-prop-2-en-(E)-ylidene]-N-(2-fluoro-phenyl)-N-methyl- propenamidine (260 mg, quantitative) as pale gum without further purification for next step reaction. M/Z=411.2 [M+1]
{(S)-1-[(S)-1-Cyclohexyl-2-((S)-2-{6-[(2-fluoro-phenyl)-methyl-amino]-pyridin-2-y!}- pyrrolidin-1-yl)-2-oxo-ethylcarbamoyl]-ethyl}-methyl-carbamic acid tert-butyl este (9) To a solution of Boc-N-methyl-L-a-alanine(155 mg, 0.76 mmol) in 5 mL of DMF at room temperature, is added diisopropylethylamine (0.58 mL, 3.3 mmol) slowly. After stirring at room temperature for 20 minutes, a solution of HOBT(111 mg, 0.82 mmol) and HBTU(311 mg, 0.82 mmol) in DMF (5 mL) is added to the reaction mixture, and the solution is transferred to another flask contained (Z)-N'-[1-[(S)-1-((S)-2-Amino-2-cyclohexyl-acetyl)- pyrrolidin-2-yl]-prop-2-en-(E)-ylidene]-N-(2-fluoro-phenyl)-N-methyI-propenamidine (260 mg, 0.63 mmol). After stirring for 1 hr, the reaction solution is diluted with EtOAc (50 mL), and washed with water ( 3 x 20 mL). The combined organic layers is concentrated. The crude product is diluted with CH2CI2 (10 mL) and dried over Na2SO4, and purified by chromatography (CH2CI2/MeOH:97/3) to give {(S)-1-[(S)-1-Cyclohexyl-2-((S)-2-{6-[(2- fluoro-phenyl)-methyI-amino]-pyridin-2-yl}-pyrrolidin-1-yl)-2-oxo-ethylcarbamoyl]-ethyl}- methyl-carbamic acid tert-butyl este (300 mg,79.5%) as pale gum. M/Z=596.2[M+1]
(S)-N-[(S)-1-Cyclohexyl-2-((S)-2-{6-[(2-fluoro-pheny!)-methyl-amino]-pyridin-2- yl}-pyrrolidin-1-yl)-2-oxo-ethyl]-2-methy!amino-propionamide (78)
To a solution of give {(S)-1-[(S)-1-Cyclohexyl-2-((S)-2-{6-[(2-fluoro-phenyl)-methyl- amino]-pyridin-2-yl}-pyrrolidin-1-yl)-2-oxo-ethylcarbamoyl]-ethyl}-methyl-carbamic acid tert-butyl este (300 mg, 0.50 mmol) in CH2CI2 ( 1 mL) at -20 °C is added TFA (5 ML, pre-cooled to -20 °C) slowly. After stirring at 0 °C for 30 min, the reaction mixture is concentrated and purified by prep HPLC (Column: Waters Sunfire prep C18 30 x 100 mm; Mobile phase: isocratic condition, CH3CN 28% / H2O 72% with 0.1 %TFA; Flow rate: 45 mL/min) to give (S)-N-[(S)-1-Cyclohexyl-2-((S)-2-{6-[(2- fluoro-phenyl)-methyl-amino]-pyridin-2-yl}-pyrrolidin-1-yl)-2-oxo-ethyl]-2- methylamino-propionamide(206 mg, 67.0%) as white solid TFA salt. (HR Mass M/Z=496.3069 [M+1]).
In order to measure the ability of the inventive compounds to bind the BIR3 peptide binding pocket an ELISA and a cell based assays are utilized.
Elisa Compounds are incubated with GST-BIR3 fusion protein and biotinylated SMAC peptide (AVPFAQK) in stretavidin-coated 96 well plates. For XIAP BIR3 Smac Elisa, a GST-BIR3 fusion containing amino acids 248-358 from XIAP is used. For CIAP1 BIR3 Smac Elisa, a GST-BIR3 fusion containing amino acids 259-364 from CIAP1 is used. Following a 30 minute incubation, wells are extensively washed. The remaining GST-BIR3 fusion protein is monitored by ELISA assay involving first, incubation with goat anti-GST antibodies followed by washing and incubation with alkaline phosphatase conjugated anti-goat antibodies. Signal is amplified using Attophos (Promega) and read with Cytoflour Ex 450nm/40 and Em 580nm. IC50S correspond to concentration of compound which displaces half of GST-BIR3 signal. The IC50 for non-biotinylated Smac is 400 nM. The IC50 values of compounds listed in Table 1 in the described ELISA assays ranged from 0.005 - 10 μM.
Cell Proliferation Assay
The ability of compounds to inhibit tumor cell growth in vitro is monitored using the CellTiter 96® AQue0us Non-Radioactive Cell Proliferation Assay (Promega). This assay is composed of solutions of a novel tetrazolium compound [3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine methosulfate) PMS. MTS is bioreduced by cells into a formazan product, the absorbance of which is measured at 490nm. The conversion of MTS into the aqueous soluble formazan product is accomplished by dehydrogenase enzymes found in metabolically active cells. The quantity of formazan product as measured by the amount of 490nm absorbance is directly proportional to the number of living cells in culture. The IC50 values of compounds listed in Table 1 in the described cell assays ranged from 0.005 - 50 μM. Example 196
Tablets 1 comprising compounds of the formula (I)
Tablets, comprising, as active ingredient, 50 mg of any one of the compounds of formula (I) mentioned in the preceding Examples 9-194 of the following composition are prepared using routine methods:
Figure imgf000116_0001
Manufacture: The active ingredient is combined with part of the wheat starch, the lactose and the colloidal silica and the mixture pressed through a sieve. A further part of the wheat starch is mixed with the 5-fold amount of water on a water bath to form a paste and the mixture made first is kneaded with this paste until a weakly plastic mass is formed.
The dry granules are pressed through a sieve having a mesh size of 3 mm, mixed with a pre-sieved mixture (1 mm sieve) of the remaining corn starch, magnesium stearate and talcum and compressed to form slightly biconvex tablets. Example 197
Tablets 2 comprising compounds of the formula (I)
Tablets, comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) of Examples 9-194 are prepared with the following composition, following standard procedures:
Figure imgf000117_0001
Manufacture: The active ingredient is mixed with the carrier materials and compressed by means of a tabletting machine (Korsch EKO, Stempeldurehmesser 10 mm). Example 198
Capsules
Capsules, comprising, as active ingredient, 100 mg of any one of the compounds of formula (I) given in Examples 9-194, of the following composition are prepared according to standard procedures:
Figure imgf000118_0001
Manufacturing is done by mixing the components and filling them into hard gelatine capsules, size 1.

Claims

We claim:
1. A compound according to formula
Figure imgf000119_0001
wherein
Ri is H; C C4 alkyl; C1-C4 alkenyl; Cι-C4 alkynyl or C3-C-ι0cycloalkyl which are unsubstituted or substituted;
R2 is H; Cι-C alkyl; C C alkenyl; C-ι-C4 alkynyl or C3-Cι0cycloalkyl which are unsubstituted or substituted;
R3 is H; -CF3; -C2F5; C C4 alkyl; Cι-C4 alkenyl; C1-C4 alkynyl; -CH2-Z or R2 and R3 together with the nitrogen form a het ring;
Z is H; -OH; F; Cl; -CH3; -CF3; -CH2CI; -CH2F or -CH2OH;
R4 is C1-C16 straight or branched alkyl; C1-C16 alkenyl; C1-C16 alkynyl; or -C3- Ciocycloalkyl; -(CH2)ι-6-Zι; -(CH2)o-6-aryl; and -(CH2)o-6-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
Zi is -N(R8)-C(O)-Cι-C10alkyl; -N(R8)-C(O)-(CH2)ι-6-C3-C7cycloalkyl; -N(R8)-C(O)- (CH2)o-6-phenyl; -N(R8)-C(O)-(CH2)ι-6-het; -C(O)-N(R9)(Rι0); -C(O)-O-C C10alkyl; - C(O)-O-(CH2)ι-6-C3-C7cycloalkyl; -C(O)-O-(CH2)o-6-phenyl; -C(O)-O-(CH2)ι-6-het; -O- C^J-d-doalkyl; -O-C(O)-(CH2)ι-6-C3-C7cycloalkyl; -O-C(O)-(CH2)o-6-phenyl; -O- C(O)-(CH2)ι-6-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted; het is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1 , 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon or nitrogen atom;
R8 is H; -CH3; -CF3 ; -CH2OH or -CH2CI;
Rg and R-io are each independently H; Cι-C alkyl; C3-C cycloalkyl; -(CH2)ι-β-C3- C7cycloalkyl; -(CH )o-6-phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or Rg and R-io together with the nitrogen form het;
R5 is H; C-i-Cio-alkyl; aryl; phenyl; C3-C7cycloalkyl;
Figure imgf000120_0001
-d- C1oalkyl-aryl; -(CH2)o-6-C3-C7cycloalkyl-(CH2)o-6-phenyl; -(CH2)o-4CH-((CH2)ι-4- phenyl)2; -(CH2)o-6-CH(phenyl)2; -indanyl; -C(O)-CrCιoalkyl; -C(O)-(CH2)ι-6-C3-C7- cycloalkyl; -C(O)-(CH2)o-6-phenyl; -(CH2)o-6-C(O)-phenyl; -(CH2)0-6-het; -C(O)-(CH2)ι- 6-het; or R5 is a residue of an amino acid, wherein the alkyl, cycloalkyl, phenyl and aryl substituents are unsubstituted or substituted;
U is as shown in structure II:
Figure imgf000120_0002
wherein n = 0-5; X is -CH or N; Ra and Rb are independently an O, S, or N atom or C0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from O, S or N, and where the alkyl may be unsubstituted or substituted; Rd is selected from: (a) -Re - Q - (Rf)p(Rg)q; or
Figure imgf000121_0001
Re is H or Re and Rd may together form a cycloalkyl or het; where if Rd and Re form a cycloalkyl or het, R5 is attached to the formed ring at a C or N atom; p and q are independently 0 or 1;
Re is C-i-s alkyl or alkylidene, and Re which may be unsubstituted or substituted;
Q is N, O, S, S(O), or S(O)2;
API and Ar2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H; -CrC10alkyl; Cι-Cι0alkylaryl; -OH; -O-C1- C10alkyl; -(CH2)o-6-C3-C7cycIoaIkyl; -O-(CH2)o-6-aryl; phenyl; aryl; phenyl-phenyl; - (CH2)i-6-het; -O-(CH2)ι-6-het; -ORn; -C(O)-Rn; -C(O)-N(Rn)(R12); -N(Rn)(R12); -S- R11; -S(O)-Rn; -S(O)2-Rn; -S(O)2-NRnR 2; -NRn-S(O)2- R12; S-Cι-C10alkyl; aryl-C C4alkyl; het-CrC^alkyl wherein alkyl, cycloalkyl, het and aryl are unsubstituted or substituted; -SO2-Cι-C2alkyl; -SO2-C1-C2alkylphenyl; -O-C C4alkyl; or Rg and Rf form a ring selected from het or aryl;
D is -CO-; -C(O)-Ci-7 alkylene or arylene; -CF2-; -O-; -S(O)r where r is 0-2; 1,3dioaxolane; or Ct-7 alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-Cι-C6aIkyl, -S-C-i- C6alky! or -CF3; or D is -N(Rh) wherein Rh is H; C1-7 alkyl (unsub or substituted); aryl; -©(C^cycloalkyl) (unsub or substituted); C(O)-C C10alkyl; C(O)-C0-C10alkyl- aryl; C-O-Cι-Cι0alkyl; C-O-Co-C10alkyl-aryl or SO2-Cι-C10-alkyl; SO2-(Co-Cι0- alkylaryl);
Rδ, R7, R'e and R'7 are each independently H; -C1-C10 alkyl; -C-i-Cio alkoxy; aryl-Cr C10 alkoxy; -OH; -O-Cι-C10alkyl; -(CH2)o-6-C3-C7cycloalkyl; -O-(CH2)r β-aryl; phenyl; - (CH2)ι-6-het; -O-(CH2)ι-6-het; -0R11; -C(O)-R1i ; -C(O)-N(R11)(R12); -N(Rn)(R12); -S- Rn; -S(O)-Rn; -S(O)2-Rn; -S(O)2-NRnRι2; -NRn-S(O)2- R12; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; and R6ι R7ι R'6 and R' can be united to form a ring system;
R11 and R12 are independently H; C1-C10 alkyl; -(CH2)o-6-C3-C7cycloalkyl; -(CH2)o-6-
(CH)o-ι(aryl)1-2; -C(O)-C1-C10alkyl; -C(O)-(CH2)ι-6-C3-C7cycloalkyl; -C(O)-O-(CH2)o-6- aryl; -C(O)-(CH2)0-6-O-fluorenyl; -C(O)-NH-(CH2)o-6-aryl; -C(O)-(CH2)0-6-aryl; -C(O)-
(CH2)ι-6-het; -C(S)-C1-Cι0alkyl; -C(SHCH2)1-6-C3-C7cycloalkyl; -C(S)-O-(CH2)0-6-aryl;
-C(S)-(CH2)0-6-O-fluorenyl; -C(S)-NH-(CH2)o-6-aryl; -C(S)-(CH2)o-6-aryl; -C(S)-(CH2)ι-6- het; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or Rn and R12 are a substituent that facilitates transport of the molecule across a cell membrane; or
R11 and R12 together with the nitrogen atom form het; wherein the alkyl substituents of Rn and Rι2 may be unsubstituted or substituted by one or more substituents selected from C-i-C-ioalkyl, halogen, OH, -O-Cι-C6aIkyl, -S-
C C6alkyl or -CF3; substituted cycloalkyl substituents of Rn and R12 are substituted by one or more substituents selected from a C-i-C-io alkene; Cι-C6alkyl; halogen; OH; -O-Cι-C6alkyl; -
S-C Cealkyl or -CF3; and substituted phenyl or aryl of Rn and R^ are substituted by one or more substituents selected from halogen; hydroxy; C1-C4 alkyl; Cι-C alkoxy; nitro; -CN; -O-C(O)-Cr
C4alkyl and -C^-O-CrOraryl, or pharmaceutically acceptable salts thereof.
2. A compound formula (I) according to claim 1 wherein Ri is H; -CrC4 alkyl; -Cι-C4 alkenyl; -Crd alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, - OH, -SH, -OCH3, -SCH3, -CN, -SCN and nitro; R2 is H; -CrC4alkyl; -C-ι-C4 alkenyl; -d-C4 alkynyl or cycloalkyl which are unsubstituted or substituted by one or more substituents selected from halogen, - OH, -SH, -OCH3, -SCH3, -CN, -SCN and nitro;
R3 is H; -CF3; -C2F5; -C1-C4alkyl; -d-C4alkenyl; -Cι-C4a)kynyl; -CH2-Z or R2 and R3 together with the nitrogen form a het;
Z is H; -OH; F; Cl; -CH3; -CF3; -CH2CI; -CH2F or -CH2OH;
R4 is Ci-Ci6 straight or branched alkyl; C Ci6 alkenyl; C -C16 alkynyl; or cycloalkyl; - (CH2)-|.6-Zι; -(CH2)o-6-phenyl; and -(CH2)0-6-het; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
Z1 is -N(R8)-C(O)-C C10alkyl; -N(R8)-C(O)-(CH2)1-6-C3-C7cycloalkyl; -N(R8)-C(O)- (CH2)o.6-phenyl; -N(R8)-C(O)-(CH2)1-6-het; -C(O)-N(R9)(R10); -C(O)-O-d-doalkyl; - C(O)-O-(CH2)1-6-C3-C7cycloalkyl; -C(O)-O-(CH2)o-6-phenyI; -C(O)-O-(CH2)ι-6-het; -O- C(O)-C1-C10alkyl; -O-C(O)-(CH2)ι-6-C3-C7cycloalkyl; -O-C(O)-(CH2)0-6-phenyI; -O- C(O)-(CH2)ι-6-het, wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted;
het is a 5-7 membered heterocyclic ring containing 1- 4 heteroatoms selected from N, O and S, or an 8-12 membered fused ring system including at least one 5-7 membered heterocyclic ring containing 1 , 2 or 3 heteroatoms selected from N, O, and S, which heterocyclic ring or fused ring system is unsubstituted or substituted on a carbon atom by halogen, hydroxy, C1-C alkyl, C1-C4 alkoxy, nitro, -O-C(O)-Cι- C4alkyl or -C(O)-O-Cι-C4-alkyl or on a nitrogen by d-d alkyl, -O-C(O)-d-C4alkyl or -C(O)-O-d-C4alkyl;
R8 is H, -CH3, -CF3 , -CH2OH or -CH2CI; Rg and R 0 are each independently H; -d-C alkyl; C3-C7cycloalkyl; -(CH2)ι-6-C3- C7cycloalkyl; -(CH2)0-6-phenyl; wherein alkyl, cycloalkyl and phenyl are unsubstituted or substituted, or R9 and R10 together with the nitrogen form het;
R5 is H; Ci-Cioalkyl; C3-C7cycloalkyl; -(CH2)ι-6-C3-C7cycloalkyl; -C C10alkyl-aryl; -
(CH2)o-δ-C3-C7cycloaIky CH2)o-6-phenyl; -(CH2)o-4CH-((CH2)ι-4-phenyl)2; -(CH2)o-6- CH(phenyl)2; -indanyl; -C(O)-Cι-Cιoalkyl; -C(O)-(CH2)ι-6-C3-C7cycloalkyl; -C(O)- (CH2)o-6-phenyl; -(CH2)0-6-het ; -C(O)-(CH2)-ι-6-het; or R5 is a residue of an amino acid, wherein alkyl, cycloalkyl, phenyl and aryl are unsubstituted or substituted;
U is a as shown in structure II:
Figure imgf000124_0001
wherein n = 0-5;
X is -CH or N;
Ra and Rb are independently an O, S, or N atom or C0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
O, S or N, and where the alkyl may be unsubstituted or substituted;
Rd is selected from: (a) Re - Q - (Rf)P(Rg)q ; or (b) Arι-D- Ar2 ; p and q are independently 0 or 1;
Re is H or Rd and Re together form cycloalkyl or het; where if Rd and Re form a cycloalkyl or heteroring, R5 is attached to the formed ring at a C or N atom; Re is d-8 alkyl which may be unsubstituted or substituted;
Q is N, O, S, S(O), or S(O)2;
Ar-i and Ar2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H or substituted or unsubstituted C0-doalkyl, or d-doalkylaryl;
D is -CO-; -C(O)-Ci-7 alkylene or arylene; -CF2-; -O-; -S(O)r where r is 0-2; 1,3dioaxolane; or Cι- alkyl-OH; where alkyl, alkylene or arylene may be unsubstituted or substituted with one or more halogens, OH, -O-Cι-C6alkyl, -S-Cr C6alkyl or -CF3; or D is -N(Rh) wherein Rh is H; d.7 alkyl (unsub or substituted); aryl; -O(d-7cycloalkyl) (unsub or substituted); C(O)-C1-C 0alkyl; C(O)-Co-C10alkyl- aryl; C-O-Cι-Cι0alkyl; C-O-Co-C10alkyl-aryl or SO2-CrCιo-alkyl; SO2-(C0-do- alkylaryl);
and R6, R7ι R'6 and R'7 are each independently H; -d-C10 alkyl; -OH; -O-Cι-C10alkyl; -(CH2)o-6-C3-C7cycloalkyl; -O-(CH2)0-6-aryl; phenyl; -(CH^-e-het; -O-(CH2)ι^-het; - 0R11 ; -C(0)-R11 ; -C(O)-N(Rn)(Ri2); -N(Rn)(R12); -S-R11; -S(0)-R11 ; -S(0)2-R11 ; - S(O)2-NRnR12; -NRn-S(O)2- R12; wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or any R6, R7, R'e and R'7 can be united to form a ring system; R11 and R12 are independently H; d-C10 alkyl; -(CH2)o-6-C3-C7cycloalkyl; -(CH2)o-6- (CHVKaryl z; -C(O)-Cι-C10alkyl; -C(OHCH2)ι-6-C3-C7cycloalkyl; -C(O)-O-(CH2)0-6- aryl; -C(O)-(CH2)o-6-0-fluorenyl; -C(O)-NH-(CH2)o-6-aryl; -C(O)-(CH2)o-6-aryl; -C(O)- (CH^-e-het; -C(S)-Cι-Cι0alkyl; -C(S)-(CH2)ι-6-C3-C7cycloalkyl; -C(S)-O-(CH2)o-6-aryl; -C(S)-(CH2)o-6-O-fluorenyl; -C(S)-NH-(CH2)o-6-aryl; -C(S)-(CH2)0-6-aryl; -C(S)-(CH2)1.6- het, wherein alkyl, cycloalkyl and aryl are unsubstituted or substituted; or R-n and R12 are a substituent that facilitates transport of the molecule across a cell membrane; or R11 and R12 together with the nitrogen are het; aryl of Rn and R-12 can be phenyl, naphthyl, or indanyl which is unsubstituted or substituted; alkyl of Rn and R12 may be unsubstituted or substituted by one or more substituents selected from a d-Cio alkene, halogen, OH, -O-Cι-C6aIkyl, -S-Cι-C6alkyl and -CF3; cycloalkyl of R-n and R-ι2 may be unsubstituted or substituted by one or more selected from a Ci-do alkene, one or more halogens, d-C^alky!, halogen, OH, -O- d-C6alkyl, -S-d-C6alkyl or -CF3; and phenyl or aryl of R-n and R12 may be unsubstituted or substituted by one or more substituents selected from halogen, hydroxy, Cι-C4 alkyl, d-C alkoxy, nitro,
-CN, -O-C(O)-C C4alkyl and -C(O)-O-d-C -aryl; or pharmaceutically acceptable salts thereof.
3. A compound according to Claim 1 wherein
R-i and R are independently H or substituted or unsubstituted Cι-C4alkyl;
R4 is C1-C-16 straight or branched alkyl, or C3-Cιocycloalkyl, wherein the alkyl or cycloalkyl may be unsubstituted or substituted;
R5 is H; d-C10alkyl; C C10alkyl-aryl; -C(O)-(CH2)0-6-Phenyl; -(CH2)o-6-C(O)- Phenyl; aryl; indanyl; naphthyl or R5 is a residue of an amino acid, wherein the alkyl or aryl substituents are unsubstituted or substituted;
U is as shown in structure II:
Figure imgf000126_0001
wherein n = 0-5; X is -CH or N;
Ra and Rb are independently an O, S, or N atom or C0-8 alkyl wherein one or more of the carbon atoms in the alkyl chain may be replaced by a heteroatom selected from
O, S or N, and where the alkyl may be unsubstituted or substituted;
Rd is selected from (a) -Re - Q - (Rf) (Rg) ; or
Figure imgf000126_0002
Rc is H or Re and Rd together form cycloalkyl or het; where if Rd and Re form a cycloalkyl or heteroring, R5 is attached to the formed ring at a C or N atom; p and q are independently 0 or 1;
Re is d-8 alkyl, or methylidene which may be unsubstituted or substituted;
Q is N, O, S, S(O), or S(O)2;
An and Ar2 are substituted or unsubstituted aryl or het;
Rf and Rg are each independently H or substituted or unsubstituted C0-CιoaIkyl; d- doalkylaryl; aryl-d-C10alkyl; het-d-C10alkyl -C(O)-d-C4-alkyl-ρhenyl; -C(O)-d-C4- alkyl; -SO2-d-C2alkyl; -SO2-C -C2alkylphenyl; -O-d-d-alky;
D is -C(O)-; d- alkylene or arylene; -O-, or -S(O)r where r is 0-2; where alkyl, alkylene or arylene which may be unsubstituted or substituted with one or more halogens; -OH; -O-d-C6alkyl; -S-d-C6alky! or -CF3; or D is NRh wherein Rh is H; d-7 alkyl (unsubtituted or substituted); aryl; -Od-7 cycloalkyl (unsubstituted or substituted); -CO-C0-ιo alkyl or aryl or SO2-C0-10 -alkyl or aryl; and Re, R7, R'e and R'7 are each independently H, -C1-C10 alkyl, or -OH, alkoxy, or aryloxy; or pharmaceutically acceptable salts thereof.
4. A compound according to Claim 1 wherein
U is a bicyclic saturated or unsaturated ring system, consisting of all carbon skeleton or with one or more heteroatoms such as O, N, S but preferably as shown in structure III:
Figure imgf000127_0001
wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R6, R7, Re- and R7';
X is CH or N;
V is O, F2, Cl2, Br2, l2, S, YH, H2, NH, or d-C4 alkyl;
W is -CH, or -N; n is 0-3; and is 0-3.
5. A compound according to Claim 1 wherein the ring carbon atoms on U are substituted with subsituents independently selected from halo, H, OH, lower alkyl or lower alkoxy, wherein alkyl or alkoxy are unsubstituted or substituted by halogen, OH, lower alkyl or lower alkoxy.
6. A compound according to Claim 1 wherein Ri and R are preferably methyl or ethyl;
R2 is especially H methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is -Ci-dalkyl; -C3-C7 cycloalky; -(CH2)ι-6cycloalkyl; or -(CH2)o-6aryl;
R5 is -d-dalkyl-phenyl; -C(O)-d-C4-aIkyl-phenyl; -C1-C4-C(O)-alkyl-pheny or ary!,R5 is particularly phenylmethyl, phenylethyl and phenylpropyl; indanyl, naphthyl;
-C(O)-CH2-phenyl or -CH2-C(O)-phenyl;
Re and R7 are H or methyl;
U has the structure of formula III:
Figure imgf000128_0001
wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for Re, R7, Re- and R7';
X is N;
V is O or H2; W is -N; n is 1; and m is 1 or 2.
7. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is H;
R4 is d-dalkyl; C3-C7 cycloalkyl; C1-C7 cycloalkyl-Cι-C7alkyl; phenyl-d-C7alkyl or aryl. R4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH2- cyclopentyl, -CH2-cycIohexyl; -CH2-cyclopropyl; phenyl or -CH2-phenyl;
R5 is -Cι-d-alkyl-phenyl; -C(O) -Cι-C4-alkyl-phenyl; -d-C 4 -C(O) -alkyl-pheny or aryl. R5 is particularly phenylethyl; indanyl, naphthyl; -C(O) -CH2-phenyl; -CH2 -C(O)
-phenyl; or (CF3O)phenylethyl;
Figure imgf000129_0001
U has the structure of formula III wherein wherein any of the ring carbon atoms can be unsubstituted or substituted with any of the substituted defined above for R6, R7, Re- and R7';
X is N;
V is O or H2; W is -N; n is 1 ; and m is 1 or 2.
8. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl; R4 is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H;
U has the structure of formula II wherein
X is N;
Re, R'e, R?, and R'7 are H; n is O;
Re is H;
Ari and Ar2 are substituted or unsubstituted phenyl or het particularly tetrazolyl, 1 ,
2,3-triazole, pyrazole, oxazole, pyrrolyl, triazine, pyrimidine, imidazol, oxadiazol; and and D is Ci alkyl which may optionally be substituted with halo, especially F.
9. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl; C3-C7 cycloalkyl; C1-C7 cycloalkyl-Cι-C7alkyl; phenyl-C1-C7alkyl or aryl;
R5 is H;
U has the structure of formula II wherein
X is N;
Re, R'e, R7, and R'7 are H; or R6 is -C(O)-d-C4-alkyl-phenyl and R'6, R7, and R'7 are
H; n is O;
Re is H;
Ari and Ar2 are substituted or unsubstituted phenyl or het, particularly triazine, pyrimidine, pyridine, oxazole, 2,4-difluorophenyl, Cl-phenyl or fluorophenyl; and D is
N(Rh), where Rh is H, Me, -CHO, -SO2, -C(O), -CHOH, CF3 or -SO2CH3.
10. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl; R4 is d-dalkyl; C3-C7 cycloalkyl; d_C7 cycloalkyl- d.C7alkyl; phenyl-C1.C7alkyl or aryl. R4 is particularly methyl, ethyl, butyl, isopropyl, t-butyl, or cyclohexyl; -CH2- cyclopentyl, -CH2-cyclohexyl; -CH2-cyclopropyl; phenyl or -CH2-phenyl;
R5 is H;
U has the structure of formula II wherein
X is N;
Re, R'e, R7, and R'7 are H; n is O;
Re is H;
An and Ar2 are substituted or unsubstituted phenyl or het particularly pyrimidine, pyridine, oxazole, 2-methyloxazole; and D is -O-.
11. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl; R4 is Cι-C4alkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl; R5 is H;
U has the structure of formula II wherein X is N;
R6, R'e, R7, and R'7 are H; n is O; Re is H;
Ari and Ar2 are substituted or unsubstituted phenyl or het; and D is S, S(O), or S(O)2.
12. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl; R is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl; R5 is H;
U has the structure of formula II wherein X is N;
Re, R'e, R7, and R'7 are H; n is O; Re is H;
APJ and Ar are substituted or unsubstituted phenyl or het, particularly oxazole, thaizole and ozadiazole; and D is C(O), or 1 ,3-dioxolane.
13. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-C alkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H or phenyl C1-C10 alkyl such as phenylethyl;
U has the structure of formula II wherein
X is N;
Re, R'e, R7, and R'7 are H; n is O;
Re and Rd are het, particularly pyrrolidine; pyrrolidin-2-one; or pyrrolidin-3-one.
14. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl or C3-C cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H, indanyl or phenyl;
U has the structure of formula II wherein X is N;
Q is O;
Re, R'e, R7, and R'7 are H; n is O;
Re is d alkyl; and p and q are 0.
15. A compound according to Claim 1 wherein R and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H, indanyl or phenyl;
U has the structure of formula II wherein
X is N;
Q is N;
Re, R'e, R7, and R'7 are H; n is O;
Re is d alkyl; and
Rg is H, d-C8 alkyl, methyl, ethyl, hexyl, heptyl, oetyl, or CH2CF3, or aryl-Cι-C4 alkyl particularly phenylethyl, furanylethyl; C3-C7 cycloalkyl particularly cyclohexyl; ethylphenyl; -C(O) -d-d-alkyl-phenyl; -C(O) -d-C4-alkyl; -d-C4-alkyl-ary! particularly -CH2-phenyl; -CH2-thiophene, -CH2-furan, -CH2-pyrrolidinyl, -CH2- imidazole, -CH2-triazole, -CH2-imidazole; and Rf is d-C2 alkyl; d-C2 alkylphenyl; -SO2.Cι-C2alkyl; -SO2_d.C2alkylphenyl; -O-
Cι-C4-alkyl particularly O-ethyl; phenyl-phenyl, 1,2,3,4tetrahydronapthalene and indanyl.
16. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl; R4 is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is H, indanyl or phenyl;
U has the structure of formula II wherein
X is N;
Q is N;
R6> R'e, R7, and R'7 are H; n is O;
Re is Cι alkyl; and
Rg and Rf form a ring selected from het or aryl particularly 2,3,4,5- tetrahydrobenzo[c]azepine; 1,2,3,4 tetrahydroquinoline; indanyl which may be substituted with d-dalkylphenyl
17. A compound according to Claim 1 wherein Ri and R3 are preferably methyl or ethyl;
R2 is especially H, methyl, ethyl, chloromethyl, diehloromethyl or trifluoromethyl;
R4 is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
Rs is phenyl;
U has the structure of formula II wherein
X is N;
Q is O, S, S(O) or S(O)2;
Re, R'e, R7, and R'7 are H; n is O;
Re is C1 alkyl; q is O;
Re is H; and Rf is C2 alkyl.
18. A compound according to Claim 1 wherein R3 and R4 have the stereochemistry indicated in formula IV, with the definitions of the variable substituents and preferences described herein above also applying to compounds having the stereochemistry indicated in formula IV.
Figure imgf000135_0001
19. A compound according to Claim 18 wherein compound with the stereochemistry of formula (IV) wherein
Ri and R3 are preferably methyl or ethyl;
R2 is H, methyl, ethyl, or substituted methyl especially chloromethyl, diehloromethyl and trifluoromethyl; preferably R2 is H or unsubstituted methyl;
R is d-dalkyl or C3-C7 cycloalkyl particularly isopropyl, t-butyl, cyclopentyl, or cyclohexyl;
R5 is -d-d-alkyl-phenyl, particularly phenylmethyl, phenylethyl and phenylpropyl, indanyl, naphthyl; and
R6 and R7 are H or methyl.
20. A compound according to Claim 1 wherein the stereochemistry for U is as shown in Figure V
Figure imgf000135_0002
21. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula I according to claim 1.
22. A method of treating a proliferative disease which comprises administering a therapeutically effective amount of a compound of formula I according to claim 1 to a mammal in need of such treatment.
23. A method of claim 22 wherein the mammal is a human.
24. A compound selected from:
Λ/-[1-Cyclohexyl-2-oxo-2-(6-phenethyl-octahydro-pyrrolo[2,3-c]pyridin-1-yl)-ethyI]-2- methylamino-acetamide;
2-Methylamino-Λ/-[2-methyl-1-(7-oxo-6-phenethyI-octahydro-pyrrolo[2,3-c]pyridine-1- carbonyl)-propyl]-propionamide;
2-Methylamino-Λ/-[2-methyl-1-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridine-1- carbonyl)-propyl]-propionamide;
2-Methylamino-/V-[2-methyl-1-(8-oxo-7-phenethyI-octahydro-pyrrolo[2,3-c]azepine-1- carbonyl)-propyl]-propionamide;
2-Methylamino-Λ/-[2-methyl-1-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridine-1- carbonyl)-propyl]-butyramide;
2-Methylamino-Λ/-[2-methyl-1-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridine-1- carbonyl)-propyl]-butyramide;
2-Methylamino-Λ/-[2-methyl-1-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-c]azepine-1- carbonyl)-propyl]-butyramide; Λ/-[1-Cyclohexyl-2-oxo-2-(7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridin-1-yl)- ethyl]-2-methylamino-propionamide;
2-Methylamino-Λ/-{2-methyl-1-[5-(3-methyl-hexa-3,5-dienyl)-6-oxo-hexahydro- pyrrolo[3,4-tj]pyrrole-1-carbonyl]-propyl}-propionamide;
2-Methylamino-Λ/-[2-methyl-1-(3-methyl-7-oxo-6-phenethyl-octahydro-pyrrolo[2,3- c]pyridine-1-carbonyI)-propyl]-propionamide;
2-Methylamino-Λ/-[2-methyl-1-(3-methyl-7-oxo-6-phenethyl-octahydro-pyrrolo[2,3- c]pyridine-1-carbonyl)-propyl]-propionamide;
Λ/-[1-(4-Benzyloxy-7-oxo-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridine-1-carbonyl)-2- methyl-propyl]-2-methylamino-propionamide;
Λ/-[1-Cyclohexyl-2-oxo-2-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-c]azepin-1-yl)- ethyl]-2-methylamino-butyramide;
Λ/-[1-Cyclohexyl-2-oxo-2-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-c]azepin-1-yl)- ethyl]-2-methylamino-butyramide;
Λ/-[1-Cyclohexyl-2-oxo-2-(7-phenethyl-octahydro-pyrrolo[2,3-c]azepin-1-yl)-ethyl]-2- methylamino-propionamide;
2-Methylamino-Λ/-[2-methyl-1-(8-oxo-7-phenethyl-octahydro-pyrrolo[2,3-c]azepine-1- carbonyl)-propyl]-butyramide;
(S)-N-{(S)-2-[(R)-2-(3-Benzyl-phenyl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethyl}-2- methylamino-propionamide;
(S)-N-{(S)-2-[(S)-2-(3-Benzyl-pheny l)-pyrrolidin-1-yl]-1-cyclohexyl-2- oxo-ethyl}-2- methyla ino-propionamide;
(S)-2-Methylamino-N-((S)-2-methyl-1 -{(S)-2-[3-(methyI-phenyl-amino)-phenyl]- pyrrolidine-1 -carbonyl}-propy l)-propionamide; (S)-N-((S)-1-Cyclohexyl-2-{(S)-2-[3 -(methyl-phenyl-amino)-phenyl]-pyrrolidin-1-yl}-2- oxo-ethyl)-2-methylamino-propionamide;
(S)-N-((S)-1 -Cyclohexyl-2-{(R)-2-[3 -(methyl-phenyl-amino)-phenyl]-pyrrolidin-1 -yl}- 2-oxo-ethyl)-2-methylamino-propionamide;
(S)-N-{(S)-1 -Cyclohexyl-2-oxo-2-[(R )-2-(3-phenoxy-phenyl)-pyrrolidin-1 -yl]-ethyl}-2- methylamino-propionamide;
(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S )-2-(3-phenoxy-phenyl)-pyrrolidin-1 -yl]-ethyl}-2- methylamino-propionamide;
(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(R )-2-(3-phenylsulfanyI-phenyl)-pyrrolidin-1-yl]- ethyl}-2-methylamino-propionamide;
(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S )-2-(3-phenylsulfanyl-phenyl)-pyrrolidin-1-yl]- ethyl}-2-methylamino-propionamide;
(S)-N-{(S)-2-[(R)-2-(3-Benzenesulfonyl-phenyl)-pyrrolidin-1-yl]-1-cyclohexyI-2-oxo- ethyl}-2-methylamino-propionamide;
(S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrroIidin-1 -yl]-1 -cyclohexyl-2-oxo- ethyl}-2-methylamino-propionamide;
(S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo- ethyl}-2-methylamino-butyramide;
(S)-N-{(S)-2-[(S)-2-(1 -Benzyl-1 H-te trazol-5-yl)-pyrrolidin-1 -yl]-1 -cyclohexyl-2-oxo- ethyl}-2-methylamino- propionamide;
(S)-N-{(S)-2-[(S)-2-(1 -Benzyl-1 H-te trazol-5-yl)-pyrrolidin-1 -yl]-1 -cyclohexyl-2-oxo- ethyl}-2-methylamino-butyramide;
(S)-N-{(S)-2-[2-(Benzyloxyimino- hyl)-pyrrolidin-1 -yl]-1 -cyclohexyl- 2-oxo-ethyl}-2- methylamino-propionamide; (S)-2-Methylamino-N-{(S)-2-methyl-1 -[2-((S)-phenyImethanesulfonylamino -methyl)- pyrrolidine-1 -carbonyl]-pr opyl}-propionamide;
(S)-2-Methylamino-N-{(S)-2-methyl-1 -[2-((S)-phenylmethanesulfonylamino -methyl)- pyrrolidine-1 -carbonyl]-pr opyl}-butyramide;
N-(1-Cyclohexyl-2-{(S)-2-[(ethyl-indan-2-yl-amino)-methyl]-pyrrolidin- 1-yl}-2-oxo- ethyl)-2-((S)-methylamino)-propionarnide;
(S)-N-[(S)-1 -Cyclohexyl-2-(2-{[(S)- indan-2-yl-(2,2,2-trifluoro-ethyl)- amino]-methyl}- pyrrolidin-1-yl)-2-oxo-ethyl]-2-methylamino-propionamide;
(S)-N-((S)-1 -Cyclohexyl-2-{2-[((S)- cyclohexyl-phenethyl-amino)-methyl] -pyrrolidin- 1-yl}-2-oxo-ethyl)-2~methylamino-propionamide;
(S)-N-((S)-2-{2-[((S)-tert-Butyl-phenethy!-amino)-methyl]-pyrrolidin-1 -yl}-1- cyclohexyl-2-oxo-ethyl)-2-methylamino-propionamide;
(S)-N-((S)-1-Cyclohexyl-2-{2-[((S)- furan-2-yimethyl-phenethy!-amino)-methyl]- pyrrolidin-1 -yl}-2-oxo-ethyl )-2-methylamino-propionamide;
(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-(2- {[(S)-phenethyl-(4-pheny!-butyl)-amino]- methyl}-pyrrolidin-1 -yl)-ethyl ]-2-methyIamino-propionamide;
(S)-N-[(S)-1-Cyclohexyl-2-(2-{[(S)- methyl-(4-phenyl-butyl)-am1n'o]-methyl}-pyrrolidin- 1 -yl)-2-oxo-ethyl]-2 -methylamino-propionamide;
N-[(S)-1 -(S)-Cyclohexyl-2-oxo-2-((R )-6-phenethyl-octahydro-pyrrolo[2,3 -c]pyridin- 1 -yl)-ethyl]-acetamide;
(S)-N-[(S)-1 -(S)-Cyclohexyl-2-oxo-2 -((R)-δ-phenethyl-octahydro-pyrrolo [2,3- c]pyridin-1-yl)-ethyl]-2-methylamino-butyramide;
(S)-2-MethyIamino-N-[(S)-2-methyl-1 -((R)-6-phenethyl-octahydro-pyrrolo [2,3- c]pyridine-1-carbonyl)-propyl] -propionamide; (S)-N-[(S)-2,2-Dimethyl-1-((R)-6-phenethyl-octahydro-pyrrolo[2,3-c]pyridine-1- carbonyl)-propyl]-2-methylamino-propionamide;
(S)-2-Methylamino-N-[(S)-2-methyl-1 -((R)-δ-phenethyl-octahydro-pyrrolo [2,3- c]pyridine-1-carbonyl)-propyl] -butyramide;
(S)-N-[(S)-2,2-Dimethyl-1 -((3aR,7aS )-6-phenethyl-octahydro-pyrrolo[2,3 -cjpyridine- 1-carbonyl)-propyl]-2-methylamino-propionamide;
(S)-N-((S)-1-CyclohexyI-2-oxo-2-{(3 aR,7aS)-6-[2-(2-trifluoromethoxy-phenyl)-ethyl]- octahydro-pyrro!o[2,3- c]pyridin-1-yl}-ethyl)-2-methylamino-propionamide;
(S)-N-((S)-1-Cyclohexyl-2-oxo-2-{(3 aR,7aS)-6-[2-(3-trifluoromethoxy-phenyl)-ethyl]- octahydro-pyrrolo[2,3- c]pyridin-1-yl}-ethyl)-2-methylamino-propionamide;
(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aR,6aR)-5-phenethyl-hexahydro-pyrrolo[3,4- b]pyrrol-1-yl)-ethyl]-2-methylamino-butyramide;
(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-5-phenethyl-hexahydro-pyrrolo[3,4- b]pyrrol-1-yl)-ethyl]-2-methylamino-butyramide;
(S)-N-[(S)-1-Cyclohexyl-2-oxo-2-((3 aS,6aS)-5-phenethyl-hexahydro-pyrrolo[3,4- b]pyrrol-1-yl)-ethyl]-2-methylamino-propionamide;
(S)-N-[(S)-1 -Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyi-hexahydro - pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]- 2-methyIamino-butyramide;
(S)-N-[(R)-1 -Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyl-hexahydro - pyrrolo[3,4-b]pyrrol-1 -yl)-ethyl]- 2-methylamino-butyramide;
(S)-N-[(S)-1 -Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyl-hexahydro - pyrrolo[3,4-b]pyrrol-1-yl)-ethyl]- 2-methylamino-propionamide;
(S)-N-[(R)-1 -Cyclohexyl-2-oxo-2-((3 aS,6aS)-6-oxo-5-phenethyl-hexahydro - pyrrolo[3,4-b]pyrrol-1 -yl)-ethyl]- 2-methylamino-propionamide; (S)-N-[(S)-1 -(R)-Cyclohexyl-2-oxo-2 -((S)-7-phenethyl-octahydro-pyrrolo [2,3- c]azepin-1-yl)-ethyl]-2-methylamino-propionamide;
(S)-N-[(S)-1-(S)-Cyclohexyl-2-oxo-2 -((R)-8-oxo-7-phenethyl-octahydro-pyrrolo[2,3- c]azepin-1-yl)-ethyl]-2- methylamino-butyramide; and pharmaceutically acceptable salts thereof.
25. A compound selected from
N-[1-cyclohexyl-2-oxo-2-(6-phenethyl-octahydro-pyrrolo[2,3-c]pyridin-1-yl)-ethyl]-2- methylamino-propionamide;
N-{1-cyclohexyl-2-oxo-2-(2-(3-phenoxy-phenyl) pyrrolidin-1-yl]-ethyl}-2-methylamino- propionamide;
N-[1-cyclohexyl-2-oxo-2-(7-phenethyl-octahydro-pyrroIo[2,3-c]azepin-1-yl)-ethyl]-2- methylaminopropionamide;
(S)-N-((S)-1-Cyclohexyl-2-{(2S,3R)-2-[(ethyl-phenethyl-amino)-methyl]- 3-methyl-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide;
N-{2-[2-(2-benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-cyclohexyl-2-oxo-ethyl}-2- methylamino-butyramide;
N-{2-[2-Benxyloxyimino-methyl)-pyrrolidin-1-yl}-1-cyclohexyl-2-oxo-ethyl-2- methylamino-propionamide; and pharmaceutically acceptable salts thereof.
26. A compound selected from (S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenoxy-phenyl)-pyrrolidin-1-yl]-ethyl}-2- methylamino-propionamide;
(S)-N-{(S)-1-Cyclohexyl-2-oxo-2-[(S)-2-(3-phenylsulfanyl-pheny!)-pyrrolidin-1-yl]- ethyl}-2-methylamino-propionamide; (S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo- ethyl}-2-methylamino-propionamide;
(S)-N-{(S)-2-[(S)-2-(2-Benzyl-2H-tetrazol-5-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo- ethyl}-2-methylamino-butyramide;
(S)-N-{(S)-2-[(S)-2-(1 -Benzyl-1 H-tetrazol-5-yl)-pyrrolidin-1 -yl]-1 -cyclohexyl-2-oxo- ethyl}-2-methylamino-propionamide;
(S)-N-{(S)-2-[(S)-2-(1 -Benzyl-1 H-tetrazol-5-yl)-pyrrolidin-1 -yl]-1 -cyclohexyl-2-oxo- ethyl}-2-methylamino-butyramide; and pharmaceutically acepetable salts thereof
PCT/EP2005/003619 2004-04-07 2005-04-06 Inhibitors of iap WO2005097791A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
JP2007506718A JP4691549B2 (en) 2004-04-07 2005-04-06 Inhibitors of IAP
BRPI0509721-5A BRPI0509721A (en) 2004-04-07 2005-04-06 iap inhibitors
ES05716547T ES2394441T3 (en) 2004-04-07 2005-04-06 IAP inhibitors
AU2005231956A AU2005231956B2 (en) 2004-04-07 2005-04-06 Inhibitors of IAP
CA2560162A CA2560162C (en) 2004-04-07 2005-04-06 Inhibitors of iap
NZ549925A NZ549925A (en) 2004-04-07 2005-04-06 Inhibitors of IAP
US10/594,413 US20080242658A1 (en) 2004-04-07 2005-04-06 Inhibitors of Iap
CN2005800186137A CN1964970B (en) 2004-04-07 2005-04-06 Inhibitors of iap
EP05716547A EP1735307B1 (en) 2004-04-07 2005-04-06 Inhibitors of iap
RS20120557A RS52545B (en) 2004-04-07 2005-04-06 Inhibitors of iap
MEP-2012-557A ME02125B (en) 2004-04-07 2005-04-06 IPA INHIBITORS
IL178104A IL178104A (en) 2004-04-07 2006-09-14 Polycyclic derivatives of n-{[(pyrrolidin-1-yl)carbonyl]methyl}-alkylaminoalkane carboxamides and pharmaceutical compositions comprising the same
TNP2006000323A TNSN06323A1 (en) 2004-04-07 2006-10-06 Inhibitors of iap
NO20065114A NO20065114L (en) 2004-04-07 2006-11-06 Inhibitors of IAP
HK07106025.9A HK1100930A1 (en) 2004-04-07 2007-06-06 Inhibitors of iap iap
US13/178,946 US8207183B2 (en) 2004-04-07 2011-07-08 Inhibitors of IAP
US13/456,274 US8338440B2 (en) 2004-04-07 2012-04-26 Inhibitors of IAP

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56018604P 2004-04-07 2004-04-07
US60/560,186 2004-04-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/594,413 A-371-Of-International US20080242658A1 (en) 2004-04-07 2005-04-06 Inhibitors of Iap
US13/178,946 Continuation US8207183B2 (en) 2004-04-07 2011-07-08 Inhibitors of IAP

Publications (1)

Publication Number Publication Date
WO2005097791A1 true WO2005097791A1 (en) 2005-10-20

Family

ID=34962601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003619 WO2005097791A1 (en) 2004-04-07 2005-04-06 Inhibitors of iap

Country Status (32)

Country Link
US (4) US20080242658A1 (en)
EP (3) EP1735307B1 (en)
JP (3) JP4691549B2 (en)
KR (2) KR20080083220A (en)
CN (1) CN1964970B (en)
AR (1) AR048927A1 (en)
AU (1) AU2005231956B2 (en)
BR (1) BRPI0509721A (en)
CA (1) CA2560162C (en)
CY (1) CY1113511T1 (en)
DK (1) DK2253614T3 (en)
EC (1) ECSP066893A (en)
ES (2) ES2396195T3 (en)
HK (1) HK1100930A1 (en)
HR (1) HRP20121023T1 (en)
IL (1) IL178104A (en)
MA (1) MA28630B1 (en)
ME (1) ME02125B (en)
MY (1) MY165401A (en)
NO (1) NO20065114L (en)
NZ (1) NZ549925A (en)
PE (2) PE20110102A1 (en)
PL (1) PL2253614T3 (en)
PT (1) PT2253614E (en)
RS (1) RS52545B (en)
RU (1) RU2425838C2 (en)
SG (1) SG152225A1 (en)
SI (1) SI2253614T1 (en)
TN (1) TNSN06323A1 (en)
TW (1) TWI417092B (en)
WO (1) WO2005097791A1 (en)
ZA (1) ZA200607696B (en)

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069063A1 (en) * 2004-12-20 2006-06-29 Genentech, Inc. Pyrrolidine inhibitors of iap
WO2006091703A2 (en) * 2005-02-23 2006-08-31 Psychenomics, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
WO2006107964A2 (en) * 2005-04-06 2006-10-12 Novartis Ag Processes to prepare 6-phenethyl-octahydro-pyrrolo [2 , 3-c] pyridine and related compounds
WO2007075525A2 (en) * 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
WO2008057172A2 (en) * 2006-10-19 2008-05-15 Novartis Ag Organic compounds
WO2008079735A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
WO2008085610A1 (en) * 2006-11-28 2008-07-17 Novartis Ag Use of iap inhibitors for the treatment of acute myeloid leukemia
WO2008067280A3 (en) * 2006-11-28 2008-08-07 Novartis Ag Combination of iap inhibitors and flt3 inhibitors
EP1973899A2 (en) * 2005-12-19 2008-10-01 Genentech, Inc. Inhibitors of iap
WO2008134679A1 (en) * 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
US7456209B2 (en) 2004-07-15 2008-11-25 Tetralogic Pharmaceuticals Corporation IAP binding compounds
US7517906B2 (en) 2005-02-25 2009-04-14 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
US7547724B2 (en) 2005-10-25 2009-06-16 Aegera Therpeutics, Inc. IAP BIR domain binding compounds
US7579320B2 (en) 2006-03-16 2009-08-25 Aegera Therapeutics, Inc. IAP BIR domain binding compounds
JP2009532497A (en) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト Combination of therapeutic agents for treating cancer
JP2009532499A (en) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト Combination for the treatment of cancer, comprising a BCR-ABL / C-KIT / PDGF-RTK inhibitor
WO2009140447A1 (en) 2008-05-16 2009-11-19 Novartis Ag Immunomodulation by iap inhibitors
WO2010033531A1 (en) * 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
WO2010021934A3 (en) * 2008-08-16 2010-06-10 Genentech, Inc. Azaindole inhibitors of iap
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
EP2242362A1 (en) * 2008-01-24 2010-10-27 Tetralogic Pharmaceuticals Corporation Iap inhibitors
WO2010138496A1 (en) * 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
WO2010138666A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
WO2011016576A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Alanine derivatives as inhibitors of apoptosis proteins
WO2011018474A1 (en) 2009-08-12 2011-02-17 Novartis Ag Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
WO2011035083A1 (en) 2009-09-18 2011-03-24 Novartis Ag Biomarkers for iap inhibitor compounds
US7985735B2 (en) 2006-07-24 2011-07-26 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
WO2011101409A1 (en) 2010-02-19 2011-08-25 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of cdk4/6
US8143426B2 (en) 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
RU2446170C2 (en) * 2006-05-16 2012-03-27 Эгера Терапьютикс Инк. Compounds bound with bir domain of iap
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
US8207183B2 (en) 2004-04-07 2012-06-26 Novartis Ag Inhibitors of IAP
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2013166344A1 (en) 2012-05-04 2013-11-07 Novartis Ag Biomarkers for iap inhibitor therapy
WO2014014314A1 (en) * 2012-07-19 2014-01-23 한미약품 주식회사 Hetrocyclic derivative having dual inhibitory activity
US8642554B2 (en) 2007-04-12 2014-02-04 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
WO2014160160A2 (en) 2013-03-13 2014-10-02 Novartis Ag Antibody drug conjugates
WO2015025019A1 (en) * 2013-08-23 2015-02-26 Boehringer Ingelheim International Gmbh New 6-alkynyl pyridine
WO2015025018A1 (en) * 2013-08-23 2015-02-26 Boehringer Ingelheim International Gmbh New bis-amido pyridines
CN104592214A (en) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 Compound containing glucosamide pyridine and alkoxy pyrazinyl structure and application thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
US20170037004A1 (en) * 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017072662A1 (en) 2015-10-29 2017-05-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
WO2018066545A1 (en) * 2016-10-04 2018-04-12 公益財団法人ヒューマンサイエンス振興財団 Heterocyclic compound
WO2018142322A1 (en) 2017-02-03 2018-08-09 Novartis Ag Anti-ccr7 antibody drug conjugates
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018198091A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising toll-like receptor agonist and combination therapies
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
EP3514178A1 (en) 2013-03-15 2019-07-24 Novartis AG Antibody drug conjugates
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US10618895B2 (en) 2013-12-20 2020-04-14 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
WO2020128612A2 (en) 2018-12-21 2020-06-25 Novartis Ag Antibodies to pmel17 and conjugates thereof
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US10870892B2 (en) 2006-04-14 2020-12-22 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
US10946017B2 (en) 2015-06-05 2021-03-16 Arvinas Operations, Inc. Tank-binding kinase-1 PROTACs and associated methods of use
US10955416B2 (en) 2006-04-14 2021-03-23 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancer
US10994015B2 (en) 2016-12-23 2021-05-04 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
WO2021220199A1 (en) 2020-04-30 2021-11-04 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11427548B2 (en) 2015-01-20 2022-08-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US11866428B2 (en) 2011-04-21 2024-01-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
US12162859B2 (en) 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CA2617642A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008109057A1 (en) * 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses
JP2010528587A (en) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション Method using expression of TNFα gene as biomarker of sensitivity to apoptosis inhibitor protein antagonist
US20100203012A1 (en) * 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
JP2011509938A (en) * 2008-01-11 2011-03-31 ジェネンテック， インコーポレイテッド Inhibitors of IAP
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2310402A1 (en) * 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CN101928326B (en) * 2009-06-24 2015-07-08 中国人民解放军军事医学科学院毒物药物研究所 Substitution five-heterocyclic alkyl aminoacyl compound and application thereof
EP2560659A4 (en) * 2010-04-19 2013-05-01 Stanford Res Inst Int COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE MYELOMA
JP2014528409A (en) 2011-09-30 2014-10-27 テトラロジック ファーマシューティカルズ コーポレーション SMAC mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
GB201121122D0 (en) 2011-12-08 2012-01-18 Dow Corning Hydrolysable silanes and elastomer compositions containing them
GB201121132D0 (en) * 2011-12-08 2012-01-18 Dow Corning Modifying polymeric materials by amines
GB201121133D0 (en) 2011-12-08 2012-01-18 Dow Corning Hydrolysable silanes
GB201121124D0 (en) 2011-12-08 2012-01-18 Dow Corning Hydrolysable silanes
GB201121128D0 (en) 2011-12-08 2012-01-18 Dow Corning Treatment of filler with silane
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
US20140303090A1 (en) * 2013-04-08 2014-10-09 Tetralogic Pharmaceuticals Corporation Smac Mimetic Therapy
NZ754814A (en) 2013-06-25 2021-07-30 Walter & Eliza Hall Inst Medical Res Method of treating intracellular infection
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN105566447B (en) * 2016-01-20 2019-09-20 广东工业大学 A kind of peptoid antagonist of anti-apoptosis protein and its synthesis method and application
CN105585583B (en) * 2016-01-20 2018-04-13 广东工业大学 A kind of non-peptides apoptosis inhibitory protein antagonist and its synthetic method and application
CN106188098B (en) * 2016-07-06 2017-11-03 广东工业大学 A kind of hydridization cancer therapy drug and preparation method and application
CN109715620B (en) * 2016-08-29 2022-05-06 密歇根大学董事会 Aminopyrimidines as ALK inhibitors
US11358950B2 (en) * 2017-11-13 2022-06-14 Chia Tai Tiangqing Pharmaceutical Group Co., Ltd. SMAC mimetics used as IAP inhibitors and use thereof
US11028088B2 (en) 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
CN113164775B (en) 2018-09-07 2025-03-18 阿尔维纳斯运营股份有限公司 Polycyclic compounds and methods for targeted degradation of rapidly accelerated fibrosarcoma polypeptides
CA3138411A1 (en) 2019-05-10 2020-11-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystallization of smac mimic used as iap inhibitor and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090070A2 (en) * 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE2714880A1 (en) * 1977-04-02 1978-10-26 Hoechst Ag CEPHEMDER DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
ATE28864T1 (en) 1982-07-23 1987-08-15 Ici Plc AMIDE DERIVATIVES.
JPS59141547A (en) 1983-02-01 1984-08-14 Eisai Co Ltd Novel peptide having analgesic action and its preparation
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
FR2575753B1 (en) * 1985-01-07 1987-02-20 Adir NOVEL PEPTIDE DERIVATIVES WITH NITROGEN POLYCYCLIC STRUCTURE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
DK167813B1 (en) * 1989-12-07 1993-12-20 Carlbiotech Ltd As PENTAPEPTIDE DERIVATIVES, PHARMACEUTICAL ACCEPTABLE SALTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH DERIVATIVE
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (en) 1995-03-30 2009-12-10 Pfizer Prod Inc Quinazolinone derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DE69619114T2 (en) 1995-07-06 2002-10-02 Novartis Ag, Basel PYROLOPYRIMIDINE AND METHOD FOR THE PRODUCTION THEREOF
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (en) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Irreversible inhibitors of tyrosine kinases.
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE938597T1 (en) 1996-09-06 2000-03-09 Obducat Ab METHOD FOR ANISOTROPE ETCHING STRUCTURES IN CONDUCTIVE MATERIALS
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DK1367057T3 (en) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothilones E and F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU758526B2 (en) 1998-02-25 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
JP4662635B2 (en) 1998-11-20 2011-03-30 コーサン バイオサイエンシーズ， インコーポレイテッド Recombinant methods and materials for producing epothilone and epothilone derivatives
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
US7718600B2 (en) * 2000-09-29 2010-05-18 The Trustees Of Princeton University IAP binding compounds
US20020160975A1 (en) * 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
AU2004291936A1 (en) * 2003-11-13 2005-06-02 Burnham Institute Compositions and methods for screening pro-apoptotic compounds
JP2007523061A (en) 2004-01-16 2007-08-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン SMAC peptide mimetics and uses thereof
JP4674231B2 (en) * 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Dimer small molecule apoptosis enhancer
CN1964970B (en) 2004-04-07 2011-08-03 诺瓦提斯公司 Inhibitors of iap
ZA200700032B (en) 2004-07-02 2008-05-28 Genentech Inc Inhibitors of IAP
ATE477254T1 (en) 2004-12-20 2010-08-15 Genentech Inc PYRROLIDINES AS INHIBITORS OF IAP
PE20080951A1 (en) 2006-08-02 2008-09-11 Novartis Ag DERIVATIVES OF 2-OXO-ETHYL-AMINO-PROPIONAMIDE-PYRROLIDIN-2-IL-SUBSTITUTED AS INHIBITORS OF THE BINDING OF THE PROTEIN Smac TO THE INHIBITOR OF THE PROTEIN OF APOPTOSIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090070A2 (en) * 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARNT C R ET AL: "SYNTHETIC SMAC/DIABLO PEPTIDES ENHANCE THE EFFECTS OF CHEMOTHERAPEUTIC AGENTS BY BINDING XIAP AND CIAP1 IN SITU", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 46, 15 November 2002 (2002-11-15), pages 44236 - 44243, XP001155278, ISSN: 0021-9258 *
DEAL M J ET AL: "Conformationally Constrained Tachykinin Analogues: Potent and Highly Selective Neurokinin NK-2-Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, no. 22, 1992, pages 4195 - 4204, XP002111931, ISSN: 0022-2623 *
KIPP R A ET AL: "Molecular targeting of inhibitor of apoptosis based on small molecule mimics of natural binding partners", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 41, no. 23, 2002, pages 7344 - 7349, XP002962287, ISSN: 0006-2960 *
WU J-W ET AL: "Structural analysis of a functional DIAP1 fragment bound to grim and hid peptides", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 8, no. 1, July 2001 (2001-07-01), pages 95 - 104, XP009018631, ISSN: 1097-2765 *

Cited By (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
US8207183B2 (en) 2004-04-07 2012-06-26 Novartis Ag Inhibitors of IAP
US8338440B2 (en) 2004-04-07 2012-12-25 Novartis Ag Inhibitors of IAP
US8110568B2 (en) 2004-07-02 2012-02-07 Genentech, Inc. Inhibitors of IAP
US8980837B2 (en) 2004-07-02 2015-03-17 Genentech, Inc. Inhibitors of IAP
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
US9840464B2 (en) 2004-07-15 2017-12-12 TetraLogic Birinapant UK Ltd. IAP binding compounds
US7456209B2 (en) 2004-07-15 2008-11-25 Tetralogic Pharmaceuticals Corporation IAP binding compounds
US8802716B2 (en) 2004-07-15 2014-08-12 Tetralogic Pharmaceuticals Corporation IAP binding compounds
US9394249B2 (en) 2004-07-15 2016-07-19 TetraLogic Birinapant UK Ltd. IAP binding compounds
US7968590B2 (en) 2004-07-15 2011-06-28 Tetralogic Pharmaceuticals Corporation IAP binding compounds
WO2006069063A1 (en) * 2004-12-20 2006-06-29 Genentech, Inc. Pyrrolidine inhibitors of iap
US8609845B2 (en) 2004-12-20 2013-12-17 Genentech, Inc. Pyrrolidine inhibitors of IAP
EA019420B1 (en) * 2004-12-20 2014-03-31 Дженентех, Инк. Pyrrolidine inhibitors of iap (apoptosis inhibitors)
KR101278732B1 (en) 2004-12-20 2013-07-09 제넨테크, 인크. Pyrrolidine inhibitors of iap
NO339157B1 (en) * 2004-12-20 2016-11-14 Genentech Inc Pyrrolidine inhibitors of IAP, and their use in a method of treating a disease or condition associated with overexpression of an inhibitor of apoptosis (IAP), especially of cancer, as well as their use in the manufacture of a drug.
AU2005319305B2 (en) * 2004-12-20 2012-08-23 Genentech, Inc. Pyrrolidine inhibitors of IAP
US9040706B2 (en) 2004-12-20 2015-05-26 Genentech, Inc. Pyrrolidine inhibitors of IAP
WO2006091703A3 (en) * 2005-02-23 2007-02-22 Psychenomics Inc Multimediator 5-ht6 receptor antagonists, and uses related thereto
WO2006091703A2 (en) * 2005-02-23 2006-08-31 Psychenomics, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
US9187490B2 (en) 2005-02-25 2015-11-17 TetraLogic Birinapant UK Ltd. Dimeric IAP inhibitors
US9920093B2 (en) 2005-02-25 2018-03-20 TetraLogic Birinapant UK Ltd. Dimeric IAP inhibitors
US8022230B2 (en) 2005-02-25 2011-09-20 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
US8497297B2 (en) 2005-02-25 2013-07-30 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
US8822525B2 (en) 2005-02-25 2014-09-02 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
US7517906B2 (en) 2005-02-25 2009-04-14 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
WO2006107964A2 (en) * 2005-04-06 2006-10-12 Novartis Ag Processes to prepare 6-phenethyl-octahydro-pyrrolo [2 , 3-c] pyridine and related compounds
WO2006107964A3 (en) * 2005-04-06 2007-01-04 Novartis Ag Processes to prepare 6-phenethyl-octahydro-pyrrolo [2 , 3-c] pyridine and related compounds
US8575113B2 (en) 2005-05-18 2013-11-05 Pharmascience Inc. BIR domain binding compounds
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US7589118B2 (en) 2005-10-25 2009-09-15 Aegera Therapeutics, Inc. IAP BIR domain binding compounds
US8063095B2 (en) 2005-10-25 2011-11-22 Pharmascience Inc. IAP BIR domain binding compounds
US7795298B2 (en) 2005-10-25 2010-09-14 Aegera Therapeutics, Inc. IAP BIR domain binding compounds
US7547724B2 (en) 2005-10-25 2009-06-16 Aegera Therpeutics, Inc. IAP BIR domain binding compounds
AU2006340014B2 (en) * 2005-12-19 2012-12-20 Genentech, Inc. Inhibitors of IAP
JP2009520041A (en) * 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド Inhibitors of IAP
EP1973899A2 (en) * 2005-12-19 2008-10-01 Genentech, Inc. Inhibitors of iap
EP1973899A4 (en) * 2005-12-19 2010-10-20 Genentech Inc Inhibitors of iap
US8247557B2 (en) 2005-12-19 2012-08-21 Genentech, Inc. IAP inhibitors
JP2009520816A (en) * 2005-12-20 2009-05-28 ノバルティス アクチエンゲゼルシャフト Combination of IAP inhibitor and taxane 7
JP2013082724A (en) * 2005-12-20 2013-05-09 Novartis Ag Combination of iap inhibitor and taxane7
WO2007075525A2 (en) * 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
EP2606933A3 (en) * 2005-12-20 2014-10-15 Novartis AG Combination of an IAP-inhibitor and a taxane
US8906936B2 (en) 2005-12-20 2014-12-09 Novartis Ag Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof
WO2007075525A3 (en) * 2005-12-20 2007-11-15 Novartis Ag Combination of an iap-inhibitor and a taxane7
EP2606933A2 (en) 2005-12-20 2013-06-26 Novartis AG Combination of an IAP-inhibitor and a taxane
US7579320B2 (en) 2006-03-16 2009-08-25 Aegera Therapeutics, Inc. IAP BIR domain binding compounds
US7645741B2 (en) 2006-03-16 2010-01-12 Aegera Therapeutics, Inc. IAP BIR domain binding compounds
US8765681B2 (en) 2006-03-16 2014-07-01 Pharmascience Inc. IAP BIR domain binding compounds
US9365614B2 (en) 2006-03-16 2016-06-14 Pharmascience Inc. IAP BIR domain binding compounds
JP2013151530A (en) * 2006-04-05 2013-08-08 Novartis Ag Combination agent for treatment of cancer, containing bcr-abl, c-kit, and pdgf-ptk inhibitor
JP2009532499A (en) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト Combination for the treatment of cancer, comprising a BCR-ABL / C-KIT / PDGF-RTK inhibitor
JP2009532497A (en) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト Combination of therapeutic agents for treating cancer
US11505833B2 (en) 2006-04-14 2022-11-22 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
US10955416B2 (en) 2006-04-14 2021-03-23 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancer
US10870892B2 (en) 2006-04-14 2020-12-22 Cell Signaling Technology, Inc. Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
US8648094B2 (en) 2006-05-16 2014-02-11 Pharmascience, Inc. IAP BIR domain binding compounds
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
RU2446170C2 (en) * 2006-05-16 2012-03-27 Эгера Терапьютикс Инк. Compounds bound with bir domain of iap
JP2009537461A (en) * 2006-05-16 2009-10-29 アエゲラ セラピューティクス インコーポレイテッド IAPBIR domain binding protein
US7985735B2 (en) 2006-07-24 2011-07-26 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
US8143426B2 (en) 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
KR101087878B1 (en) * 2006-08-02 2011-11-30 노파르티스 아게 SMAC Peptide Mimetics Useful as IAP Inhibitors
AU2007281230B2 (en) * 2006-08-02 2011-09-08 Novartis Ag Smac peptidomimetics useful as IAP inhibitors
NO342230B1 (en) * 2006-08-02 2018-04-23 Novartis Ag SMAC peptidometics useful as IAP inhibitors and intermediates for their preparation
US20140004101A1 (en) * 2006-08-02 2014-01-02 Novartis Ag Smac peptidometics useful as iap inhibitors
CN102558165B (en) * 2006-08-02 2014-08-13 诺华股份有限公司 Smac peptidomimetics useful as iap inhibitors
US8552003B2 (en) 2006-08-02 2013-10-08 Novartis Ag (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses
CN102558165A (en) * 2006-08-02 2012-07-11 诺瓦提斯公司 Smac peptidomimetics useful as iap inhibitors
US8546336B2 (en) 2006-08-02 2013-10-01 Novartis Ag SMAC peptidometics useful as IAP inhibitors
JP4875749B2 (en) * 2006-08-02 2012-02-15 ノバルティス アーゲー SMAC peptide mimetics useful as IAP inhibitors
CN101511860B (en) * 2006-08-02 2013-05-01 诺瓦提斯公司 SMAC peptidomimetics useful as IAP inhibitors
EP2537850A1 (en) 2006-08-02 2012-12-26 Novartis AG Organic compounds
EA021671B1 (en) * 2006-08-02 2015-08-31 Новартис Аг Smac PEPTIDOMIMETIC USEFUL AS IAP INHIBITOR (INHIBITOR OF APOPTOSIS PROTEINS)
EP2537846A1 (en) 2006-08-02 2012-12-26 Novartis AG Organic compounds
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
JP2010506847A (en) * 2006-10-12 2010-03-04 ノバルティス アーゲー Pyrrolidine derivatives as IAP inhibitors
WO2008045905A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
JP2010507096A (en) * 2006-10-19 2010-03-04 ノバルティス アーゲー Organic compounds
WO2008057172A2 (en) * 2006-10-19 2008-05-15 Novartis Ag Organic compounds
WO2008057172A3 (en) * 2006-10-19 2008-09-12 Novartis Ag Organic compounds
WO2008067280A3 (en) * 2006-11-28 2008-08-07 Novartis Ag Combination of iap inhibitors and flt3 inhibitors
WO2008085610A1 (en) * 2006-11-28 2008-07-17 Novartis Ag Use of iap inhibitors for the treatment of acute myeloid leukemia
JP2010511059A (en) * 2006-11-28 2010-04-08 ノバルティス アーゲー Combination of IAP inhibitor and FLT3 inhibitor
US8492429B2 (en) 2006-11-28 2013-07-23 Novartis Ag Combination of IAP inhibitors and FLT3 inhibitors
AU2007325280B2 (en) * 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
US20100056467A1 (en) * 2006-11-28 2010-03-04 Novartis Ag Combination of iap inhibitors and flt3 inhibitors
US8063218B2 (en) 2006-12-19 2011-11-22 Genentech, Inc. Imidazopyridine inhibitors of IAP
RU2466131C2 (en) * 2006-12-19 2012-11-10 Дженентек, Инк. Imidazopyridine iap inhibitors
WO2008079735A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
JP2010513561A (en) * 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド IAP imidazopyridine inhibitors
US8642554B2 (en) 2007-04-12 2014-02-04 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
RU2491276C2 (en) * 2007-04-30 2013-08-27 Дженентек, Инк. Iap inhibitors
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
WO2008134679A1 (en) * 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
EP2242362A4 (en) * 2008-01-24 2012-04-11 Tetralogic Pharm Corp Iap inhibitors
EP2242362A1 (en) * 2008-01-24 2010-10-27 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US10786491B2 (en) 2008-05-16 2020-09-29 Novartis Ag Immunomodulation by IAP inhibitors
EP2698158A1 (en) 2008-05-16 2014-02-19 Novartis AG Immunomodulation by IAP Inhibitors
US9750729B2 (en) 2008-05-16 2017-09-05 Dana-Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
EP3701947A1 (en) * 2008-05-16 2020-09-02 Novartis AG Immunomodulation by iap inhibitors
WO2009140447A1 (en) 2008-05-16 2009-11-19 Novartis Ag Immunomodulation by iap inhibitors
US11382905B2 (en) 2008-05-16 2022-07-12 Novartis Ag Immunomodulation by IAP inhibitors
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
WO2010021934A3 (en) * 2008-08-16 2010-06-10 Genentech, Inc. Azaindole inhibitors of iap
CN102124004A (en) * 2008-08-16 2011-07-13 健泰科生物技术公司 Azaindole inhibitors of iap
WO2010033531A1 (en) * 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
US8399683B2 (en) 2008-09-17 2013-03-19 Tetralogic Pharmaceuticals IAP inhibitors
US10329626B2 (en) 2009-01-09 2019-06-25 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
US9533980B2 (en) 2009-01-09 2017-01-03 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
CN102458115A (en) * 2009-05-28 2012-05-16 泰特拉洛吉克药业公司 Iap inhibitors
CN102458116B (en) * 2009-05-28 2014-12-31 泰特拉洛吉克药业公司 IAP inhibitors
WO2010138496A1 (en) * 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
CN102458116A (en) * 2009-05-28 2012-05-16 泰特拉洛吉克药业公司 Iap inhibitors
CN102458115B (en) * 2009-05-28 2014-06-11 泰特拉洛吉克药业公司 Iap inhibitors
US20120094917A1 (en) * 2009-05-28 2012-04-19 Tetralogic Pharmaceuticals Corp Iap inhibitors
US8415486B2 (en) 2009-05-28 2013-04-09 Tetralogic Pharmaceuticals Corp. IAP inhibitors
US8481495B2 (en) 2009-05-28 2013-07-09 Tetralogic Pharmaceuticals Corporation IAP inhibitors
WO2010138666A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
US8986993B2 (en) 2009-07-02 2015-03-24 Tetralogic Pharmaceuticals Corporation SMAC mimetic for treating myelodysplastic syndromes
US10596220B2 (en) 2009-07-02 2020-03-24 Medivir Ab SMAC mimetic
US11351221B2 (en) 2009-07-02 2022-06-07 Medivir Ab SMAC mimetic
US8603816B2 (en) 2009-07-02 2013-12-10 Tetralogic Pharmaceuticals Corp. SMAC mimetic
US10314881B2 (en) 2009-07-02 2019-06-11 Medivir Ab SMAC mimetic
US11951147B2 (en) 2009-07-02 2024-04-09 Medivir Ab SMAC mimetic
US10034912B2 (en) 2009-07-02 2018-07-31 TetraLogic Birinapant UK Ltd. SMAC Mimetic
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011016576A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Alanine derivatives as inhibitors of apoptosis proteins
WO2011018474A1 (en) 2009-08-12 2011-02-17 Novartis Ag Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
US9540363B2 (en) 2009-08-12 2017-01-10 Novartis Ag Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
US10093665B2 (en) 2009-08-12 2018-10-09 Novartis Ag Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
RU2671196C1 (en) * 2009-08-12 2018-10-30 Новартис Аг Solid oral formulations and crystalline forms of apoptosis protein inhibitor
CN102612651A (en) * 2009-09-18 2012-07-25 诺瓦提斯公司 Biomarkers for iap inhibitor compounds
WO2011035083A1 (en) 2009-09-18 2011-03-24 Novartis Ag Biomarkers for iap inhibitor compounds
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
WO2011101409A1 (en) 2010-02-19 2011-08-25 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
US11866428B2 (en) 2011-04-21 2024-01-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2013166344A1 (en) 2012-05-04 2013-11-07 Novartis Ag Biomarkers for iap inhibitor therapy
WO2014014314A1 (en) * 2012-07-19 2014-01-23 한미약품 주식회사 Hetrocyclic derivative having dual inhibitory activity
WO2014160160A2 (en) 2013-03-13 2014-10-02 Novartis Ag Antibody drug conjugates
EP3514178A1 (en) 2013-03-15 2019-07-24 Novartis AG Antibody drug conjugates
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
WO2015025019A1 (en) * 2013-08-23 2015-02-26 Boehringer Ingelheim International Gmbh New 6-alkynyl pyridine
WO2015025018A1 (en) * 2013-08-23 2015-02-26 Boehringer Ingelheim International Gmbh New bis-amido pyridines
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
US11225476B2 (en) 2013-12-20 2022-01-18 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11643410B2 (en) 2013-12-20 2023-05-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10618895B2 (en) 2013-12-20 2020-04-14 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US12202828B2 (en) 2013-12-20 2025-01-21 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
US11427548B2 (en) 2015-01-20 2022-08-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN104592214A (en) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 Compound containing glucosamide pyridine and alkoxy pyrazinyl structure and application thereof
US10946017B2 (en) 2015-06-05 2021-03-16 Arvinas Operations, Inc. Tank-binding kinase-1 PROTACs and associated methods of use
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
US20170037004A1 (en) * 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
US12171831B2 (en) 2015-08-19 2024-12-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain- containing proteins
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US11554171B2 (en) 2015-08-19 2023-01-17 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3797797A1 (en) 2015-10-29 2021-03-31 Novartis AG Antibody conjugates comprising toll-like receptor agonist
WO2017072662A1 (en) 2015-10-29 2017-05-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
WO2018066545A1 (en) * 2016-10-04 2018-04-12 公益財団法人ヒューマンサイエンス振興財団 Heterocyclic compound
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
US11597720B2 (en) 2016-12-01 2023-03-07 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US12172981B2 (en) 2016-12-01 2024-12-24 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11104666B2 (en) 2016-12-01 2021-08-31 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10899742B1 (en) 2016-12-01 2021-01-26 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US10994015B2 (en) 2016-12-23 2021-05-04 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
US11986531B2 (en) 2016-12-23 2024-05-21 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US11857519B2 (en) 2016-12-24 2024-01-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US11384063B2 (en) 2017-01-26 2022-07-12 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
WO2018142322A1 (en) 2017-02-03 2018-08-09 Novartis Ag Anti-ccr7 antibody drug conjugates
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
WO2018198091A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising toll-like receptor agonist and combination therapies
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
US12036209B2 (en) 2017-11-17 2024-07-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
EP4306111A2 (en) 2018-07-10 2024-01-17 Novartis AG 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128612A2 (en) 2018-12-21 2020-06-25 Novartis Ag Antibodies to pmel17 and conjugates thereof
EP4406555A2 (en) 2018-12-21 2024-07-31 Novartis AG Antibodies to pmel17 and conjugates thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
WO2021220199A1 (en) 2020-04-30 2021-11-04 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
US12162859B2 (en) 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP4427590A2 (en) 2021-04-16 2024-09-11 Novartis AG Antibody drug conjugates and methods for making thereof
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
US12156916B2 (en) 2022-09-07 2024-12-03 Arvinas Operations, Inc. Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Also Published As

Publication number Publication date
US20080242658A1 (en) 2008-10-02
RU2425838C2 (en) 2011-08-10
AU2005231956A1 (en) 2005-10-20
KR20080083220A (en) 2008-09-16
CN1964970B (en) 2011-08-03
SI2253614T1 (en) 2013-01-31
HRP20121023T1 (en) 2013-01-31
MA28630B1 (en) 2007-06-01
HK1100930A1 (en) 2007-10-05
KR100892185B1 (en) 2009-04-07
US8207183B2 (en) 2012-06-26
TWI417092B (en) 2013-12-01
US20050234042A1 (en) 2005-10-20
DK2253614T3 (en) 2013-01-07
CY1113511T1 (en) 2016-06-22
ES2394441T3 (en) 2013-01-31
TW200602029A (en) 2006-01-16
PE20110102A1 (en) 2011-02-07
JP2007532504A (en) 2007-11-15
ZA200607696B (en) 2008-03-26
US8338440B2 (en) 2012-12-25
JP4691549B2 (en) 2011-06-01
US20110281875A1 (en) 2011-11-17
EP1735307A1 (en) 2006-12-27
NO20065114L (en) 2007-01-08
AR048927A1 (en) 2006-06-14
EP2253614A1 (en) 2010-11-24
MY165401A (en) 2018-03-21
PE20060166A1 (en) 2006-04-25
CA2560162C (en) 2013-05-21
EP2253614B1 (en) 2012-09-19
IL178104A0 (en) 2006-12-31
NZ549925A (en) 2010-08-27
PT2253614E (en) 2013-01-09
AU2005231956B2 (en) 2009-11-05
CN1964970A (en) 2007-05-16
ME02125B (en) 2013-04-30
CA2560162A1 (en) 2005-10-20
IL178104A (en) 2015-08-31
RS52545B (en) 2013-04-30
EP2065368A1 (en) 2009-06-03
US7419975B2 (en) 2008-09-02
KR20060134200A (en) 2006-12-27
ES2396195T3 (en) 2013-02-19
RU2006139010A (en) 2008-05-20
BRPI0509721A (en) 2007-09-25
JP2010215635A (en) 2010-09-30
ECSP066893A (en) 2006-11-24
PL2253614T3 (en) 2013-03-29
SG152225A1 (en) 2009-05-29
JP2013049733A (en) 2013-03-14
TNSN06323A1 (en) 2008-02-22
EP1735307B1 (en) 2012-08-29
US20120207769A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
EP1735307B1 (en) Inhibitors of iap
EP2903998B1 (en) Iap antagonists
AU768720B2 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors
EP2861581B9 (en) 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer.
US20110230419A1 (en) Iap binding compounds
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
EP1587787A1 (en) Viral polymerase inhibitors
JP2004002367A (en) Pharmaceutical composition
WO2011150190A2 (en) Hcv inhibitor compounds and methods of use thereof
EP1819332B1 (en) Pyrrolopyridine-2-carboxylic acid amides
MXPA06011583A (en) Inhibitors of iap

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006/07696

Country of ref document: ZA

Ref document number: 178104

Country of ref document: IL

Ref document number: 200607696

Country of ref document: ZA

Ref document number: 2005231956

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2560162

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 549925

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12006501862

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 06098543

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2005231956

Country of ref document: AU

Date of ref document: 20050406

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005231956

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011583

Country of ref document: MX

Ref document number: 2007506718

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3723/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005716547

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067023240

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006139010

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580018613.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020067023240

Country of ref document: KR

Ref document number: 2005716547

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0509721

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10594413

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2012/0557

Country of ref document: RS